10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_____________________

Form 10-Q

________________

(Mark One)

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2022

OR

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ______ to ______

Commission File No. 001-40235

Organon & Co.

(Exact name of registrant as specified in its charter)

Delaware		46-4838035
(State or other jurisdiction of incorporation)		(I.R.S. Employer Identification No.)
30 Hudson Street, Floor 33
Jersey City,	New Jersey	07302
(Address of principal executive offices) (zip code)

(Registrant’s telephone number, including area code) (551) 430-6900

	Not Applicable
(Former name, former address and former fiscal year, if changed since last report.)

Securities registered pursuant to Section 12(b) of the Act:
Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock ($0.01 par value)	OGN	New York Stock Exchange

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☒	Smaller reporting company	☐
		Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

The number of shares of common stock outstanding as of the close of business on October 30, 2022: 254,364,409

Table of Contents

		Page No.
PART I	FINANCIAL INFORMATION	3
Item 1.	Financial Statements (unaudited)	3
	Condensed Consolidated Statements of Income	3
	Condensed Consolidated Statements of Comprehensive Income	4
	Condensed Consolidated Balance Sheets	5
	Condensed Consolidated Statements of Equity	6
	Condensed Consolidated Statements of Cash Flows	8
	Notes to Condensed Consolidated Financial Statements	9
Item 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations	29
Item 3.	Quantitative and Qualitative Disclosures about Market Risk	38
Item 4.	Controls and Procedures	39
PART II	OTHER INFORMATION	40
Item 1.	Legal Proceedings	40
Item 1A.	Risk Factors	40
Item 6.	Exhibits	41
	Signatures

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements

Organon & Co.

Condensed Consolidated Statements of Income

(Unaudited, $ in millions except shares in thousands and per share amounts)

 

	Three Months Ended September 30,				Nine Months Ended September 30,
	2022		2021		2022		2021
Revenues	$	1,537	$	1,600	$	4,689	$	4,701
Costs, Expenses and Other
Cost of sales	551		609		1,700		1,783
Selling, general and administrative	440		388		1,234		1,186
Research and development	127		86		329		229
Acquired in-process research and development and milestones	10		25		107		25
Restructuring costs	11		1		11		3
Interest expense	108		98		303		160
Exchange losses (gains)	4		1		(21)		6
Other expense, net	4		3		15		16
	1,255		1,211		3,678		3,408
Income From Continuing Operations Before Income Taxes	282		389		1,011		1,293
Taxes on Income	55		66		202		144
Net Income From Continuing Operations	227		323		809		1,149
Loss From Discontinued Operations - Net of Tax	—		—		—		—
Net Income	$	227	$	323	$	809	$	1,149
Earnings per Share - Basic:
Continuing operations	$	0.89	$	1.27	$	3.19	$	4.53
Discontinued operations	—		—		—		—
Net Earnings per Share - Basic	$	0.89	$	1.27	$	3.19	$	4.53
Earnings per Share - Diluted:
Continuing operations	$	0.89	$	1.27	$	3.17	$	4.52
Discontinued operations	—		—		—		—
Net Earnings per Share - Diluted	$	0.89	$	1.27	$	3.17	$	4.52
Weighted Average Shares Outstanding:
Basic	254,348		253,534		253,986		253,530
Diluted	255,067		254,172		255,094		254,011

The accompanying notes are an integral part of these interim Condensed Consolidated Financial Statements.

-3-

Organon & Co.

Condensed Consolidated Statements of Comprehensive Income

(Unaudited, $ in millions)

 

	Three Months Ended September 30,				Nine Months Ended September 30,
	2022		2021		2022		2021
Net Income	$	227	$	323	$	809	$	1,149
Other Comprehensive (Loss) Income, Net of Taxes:
Benefit plan net loss and prior service credit, net of amortization	—		(3)		—		(11)
Cumulative translation adjustment	(97)		(23)		(173)		129
	(97)		(26)		(173)		118
Comprehensive Income	$	130	$	297	$	636	$	1,267

The accompanying notes are an integral part of these interim Condensed Consolidated Financial Statements.

-4-

Organon & Co.

Condensed Consolidated Balance Sheets

(Unaudited, $ in millions except shares in thousands)

	September 30, 2022		December 31, 2021
Assets
Current Assets
Cash and cash equivalents	$	499	$	737
Accounts receivable (net of allowance for doubtful accounts of $8 in 2022 and $7 in 2021)	1,440		1,382
Inventories (excludes inventories of $96 in 2022 and $76 in 2021 classified in Other Assets)	879		915
Other current assets	774		726
Total current assets	3,592		3,760
Property, plant and equipment, net	906		973
Goodwill	4,603		4,603
Other intangibles, net	670		651
Other assets	666		694
	$	10,437	$	10,681
Liabilities and Equity
Current Liabilities
Current portion of long-term debt	$	8	$	9
Trade accounts payable	1,028		1,382
Accrued and other current liabilities	1,075		1,021
Income taxes payable	217		185
Total current liabilities	2,328		2,597
Long-term debt	8,691		9,125
Deferred income taxes	43		4
Other noncurrent liabilities	441		463
Commitments and Contingencies
Organon & Co. Equity
Common stock, $0.01 par value Authorized - 500,000 Issued and outstanding - 254,364 in 2022 and 253,545 in 2021	3		3
Accumulated deficit	(383)		(998)
Accumulated other comprehensive loss	(686)		(513)
Total Deficit	(1,066)		(1,508)
	$	10,437	$	10,681

The accompanying notes are an integral part of these interim Condensed Consolidated Financial Statements.

-5-

Organon & Co.

Condensed Consolidated Statements of Equity

(Unaudited, $ in millions, except shares in thousands)

	Common Stock			Additional Paid-In Capital		Accumulated Deficit		Net Investment from Merck & Co., Inc.		Accumulated Other Comprehensive Loss		Total
	Shares	Par Value
Balance at July 1, 2021	253,516	$	3	$	—	$	(1,473)	$	—	$	(464)	$	(1,934)
Net income	—	—		—		323		—		—		323
Other comprehensive loss, net of taxes	—	—		—		—		—		(26)		(26)
Cash dividends declared on common stock ($0.28 per share)	—	—		—		(74)		—		—		(74)
Stock-based compensation	29	—		—		15		—		—		15
Net transfers from Merck & Co., Inc., including Separation Adjustments	—	—		—		81		—		(3)		78
Balance at September 30, 2021	253,545	$	3	$	—	$	(1,128)	$	—	$	(493)	$	(1,618)
Balance at July 1, 2022	254,321	$	3	$	—	$	(551)	$	—	$	(589)	$	(1,137)
Net income	—	—		—		227		—		—		227
Other comprehensive loss, net of taxes	—	—		—		—		—		(97)		(97)
Cash dividends declared on common stock ($0.28 per share)	—	—		—		(74)		—		—		(74)
Stock-based compensation plans and other	43	—		—		15		—		—		15
Balance at September 30, 2022	254,364	$	3	$	—	$	(383)	$	—	$	(686)	$	(1,066)

The accompanying notes are an integral part of these interim Condensed Consolidated Financial Statements.

-6-

Organon & Co.

Condensed Consolidated Statements of Equity (continued)

(Unaudited, $ in millions, except shares)

	Common Stock			Additional Paid-In Capital		Accumulated Deficit		Net Investment from Merck & Co., Inc.		Accumulated Other Comprehensive (Loss) Income		Total
	Shares	Par Value
Balance at January 1, 2021	—	$	—	$	—	$	—	$	6,108	$	(622)	$	5,486
Net income	—	—		—		419		730		—		1,149
Other comprehensive income, net of taxes	—	—		—		—		—		118		118
Cash dividends declared on common stock	—	—		—		(74)		—		—		(74)
Stock-based compensation	29	—		—		23		—		—		23
Net transfers from Merck & Co., Inc., including Separation Adjustments	—	—		—		81		588		11		680
Net consideration paid to Merck & Co., Inc. in connection with Separation	—	—		—		—		(9,000)		—		(9,000)
Issuance of common stock in connection with the Separation and reclassification of Net investment from Merck & Co., Inc.	253,516	3		—		(1,577)		1,574		—		—
Balance at September 30, 2021	253,545	$	3	$	—	$	(1,128)	$	—	$	(493)	$	(1,618)
Balance at January 1, 2022	253,550	$	3	$	—	$	(998)	$	—	$	(513)	$	(1,508)
Net income	—	—		—		809		—		—		809
Other comprehensive loss, net of taxes	—	—		—		—		—		(173)		(173)
Cash dividends declared on common stock	—	—		—		(218)		—		—		(218)
Stock-based compensation plans and other	814	—				41		—		—		41
Net transfers from Merck & Co., Inc., including Separation Adjustments	—	—		—		(17)		—		—		(17)
Balance at September 30, 2022	254,364	$	3	$	—	$	(383)	$	—	$	(686)	$	(1,066)

The accompanying notes are an integral part of these interim Condensed Consolidated Financial Statements.

-7-

Organon & Co.

Condensed Consolidated Statements of Cash Flows

(Unaudited, $ in millions)

	Nine Months Ended September 30,
	2022		2021
Cash Flows from Operating Activities
Net income from continuing operations	$	809	$	1,149
Adjustments to reconcile net income from continuing operations to net cash flows provided by operating activities:
Depreciation	72		64
Amortization	88		69
Impairment of assets	9		—
Acquired in-process research and development and milestones	107		25
Deferred income taxes	(18)		(212)
Stock-based compensation	52		44
Unrealized foreign exchange (gain) loss	(45)		37
Other	24		7
Net changes in assets and liabilities
Accounts receivable	(119)		(376)
Inventories	(134)		(90)
Other current assets	(76)		177
Trade accounts payable	(323)		944
Accrued and other current liabilities	108		386
Due from/due to related party	—		(164)
Income taxes payable	45		7
Other	(8)		46
Net Cash Flows Provided by Operating Activities from Continuing Operations	591		2,113
Cash Flows from Investing Activities
Capital expenditures	(133)		(133)
Proceeds from sale of property, plant and equipment	3		2
Acquired In Process Research & Development	(105)		(25)
Purchase of product rights and asset acquisition, net of cash acquired	(124)		(192)
Net Cash Flows Used in Investing Activities from Continuing Operations	(359)		(348)
Cash Flows from Financing Activities
Proceeds from issuance of long-term debt	—		9,470
Repayments of debt	(106)		(10)
Payment of long-term debt issuance costs	—		(118)
Repayments of short-term borrowings from Merck & Co., Inc., net	—		(1,512)
Net consideration paid to Merck & Co. Inc. in connection with the Separation	—		(9,000)
Net transfers (to) from Merck & Co., Inc.	(17)		454
Employee withholding taxes related to share-based awards	(11)		—
Dividend payments	(217)		(74)
Net Cash Flows Used in Financing Activities from Continuing Operations	(351)		(790)
Discontinued Operations
Net Cash Provided by Operating Activities	—		298
Net Cash Used in Investing Activities	—		—
Net Cash Used in Financing Activities	—		(356)
Net Cash Flows Used in Discontinued Operations	—		(58)
Effect of Exchange Rate Changes on Cash and Cash Equivalents from Continuing Operations	(119)		21
Effect of Exchange Rate Changes on Cash and Cash Equivalents from Discontinued Operations	—		—
Net (Decrease) Increase in Cash and Cash Equivalents	(238)		938
Cash and Cash Equivalents, Beginning of Period	737		12
Cash and Cash Equivalents of Discontinued Operations, Beginning of Period	—		58
Total Cash and Cash Equivalents, End of Period	499		1,008
Less: Cash and Cash Equivalents of Discontinued Operations, End of Period	—		—
Cash and Cash Equivalents, End of Period	$	499	$	1,008

 The accompanying notes are an integral part of these interim Condensed Consolidated Financial Statements.

-8-

Notes to Condensed Consolidated Financial Statements (unaudited)

1. Background and Nature of Operations

Organon & Co. (“Organon” or the “Company”) is a global health care company formed through a spinoff from Merck & Co., Inc. (“Merck”) to focus on improving the health of women throughout their lives. Organon develops and delivers innovative health solutions through a portfolio of prescription therapies within women's health, biosimilars and established brands (the "Organon Products"). Organon has a portfolio of more than 60 medicines and products across a range of therapeutic areas. The Company sells these products through various channels including drug wholesalers and retailers, hospitals, government agencies and managed health care providers such as health maintenance organizations, pharmacy benefit managers and other institutions. The Company operates six manufacturing facilities, which are located in Belgium, Brazil, Indonesia, Mexico, the Netherlands and the United Kingdom. Unless otherwise indicated, trademarks appearing in italics throughout this document are trademarks of, or are used under license by, the Organon group of companies.

The Company’s operations include the following product portfolios:

•Women’s Health: the Company has a portfolio of contraception and fertility brands, such as Nexplanon® (etonogestrel implant) (sold as Implanon NXT™ in some countries outside the U.S.), a long-acting reversible contraceptive, which is a class of contraceptives that are recognized as the most effective type of hormonal contraception available to patients with a lower long-term average cost.

•Biosimilars: the Company’s current portfolio spans across immunology and oncology treatments. All five of the biosimilars in Organon’s portfolio have launched in certain countries globally, including two biosimilars in the United States.

•Established Brands: the Company has a portfolio of established brands, which generally are beyond market exclusivity, including leading brands in cardiovascular, respiratory, dermatology and non-opioid pain management.

On June 2, 2021, Organon and Merck entered into a Separation and Distribution Agreement (the "Separation and Distribution Agreement"). Pursuant to the Separation and Distribution Agreement, Merck agreed to spin off the Organon Products into Organon, a new, publicly-traded company (the "Separation").

In connection with the Separation, on June 2, 2021, Merck distributed (the "Distribution"), on a pro rata basis, to holders of the outstanding shares of common stock of Merck, par value $0.50 per share (the "Merck Common Stock") on May 17, 2021 (the "Record Date"), all of the outstanding shares of common stock, par value $0.01 per share, of Organon (the "Common Stock"). Each Merck stockholder was entitled to receive one-tenth of a share of the Common Stock for each share of Merck Common Stock held on the Record Date. Organon is now a standalone publicly-traded company and, on June 3, 2021, regular-way trading of the Common Stock commenced on the New York Stock Exchange under the ticker symbol "OGN."

The Separation was completed pursuant to the Separation and Distribution Agreement and other agreements with Merck related to the Separation, including, but not limited to a tax matters agreement (the "Tax Matters Agreement" or "TMA"), an employee matters agreement (the "Employee Matters Agreement" or "EMA") and a transition services agreement (the "Transition Service Agreement" or "TSA"). Following the Separation, certain functions continue to be provided by Merck under the TSA or are being performed using the Company’s own resources or third-party service providers. Under the TSA, Merck is providing Organon various services and, similarly, Organon is providing Merck various services. The provision of services under the TSA generally will terminate within 25 months following the spin-off; however, the provision of certain services has been extended to at least 31 months. Additionally, under manufacturing and supply agreements, the Company manufactures certain products for Merck, or its applicable affiliate and Merck manufactures certain products for the Company or its applicable affiliate (see Note 13 for additional details). The Company incurred certain costs in its establishment as a standalone public company and expects to incur ongoing additional costs associated with operating as an independent, publicly-traded company.

2. Basis of Presentation

The unaudited financial statements for all periods presented, including the historical results of the Company prior to June 2, 2021, are referred to as "Condensed Consolidated Financial Statements," and have been prepared pursuant to the rules and regulations for reporting on Form 10-Q. Accordingly, certain information and disclosures required by U.S. generally accepted accounting principles ("GAAP") for complete consolidated financial statements are not included herein. The results of operations of any interim period are not necessarily indicative of the results of operations for the full year. In the Company’s opinion, all adjustments necessary for a fair statement of these interim statements have been included and are of a normal and recurring nature. All intercompany transactions and accounts within Organon have been eliminated. These interim statements should be read in conjunction with the audited financial statements and notes thereto included in Organon’s Annual Report on Form 10-K for the year ended December 31, 2021.

-9-

Notes to Condensed Consolidated Financial Statements (unaudited) (continued)

Prior to the Separation on June 2, 2021, the Company’s historical Consolidated Financial Statements were prepared on a standalone basis and were derived from Merck’s consolidated financial statements and accounting records. The assets, liabilities, revenue and expenses of the Company were reflected in the Condensed Consolidated Financial Statements on a historical cost basis, as included in the consolidated financial statements of Merck, using the historical accounting policies applied by Merck, following a legal entity approach. For such periods prior to the Separation, certain corporate and shared costs were allocated to the Company based on a specific identification basis or, when specific identification was not practicable, a proportional cost allocation method. Refer to Note 2 of the audited Consolidated Financial Statements in the Company's 2021 Form 10-K for additional details on Organon's basis of presentation during periods prior to the Separation, at Separation and post Separation.

The Company’s historical results prior to the Separation included certain Merck non-U.S. legal entities that were conveyed to Organon in connection with the Separation (collectively, the "Transferred Entities" and each, a "Transferred Entity") and included operations related to other Merck products that were retained by Merck (the "Merck Retained Products"). The Merck Retained Products business of the Transferred Entities was contributed by the Company to Merck and its affiliates and any remaining assets and liabilities were transferred as of June 2, 2021. Accordingly, the historical results of operations of the Merck Retained Products have been reflected as discontinued operations in these Condensed Consolidated Financial Statements.

For periods prior to the Separation, income tax expense in the Condensed Consolidated Statement of Income was calculated on a separate tax return basis and the Company’s operations were included in the tax returns of certain legal entities established to operate the Organon Products business (the "Organon Entities"), Transferred Entities, or the respective Merck entities of which the Company’s business was a part. As of June 2, 2021, and in connection with the Separation, the Company adjusted its deferred tax balances and computed its related tax provision to reflect operations as a standalone entity. As a standalone entity, the Company files tax returns on its own behalf, and tax balances and effective income tax rates may differ from the amounts reported in the historical periods.

Certain assets and liabilities, including accounts receivables, inventories and trade payables included on the Condensed Consolidated Balance Sheet prior to the Separation, were retained by Merck post-Separation and therefore were recorded through Net investment from Merck & Co., Inc. in the Company’s Condensed Consolidated Financial Statements. As part of the Separation, Net investment from Merck & Co., Inc. was reclassified to Common Stock and Accumulated Deficit.

Use of Estimates

The presentation of these Condensed Consolidated Financial Statements and accompanying notes in conformity with U.S. GAAP require management to make estimates and assumptions that affect the amounts reported, as further described in our Form 10-K for the year ended December 31, 2021. Accordingly, actual results could differ materially from management's estimates and assumptions.

Due to the significant uncertainty that exists relative to the duration and overall impact of the COVID-19 pandemic, our future operating performance, particularly in the short-term, may be subject to volatility. The assessment of certain accounting matters and specifically its effect on the Company's results require consideration of forecasted financial information in the context of the information reasonably available to the Company and the unknown future impacts of the COVID-19 pandemic as of September 30, 2022 and through the date of this report.

Recently Adopted Accounting Standards

There were no recently issued accounting standards adopted by the Company during the three and nine months ended September 30, 2022. Refer to Note 3 of the audited Consolidated Financial Statements in Organon's Form 10-K for the year ended December 31, 2021 for standards adopted in 2021.

Recently Issued Accounting Standards Not Yet Adopted

In March 2022, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2022-02, Financial Instruments—Credit Losses (Topic 326): Troubled Debt Restructurings and Vintage Disclosures, an amendment to the accounting for credit losses on financial instruments. This amendment eliminates the recognition and measurement guidance on troubled debt restructurings for creditors that have adopted the new credit losses guidance in Accounting Standards Codification 326 ("ASC 326") and requires enhanced disclosures about loan modifications for borrowers experiencing financial difficulty. The new guidance also requires public business entities to present gross write-offs by year of origination in their

-10-

Notes to Condensed Consolidated Financial Statements (unaudited) (continued)

vintage disclosures. The guidance is effective for the Company on January 1, 2023, including interim periods. Early adoption is permitted, and the amendment applied prospectively, except for the recognition and remeasurement of troubled debt restructurings. Entities can elect to adopt the guidance on troubled debt restructurings using either a prospective or modified retrospective transition. If an entity elects to apply a modified retrospective transition, it will record a cumulative effect adjustment to retained earnings in the period of adoption. The Company does not expect the adoption of this guidance to have a material impact on the Consolidated Financial Statements.

In November 2021, the FASB issued ASU 2021-10, Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance, new guidance requiring disclosures about transactions with a government that have been accounted for by analogizing to a grant or contribution accounting model. The guidance increases transparency about the types of transactions, the accounting for the transactions, and the effect of the transactions to the Company’s financial statements. The guidance is effective for annual periods in 2022 and can be applied on a prospective or retrospective basis. The Company is currently evaluating the impact of adoption on its Consolidated Financial Statements. The Company does not anticipate a material impact to its Consolidated Financial Statements.

In October 2021, the FASB issued ASU 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers, guidance to improve the accounting for contract assets and contract liabilities from acquired revenue contracts with customers in a business combination. The guidance addresses diversity in practice and inconsistency related to the recognition of an acquired contract liability, payment terms and their effect on subsequent revenue recognized by an acquirer. The guidance is effective for the Company on January 1, 2023 and its amendments will be applied prospectively to business combinations occurring on or after the effective date of the guidance. Early adoption is permitted, including adoption in an interim period and subject to different transition requirements. The adoption of this guidance will not have an impact on the Company’s Consolidated Financial Statements for prior acquisitions; however, the impact in future periods will be dependent upon the contract assets and contract liabilities acquired in future business combinations.

In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting, optional guidance to ease the potential burden in accounting for (or recognizing the effects of) reference rate reform on financial reporting and subsequently issued clarifying amendments. The guidance provides optional expedients and exceptions for applying GAAP to contracts, hedging relationships, and other transactions that reference the London Interbank Offered Rate ("LIBOR") or another reference rate expected to be discontinued because of reference rate reform. The optional guidance is effective upon issuance and can be applied on a prospective basis at any time between January 1, 2020 and December 31, 2022. The Company is currently evaluating the impact of adoption on its Consolidated Financial Statements. The Company does not anticipate a material impact to its Consolidated Financial Statements.

3. Samsung Collaboration

The Company has an agreement with Samsung Bioepis Co., Ltd. ("Samsung Bioepis") to develop and commercialize multiple pre-specified biosimilar candidates, which have since launched and are part of the Company’s product portfolio. Under the agreement, Samsung Bioepis is responsible for preclinical and clinical development, process development and manufacturing, clinical trials and registration of product candidates, and the Company has an exclusive license for worldwide commercialization with certain geographic exceptions specified on a product-by-product basis. The Company’s access rights to each product under the agreement last for 10 years from each product’s launch date on a market-by-market basis. Gross profits are shared equally in all markets with the exception of Brazil where gross profits are shared 65% to Samsung Bioepis and 35% to the Company. Since the Company is the principal on sales transactions with third parties, the Company recognizes sales, cost of sales and selling, general and administrative expenses on a gross basis. Generally, profit sharing adjustments are recorded either to Cost of sales (after commercialization) or Selling, general and administrative expenses (prior to commercialization).

In August 2022, the U.S. Food and Drug Administration ("FDA") approved the citrate-free, high-concentration (100 mg/mL) formulation of Hadlima™ (adalimumab-bwwd), a biosimilar referencing Humira® (adalimumab) (trademark of Abbvie Biotechnology Ltd). During the third quarter of 2022, Organon paid Samsung Bioepis $18 million. This amount was recognized as an intangible asset which will be amortized over the estimated useful life of approximately 10 years.

Samsung Bioepis is eligible for additional payments associated with pre-specified clinical and regulatory milestones. As of September 30, 2022, potential future regulatory milestone payments of $25 million remain under the agreement.

-11-

Notes to Condensed Consolidated Financial Statements (unaudited) (continued)

Summarized information related to this collaboration is as follows:

	Three Months Ended September 30,				Nine Months Ended September 30,
($ in millions)	2022		2021		2022		2021
Sales	$	129	$	139	$	346	$	305
Cost of sales	86		83		221		183
Selling, general and administrative	18		18		60		50

($ in millions)	September 30, 2022		December 31, 2021
Receivables from Samsung included in Other current assets	$	10	$	15
Payables to Samsung included in Trade accounts payable	24		21

4. Acquisitions and Licensing Arrangements

Cirqle Biomedical ("Cirqle")

In July 2022, the Company entered into a research collaboration and license agreement with Cirqle for a novel investigational non-hormonal, on-demand contraceptive candidate. Under the terms of the agreement, Cirqle is responsible for conducting preclinical studies according to the mutually agreed research plan. Organon obtained exclusive worldwide rights to develop and commercialize the asset.

Under the terms of the research collaboration and license agreement, Organon expensed a $10 million upfront payment during the third quarter of 2022. Cirqle is eligible to receive potential regulatory and commercial milestone payments of up to $360 million and tiered royalties based on net sales. As of September 30, 2022, the Company recognized the $10 million upfront payment as Acquired in-process research and development and milestones expense. The remaining potential milestone payments will be recognized by Organon when achievement of the contractual milestones is probable.

Shanghai Henlius Biotech, Inc. ("Henlius")

In June 2022, Organon and Henlius, a global biopharmaceutical company, entered into a definitive agreement whereby Organon is licensing commercialization rights for biosimilar candidates referencing Perjeta® (pertuzumab, HLX11), (a trademark of Genentech, Inc.), used for the treatment of certain patients with HER2+ breast cancer in combinations with trastuzumab and chemotherapy and Prolia®/Xgeva® (denosumab, HLX14), (trademarks of Amgen Inc.) used for the treatment of certain patients with osteoporosis with high risk of fracture and for the prevention of skeletal-related events in patients with multiple myeloma and in patients with bone metastasis from solid tumors. Organon obtained exclusive global commercialization rights except for China; including Hong Kong, Macau and Taiwan. The agreement includes an option to negotiate an exclusive license for global commercialization rights for a biosimilar candidate referencing Yervoy® (ipilimumab, HLX13) (a trademark of Bristol-Myers Squibb Company). Ipilimumab is used for the treatment of certain patients with unresectable or metastatic melanoma, as adjuvant treatment of certain patients with cutaneous melanoma, certain patients with renal cell carcinoma, colorectal cancer, hepatocellular carcinoma, non-small cell lung cancer, malignant pleural mesothelioma and esophageal cancer.

Under the terms of the license agreement, Organon paid a $73 million upfront payment during the third quarter of 2022, of which $3 million was reflected in Other current assets. Henlius is eligible to receive potential developmental, regulatory and commercial milestone payments of up to $468 million. During the nine months ended September 30, 2022, the Company paid milestones of $97 million, reflecting a $70 million upfront payment and $27 million related to certain development milestones which were recognized as Acquired in-process research and development and milestones expense during the second quarter of 2022. The remaining potential milestone payments will be recognized by Organon when achievement of the contractual milestones is probable. Henlius will be responsible for development and, if approved, will supply the products to Organon.

-12-

Notes to Condensed Consolidated Financial Statements (unaudited) (continued)

Daré Bioscience, Inc. ("Daré")

In March 2022, Organon and Daré, a leader in women’s health innovation, entered into an agreement whereby Organon licensed the global commercial rights to Xaciato® (clindamycin phosphate vaginal gel, 2%). Xaciato is an FDA-approved medication for the treatment of bacterial vaginosis (BV) in females 12 years of age and older. Xaciato received both Qualified Infectious Disease Product (QIDP) and Fast Track designations from the FDA for the treatment of bacterial vaginosis.

Under the terms of the license agreement, Organon paid a $10 million upfront payment during the third quarter of 2022. Daré is eligible to receive potential regulatory and commercial milestone payments of up to $182.5 million and tiered double-digit royalties based on net sales. Xaciato is expected to be available commercially in the U.S. in the first half of 2023. During the nine months ended September 30, 2022 management determined that the first commercial milestone was deemed probable of occurring, and recognized an intangible asset of $12.5 million reflecting the $10 million upfront payment and $2.5 million commercial milestone. The intangible asset will be amortized over its useful life of 12 years. The remaining potential milestone payments will be recognized by Organon when achievement of the contractual milestones is probable.

Bayer AG

In February 2022, Organon acquired the product rights and related inventory from Bayer AG to Marvelon™ (ethinylestradiol, desogestrel) and Mercilon™ (ethinylestradiol, desogestrel), combined oral hormonal daily contraceptive pills, in China, including Hong Kong and Macau, and entered into an agreement to acquire the rights to these products in Vietnam. Marvelon and Mercilon are already owned, manufactured, and marketed by Organon as prescription oral contraceptives in 20 other markets. The transaction was accounted for as an asset acquisition. In the first quarter of 2022, Organon paid $30 million to acquire the product rights and inventory in China and accrued an additional $35 million related to these rights which was paid during the second quarter of 2022. In the third quarter of 2022, Organon paid $30 million to acquire the product rights in Vietnam. This resulted in Organon recognizing an intangible asset of $72 million in total related to the product rights with the remainder of the consideration recorded to Inventories for the fair value of acquired inventory during 2022. The intangible assets related to currently marketed products will be amortized over their estimated useful lives of 10 years.

Alydia Health

During the three months ended September 30, 2022, a cumulative sales-based contingent milestone payment, related to the Jada system device, was determined to be probable of being achieved and the Company recognized an intangible asset and noncurrent liability of $25 million. The intangible asset is subject to amortization over its expected useful life.

For details regarding Organon's 2021 acquisitions and licensing agreements, see Note 5 to the audited Consolidated Financial Statements in the Company's 2021 Form 10-K.

5. Financial Instruments

Foreign Currency Risk Management

The Company has a balance sheet risk management and a net investment hedging program to mitigate against volatility of changes in foreign exchange rates.

The Company uses a balance sheet risk management program to mitigate the exposure of net monetary assets of its subsidiaries that are denominated in a currency other than a subsidiary’s functional currency from the effects of volatility in foreign exchange. In these instances, Organon principally utilizes forward exchange contracts to offset the effects of exchange on exposures denominated in developed country currencies, primarily the euro, Swiss franc and Japanese yen. For exposures in developing country currencies, the Company enters into forward contracts to partially offset the effects of exchange on exposures when it is deemed economical to do so based on a cost-benefit analysis that considers the magnitude of the exposure, the volatility of the exchange rate and the cost of the hedging instrument.

Monetary assets and liabilities denominated in a currency other than the functional currency of a given subsidiary are remeasured at spot rates in effect on the balance sheet date with the effects of changes in spot rates reported in Other (income) expense, net. The forward contracts are not designated as hedges and are marked to market through Other (income) expense, net. Accordingly, fair value changes in the forward contracts help mitigate the changes in the value of the remeasured assets and liabilities attributable to changes in foreign currency exchange rates, except to the extent of the spot-forward differences. These differences are not significant due to the short-term nature of the contracts, which typically have average maturities at inception of less than one year. The notional amount of forward contracts was $1.3 billion as of September 30, 2022 and $2.1 billion as of

-13-

Notes to Condensed Consolidated Financial Statements (unaudited) (continued)

December 31, 2021. The cash flows from these contracts are reported as operating activities in the Condensed Consolidated Statements of Cash Flows.

The Company measures fair value based on the prices that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value measurements are based on a three-tier hierarchy that prioritizes the inputs used to measure fair value. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs for which little or no market data exists, therefore requiring an entity to develop its own assumptions.

The following financial instruments were recorded at their estimated fair value. The recurring fair value measurement of our assets and liabilities were as follows:

($ in millions)	Fair Value Measurement Level	September 30, 2022		December 31, 2021
Forward contracts in Other current assets	2	$	35	$	19
Forward contracts in Accrued and other current liabilities	2	23		5

Foreign exchange risk is also managed through the use of economic hedges on foreign currency debt (see Note 7). In each quarter subsequent to the Separation, €1.75 billion in the aggregate of both the euro-denominated term loan (€750 million) and of the 2.875% euro-denominated secured notes (€1.25 billion) has been designated and is effective as an economic hedge of the net investment in euro-denominated subsidiaries.

Foreign currency gains due to spot rate fluctuations on the euro-denominated debt instruments included in foreign currency translation adjustments were as follows:

	Three Months Ended September 30,				Nine Months Ended September 30,
($ in millions)	2022		2021		2022		2021
Foreign currency gains in Other comprehensive income	$	176	$	38	$	303	$	94

The Condensed Consolidated Statements of Income include the impact of actual net gains and losses of Organon's derivative financial instruments, as well as the impact of Merck’s derivative financial instruments prior to the Separation allocated to the Company utilizing a proportional allocation method:

	Three Months Ended September 30,				Nine Months Ended September 30,
($ in millions)	2022		2021		2022		2021
Allocated net loss in Revenues	$	—	$	1	$	—	$	56
Foreign exchange loss (gain) in Other expense, net	4		1		(21)		6

Prior to the Separation, Merck managed the impact of foreign exchange rate movements on its affiliates’ earnings, cash flows and fair values of assets and liabilities through operational means and through the use of various financial instruments, including derivative instruments. Merck established revenue hedging and balance sheet risk management programs that the Company participated in to protect against the volatility of future foreign currency cash flows and changes in fair value caused by volatility in exchange rates.

Organon has established accounts receivable factoring agreements with financial institutions in certain countries to sell accounts receivable. Under these agreements, Organon factored $61 million and $87 million of accounts receivable as of September 30, 2022 and December 31, 2021, respectively, which reduced outstanding accounts receivable. The cash received from the financial institutions is reported within operating activities in the Condensed Consolidated Statements of Cash Flows.

-14-

Notes to Condensed Consolidated Financial Statements (unaudited) (continued)

6. Inventories

Inventories consisted of:

($ in millions)	September 30, 2022		December 31, 2021
Finished goods	$	403	$	377
Raw materials	71		95
Work in process	479		490
Supplies	40		40
Total (approximates current cost)	$	993	$	1,002
Decrease to LIFO costs	(18)		(11)
	$	975	$	991
Recognized as:
Inventories	$	879	$	915
Other assets	96		76
Inventories valued under the last in, first out ("LIFO") method	82		52

Amounts recognized as Other assets are comprised primarily of raw materials and work in process inventories and are not expected to be converted to finished goods that will be sold within one year. The Company has a long-term vendor supply contract conveyed as part of the Separation that includes certain annual minimum purchase commitments.

During the third quarter of 2021, the Company recorded $24 million within Other noncurrent liabilities due to estimated unavoidable losses associated with the supply contract. The charge was recognized as a component of Cost of sales during the third quarter of 2021 and the nine months ended September 30, 2021.

7. Long-Term Debt

The following is a summary of Organon's total debt:

($ in millions)	September 30, 2022		December 31, 2021
Term Loan B Facility:
LIBOR plus 300 bps term loan due 2028	$	2,793	$	2,893
LIBOR plus 300 bps euro-denominated term loan due 2028 (€750 million)	708		843
4.125% secured notes due 2028	2,100		2,100
2.875% euro-denominated secured notes due 2028 (€1.25 billion)	1,196		1,412
5.125% notes due 2031	2,000		2,000
Other borrowings	8		10
Other (discounts and debt issuance costs)	(106)		(124)
Total principal long-term debt	$	8,699	$	9,134
Less: Current portion of long-term debt	8		9
Total Long-term debt, net of current portion	$	8,691	$	9,125

Other borrowings represent debt assumed in connection with the acquisition of Forendo Pharma in December 2021.

In June 2021, the Company entered into a credit agreement (the “Senior Credit Agreement”) providing for a Term Loan B Facility, consisting of (i) a U.S. Dollar-denominated senior secured “tranche B” term loan in the amount of $3.0 billion due 2028 (ii) a euro-denominated senior secured “tranche B” term loan in the amount of €750 million due 2028; and (iii) a Revolving Credit Facility (“Revolving Credit Facility”), in an aggregate principal amount of up to $1 billion, with a five-year term that matures in 2026.

-15-

Notes to Condensed Consolidated Financial Statements (unaudited) (continued)

The interest rate on revolving loans under the Revolving Credit Facility is subject to a step-down based on meeting a leverage ratio target. A commitment fee applies to the unused portion of the Revolving Credit Facility, initially equal to 0.50% and subject to a step-down to 0.375% based on meeting a leverage ratio target. There were no outstanding balances under the Revolving Credit Facility as of September 30, 2022 or December 31, 2021.

Long-term debt was recorded at the carrying amount. The estimated fair value of long-term debt (including current portion) is as follows:

($ in millions)	September 30, 2022		December 31, 2021
Long-term debt (includes a reduction for amortized debt issuance costs)	$	7,772	$	9,412

Fair value was estimated using inputs other than quoted prices in active markets for identical assets and liabilities that are observable either directly or indirectly for substantially the full term of the asset or liability and would be considered Level 2 in the fair value hierarchy.

The Company made interest payments of $218 million for the nine months ended September 30, 2022 related to its debt instruments. The average maturity of the Company's long-term debt as of September 30, 2022 is approximately 6.3 years and the weighted-average interest rate on total borrowings as of September 30, 2022 is 4.5%.

On June 6, 2022, the Company made a discretionary prepayment of $100 million on the U.S. Dollar-denominated term loan.

The schedule of principal payments required on long-term debt for the next five years and thereafter is as follows:

($ in millions)
2022	$	2
2023	8
2024	8
2025	8
2026	11
Thereafter	8,768

The Senior Credit Agreement contains customary financial covenants, including a total leverage ratio covenant, which measures the ratio of (i) consolidated total debt to (ii) consolidated earnings before interest, taxes, depreciation and amortization, and subject to other adjustments, that must meet certain defined limits which are tested on a quarterly basis. In addition, the Senior Credit Agreement contains covenants that limit, among other things, Organon’s ability to prepay, redeem or repurchase its subordinated and junior lien debt, incur additional debt, make acquisitions, merge with other entities, pay dividends or distributions, redeem or repurchase equity interests, and create or become subject to liens. As of September 30, 2022, the Company is in compliance with all financial covenants and no default or event of default has occurred.

8. Contingencies

Organon is involved in various claims and legal proceedings of a nature considered normal to its business, including product liability, intellectual property, and commercial litigation, as well as certain additional matters including governmental and environmental matters. In the opinion of Organon as of September 30, 2022, it is unlikely that the resolution of these matters will be material to Organon's financial condition, results of operations or cash flows.

Given the nature of the litigation discussed in this note and the complexities involved in these matters, Organon is unable to reasonably estimate a possible loss or range of possible loss for such matters until Organon knows, among other factors, (i) what claims, if any, will survive dispositive motion practice, (ii) the extent of the claims, including the size of any potential class, particularly when damages are not specified or are indeterminate, (iii) how the discovery process will affect the litigation, (iv) the settlement posture of the other parties to the litigation, and (v) any other factors that may have a material effect on the litigation.

Organon records accruals for contingencies when it is probable that a liability has been incurred and the amount can be reasonably estimated. These accruals are adjusted periodically as assessments change or additional information becomes available. Individually significant contingent losses are accrued when probable and reasonably estimable. Legal defense costs expected to be incurred in connection with a loss contingency are accrued when probable and reasonably estimable.

-16-

Notes to Condensed Consolidated Financial Statements (unaudited) (continued)

Organon's decision to obtain insurance coverage is dependent on market conditions, including cost and availability, existing at the time such decisions are made. Organon has evaluated its risks and has determined that the cost of obtaining product liability insurance outweighs the likely benefits of the coverage that is available and, as such, has no insurance for most product liabilities.

Reference is made below to certain litigation in which Merck, but not Organon, is named as a defendant. Pursuant to the Separation and Distribution Agreement, Organon is required to indemnify Merck for liabilities relating to, arising from, or resulting from such litigation.

Product Liability Litigation

Fosamax

Merck is a defendant in product liability lawsuits in the United States involving Fosamax® (alendronate sodium) (the "Fosamax Litigation"). As of September 30, 2022, approximately 3,285 cases comprising the Fosamax Litigation are pending against Merck in either federal or state court. Plaintiffs in the vast majority of these cases generally allege that they sustained femur fractures and/or other bone injuries ("Femur Fractures") in association with the use of Fosamax.

All federal cases involving allegations of Femur Fractures have been or will be transferred to a multidistrict litigation in the District of New Jersey ("Femur Fracture MDL"). In the only bellwether case tried to date in the Femur Fracture MDL, Glynn v. Merck, the jury returned a verdict in Merck's favor. In addition, in June 2013, the Femur Fracture MDL court granted Merck's motion for judgment as a matter of law in the Glynn case and held that the plaintiff's failure to warn claim was preempted by federal law.

In August 2013, the Femur Fracture MDL court entered an order requiring plaintiffs in the Femur Fracture MDL to show cause why those cases asserting claims for a femur fracture injury that took place prior to September 14, 2010, should not be dismissed based on the court's preemption decision in the Glynn case. Pursuant to the show cause order, in March 2014, the Femur Fracture MDL court dismissed with prejudice approximately 650 cases on preemption grounds. Plaintiffs in approximately 515 of those cases appealed that decision to the U.S. Court of Appeals for the Third Circuit ("Third Circuit"). In March 2017, the Third Circuit issued a decision reversing the Femur Fracture MDL court's preemption ruling and remanding the appealed cases back to the Femur Fracture MDL court. In May 2019, the U.S. Supreme Court decided that the Third Circuit had incorrectly concluded that the issue of preemption should be resolved by a jury, and accordingly vacated the judgment of the Third Circuit and remanded the proceedings back to the Third Circuit to address the issue in a manner consistent with the Supreme Court's opinion. In November 2019, the Third Circuit remanded the cases back to the District Court in order to allow that court to determine in the first instance whether the plaintiffs' state law claims are preempted by federal law under the standards described by the Supreme Court in its opinion. On March 23, 2022, the District Court granted Merck's motion and ruled that plaintiffs' failure to warn claims are preempted as a matter of law to the extent they assert that Merck should have added a Warning or Precaution regarding atypical femur fractures prior to October 2010. On July 11, 2022, the District Court entered an Order to Show Cause as to why the Court should not dismiss either with prejudice or conditionally all of plaintiffs' claims that are not dependent on the preempted failure to warn claims.

Accordingly, as of September 30, 2022, approximately 975 cases were actively pending in the Femur Fracture MDL.

As of September 30, 2022, approximately 2,030 cases alleging Femur Fractures have been filed in New Jersey state court and are pending in Middlesex County. The parties selected an initial group of cases to be reviewed through fact discovery, and Merck has continued to select additional cases to be reviewed.

As of September 30, 2022, approximately 275 cases alleging Femur Fractures have been filed and are pending in California state court. All of the Femur Fracture cases filed in California state court have been coordinated before a single judge in Orange County, California.

Additionally, there are four Femur Fracture cases pending in other state courts.

Discovery is presently stayed in the Femur Fracture MDL and in the state court in California.

-17-

Notes to Condensed Consolidated Financial Statements (unaudited) (continued)

Nexplanon/Implanon

Merck is a defendant in lawsuits brought by individuals relating to the use of Nexplanon and Implanon™ (etonogestrel implant). In the United States, as of September 30, 2022, there was one filed product liability action involving Nexplanon pending in the Western District of Arkansas (in which Organon is also named as a defendant). The court's schedule for the matter provides for a trial date in the fourth quarter of 2023, should it be necessary. In addition, there were two filed product liability actions involving Implanon, both of which are pending in the Northern District of Ohio as well as 56 unfiled cases involving Implanon alleging similar injuries, which have been tolled under a written tolling agreement. As of September 30, 2022, Merck had 18 cases pending outside the United States, of which 12 relate to Implanon and six relate to Nexplanon.

Propecia/Proscar

Merck is a defendant in product liability lawsuits in the United States involving Propecia® (finasteride) and/or Proscar® (finasteride). The federal lawsuits were consolidated for pretrial purposes in federal multidistrict litigation in the Eastern District of New York (the "MDL"), and the matters in state court in New Jersey were consolidated in Middlesex County ("N.J. Coordinated Proceedings"). In 2018, Merck and the plaintiffs' Executive Committee in the MDL and the plaintiffs' Liaison Counsel in the N.J. Coordinated Proceedings entered into an agreement to resolve the lawsuits for an aggregate amount of $4.3 million. The settlement was subject to certain contingencies, including 95% plaintiff participation and a per plaintiff clawback if the participation rate was less than 100%. The contingencies were satisfied and the settlement agreement has been finalized.

As of September 30, 2022, only three cases remain pending in the United States, (1) a case currently pending in the MDL; (2) a matter involving Propecia in state court in Los Angeles, California in which Merck's motion for summary judgment was granted and subsequently appealed; and (3) a matter involving Proscar in the United States District Court for the Eastern District of California in which Merck's motion to dismiss was granted by the District Court. In the Propecia case in the MDL, the Court granted Merck's motion for partial summary judgment on September 8, 2022. In the Proscar case, the plaintiff can appeal the decision. The Company is also defending 16 product liability cases outside the United States, two of which are class actions and four of which are putative class actions.

Governmental Proceedings

From time to time, Organon's subsidiaries may receive inquiries and may be the subject of preliminary investigation activities from competition and/or other governmental authorities, including in markets outside the United States. These authorities may include regulators, administrative authorities, and law enforcement and other similar officials, and these preliminary investigation activities may include site visits, formal or informal requests or demands for documents or materials, inquiries or interviews and similar matters. Certain of these preliminary inquiries or activities may lead to the commencement of formal proceedings. Should those proceedings be determined adversely to Organon, monetary fines and/or remedial undertakings may be required. Subject to certain exceptions specified in the Separation and Distribution Agreement, Organon assumed liability for all pending and threatened legal matters related to products transferred to Organon, including competition investigations resulting from enforcement activity concerning Merck's conduct involving Organon's products. Organon could be obligated to indemnify Merck for fines or penalties, or a portion thereof, resulting from such investigations. In one such enforcement matter in Spain concerning NuvaRing® (etonogestrel/ethinyl estradiol vaginal ring), the National Commission on Markets and Competition (CNMC) recently imposed a fine on Merck in the amount of €39 million for abuse of a dominant position in the market for contraceptive vaginal rings from June 2017 to April 2018. The CNMC decision to impose the fine is appealable to the National High Court in Spain. If the fine ultimately stands, Organon could be obligated to indemnify Merck for a portion thereof.

Hadlima™ (adalimumab-bwwd)

In July 2021, Organon received a Civil Investigation Demand ("CID") from the Office of the Attorney General for the State of Washington. The CID requests answers to interrogatories, as well as various documents, regarding certain activities related to adalimumab and adalimumab biosimilars. Organon is cooperating with the government's investigation and has produced information in response to the CID.

-18-

Notes to Condensed Consolidated Financial Statements (unaudited) (continued)

Patent Litigation

From time to time, generic manufacturers of pharmaceutical products file Abbreviated New Drug Applications ("ANDAs") with the U.S. Food and Drug Administration ("FDA") seeking to market generic forms of Organon's products prior to the expiration of relevant patents owned by Organon. To protect its patent rights, Organon may file patent infringement lawsuits against such generic companies. Similar lawsuits defending Organon's patent rights may exist in other countries. Organon intends to vigorously defend its patents, which it believes are valid, against infringement by companies attempting to market products prior to the expiration of such patents. As with any litigation, there can be no assurance of the outcomes, which, if adverse, could result in significantly shortened periods of exclusivity for these products, potential payment of damages and legal fees, and, with respect to products acquired through acquisitions, potentially significant intangible asset impairment charges.

Nexplanon

In June 2017, Microspherix LLC ("Microspherix") sued Organon in the U.S. District Court for the District of New Jersey asserting that the manufacturing, use, sale and importation of Nexplanon infringed several of Microspherix's patents that claim radio-opaque, implantable drug delivery devices. Microspherix is claiming damages from September 2014 until the patents expired in May 2021. Organon brought Inter Partes Review ("IPR") proceedings in the United States Patent and Trademark Office ("USPTO") and successfully stayed the district court action. The USPTO invalidated some, but not all, of the claims asserted against Organon. Organon appealed the decisions that found claims valid, and the Court of Appeals for the Federal Circuit affirmed the USPTO's decisions. The matter is no longer stayed in the district court, and Organon is currently litigating the invalidity and non-infringement of the remaining asserted claims. A claim construction hearing was held on March 2, 2022, and any further dates in the schedule will be set based on the date the court issues a claim construction order.

Other Litigation

There are various other pending legal proceedings involving Organon, principally product liability and intellectual property lawsuits. While it is not feasible to predict the outcome of such proceedings, in the opinion of Organon as of September 30, 2022, either the likelihood of loss is remote or any reasonably possible loss associated with the resolution of such proceedings is not expected to be material to Organon's financial condition, results of operations or cash flows either individually or in the aggregate.

Legal Defense Reserves

Legal defense costs expected to be incurred in connection with a loss contingency are accrued when probable and reasonably estimable. Some of the significant factors considered in the review of these legal defense reserves are as follows: the actual costs incurred by Organon; the development of Organon's legal defense strategy and structure in light of the scope of its litigation; the number of cases being brought against Organon; and the costs and outcomes of completed trials and the most current information regarding anticipated timing, progression, and related costs of pre-trial activities and trials in the associated litigation. The legal defense reserve as of September 30, 2022 and December 31, 2021 was $15 million and $9 million, respectively, and represented Organon's best estimate of the minimum amount of defense costs to be incurred in connection with its outstanding litigation; however, events such as additional trials and other events that could arise in the course of its litigation could affect the ultimate amount of legal defense costs to be incurred by Organon. Organon will continue to monitor its legal defense costs and review the adequacy of the associated reserves and may determine to increase the reserves at any time in the future if, based upon the factors set forth, it believes it would be appropriate to do so.

9. Stock-Based Compensation Plans

The Company grants stock option awards, performance share units ("PSUs") and restricted share units ("RSUs") pursuant to its 2021 Incentive Stock Plan.

Employee stock options are granted to purchase shares of Company stock at the fair market value at the time of grant. Generally, stock options have a contractual term of ten years and vest one-third each year over a three-year period, subject to limited exceptions.

RSUs are stock awards that are granted to employees and entitle the holder to shares of common stock as the awards vest. RSU awards generally vest one-third each year over a three-year period. The fair value of the stock option and RSU awards is determined and fixed on the grant date based on the Company’s stock price.

-19-

Notes to Condensed Consolidated Financial Statements (unaudited) (continued)

The terms of the Company's PSU awards allow the recipients of such awards to earn a variable number of common shares based on the cumulative results of specified performance factors. The Company has PSU awards based on the following performance factors:

•total stockholder return of the Company relative to an index of peer companies ("relative TSR") specified in the awards

•the results of the cumulative free cash flow ("FCF") of the Company over a three year period

For FCF and TSR awards, the Company recognizes compensation costs ratably over the performance period. The PSU Awards will generally vest at the end of the three year performance period, however, the number of shares delivered will vary based upon the attained level of performance. For PSUs with a performance-based FCF goal, stock-based compensation expense is recognized based on the probability of the achievement of the financial performance metric for the respective vesting period and is assessed at each reporting date. For PSUs with a market-based relative TSR goal, stock-based compensation expense is recognized based on the estimated fair value of the award at the grant date regardless of the actual number of shares earned. PSU awards generally vest after three years.

For RSUs and PSUs, dividends declared during the vesting period are payable to the employees only upon vesting. RSU and PSU distributions will be in shares of Company stock after the end of the vesting or performance period, subject to the terms applicable to such awards.

Stock-based compensation expense incurred by the Company was as follows:

	Three Months Ended September 30,				Nine Months Ended September 30,
($ in millions)	2022		2021		2022		2021
Stock-based compensation expense recognized in:
Cost of sales	$	3	$	3	$	9	$	8
Selling, general and administrative	12		10		35		26
Research and development	3		2		8		10
Income tax benefits	3		3		11		9

The Company used the Black-Scholes model to determine the fair value of the stock options as of the grant date using the following assumptions:

	Nine Months Ended September 30,
	2022
Expected dividend yield	3.12	%
Risk-free interest rate	2.47	%
Expected volatility	43.43	%
Expected life (years)	5.89

-20-

Notes to Condensed Consolidated Financial Statements (unaudited) (continued)

A summary of the equity award transactions for the nine months ended September 30, 2022 are as follows:

	Stock Options					Restricted Share Units			Performance Share Units
(shares in thousands)	Shares	Weighted average exercise price		Weighted average grant date fair value		Shares	Weighted average grant date fair value		Shares	Weighted average grant date fair value
Outstanding as of January 1, 2022	4,394	$	34.35	$	8.63	3,280	$	36.69	120	$	51.63
Granted	556	$	34.93	$	11.34	2,299	$	34.87	373	$	45.23
Vested/Exercised	(15)	$	37.39	$	9.72	(1,251)	$	37.50	—	$	—
Forfeited/Cancelled	(160)	$	35.72	$	9.70	(242)	$	35.76	(7)	$	51.63
Outstanding as of September 30, 2022	4,775	$	34.36	$	8.91	4,086	$	35.48	486	$	46.72

The following table summarizes information about equity awards outstanding that are vested and expected to vest and equity awards outstanding that are exercisable as of September 30, 2022:

	Equity Awards Vested and Expected to Vest						Equity Awards That are Exercisable
(shares in thousands; aggregate intrinsic value in millions)	Awards	Weighted Average Exercise Price		Aggregate Intrinsic Value		Remaining Term	Awards	Weighted Average Exercise Price		Aggregate Intrinsic Value		Remaining Term
Stock Options	4,585	$	34.36	$	—	7.48	2,429	$	32.98	$	—	6.23
Restricted Share Units	3,781			96		2.03
Performance Share Units	402			11		2.63

The amount of unrecognized compensation costs as of September 30, 2022 was $145 million, which will be recognized in operating expense ratably over the weighted average vesting period of 2.08 years.

10. Taxes on Income

The effective income tax rates were 19.6% and 17.1% for the three months ended September 30, 2022 and 2021, respectively, and 20.0% and 11.2% for the nine months ended September 30, 2022 and 2021, respectively. These effective income tax rates reflect the beneficial impact of foreign earnings, offset by the impact of U.S. inclusions under the Global Intangible Low-Taxed Income regime. The effective income tax rate for the first nine months of 2021 reflects the beneficial impact of foreign earnings, a $70 million tax benefit relating to a portion of the non-U.S. step-up of tax basis as well as the income tax benefit recognized in connection with the conclusion of the Internal Revenue Service (IRS) examination of Merck’s 2015-2016 U.S. federal income tax returns. As a result, the Company reflected an allocation from Merck of $18 million representing the Company's portion of the payment made to the IRS in the Condensed Consolidated Financial Statements. The Company's portion of reserves for unrecognized tax benefits for the years under examination exceeded the allocated adjustments relating to this examination period and therefore the Company included a $29 million net tax benefit also included in the nine months ended September 30, 2021. This net benefit reflects reductions in reserves for unrecognized tax benefits and other related liabilities for tax positions relating to the years that were under examination.

On August 16, 2022, the U.S. enacted the Inflation Reduction Act of 2022. Provisions of the bill that relate to tax include the minimum tax on book income, a 1% excise tax on stock buybacks and certain tax incentives to promote clean energy. There are no impacts of the legislation to the third quarter 2022 results. The Company is currently assessing future impacts of this recently enacted legislation.

-21-

Notes to Condensed Consolidated Financial Statements (unaudited) (continued)

11. Other Comprehensive Income (Loss)

Changes in Accumulated other comprehensive loss (income) by component are as follows:

($ in millions)	Employee Benefit Plans		Cumulative Translation Adjustment		Accumulated Other Comprehensive Loss
Balance at July 1, 2021, net of taxes	$	(26)	$	(438)	$	(464)
Other comprehensive loss, pretax	(3)		(23)		(26)
Tax	—		—		—
Other comprehensive loss, net of taxes	(3)		(23)		(26)
Transfer of benefit plans from Merck affiliates	(3)		—		(3)
Balance at September 30, 2021, net of taxes	$	(32)	$	(461)	$	(493)
Balance at July 1, 2022, net of taxes	$	(13)	$	(576)	$	(589)
Other comprehensive loss, pretax	—		(97)		(97)
Tax	—		—		—
Other comprehensive loss, net of taxes	—		(97)		(97)
Balance at September 30, 2022, net of taxes	$	(13)	$	(673)	$	(686)

($ in millions)	Employee Benefit Plans		Cumulative Translation Adjustment		Accumulated Other Comprehensive (Loss) Income
Balance at January 1, 2021, net of taxes	$	(32)	$	(590)	$	(622)
Other comprehensive (loss) income, pretax	(1)		129		128
Tax	(10)		—		(10)
Other comprehensive (loss) income, net of taxes	(11)		129		118
Transfer of benefit plans to/from Merck affiliates	11		—		11
Balance at September 30, 2021, net of taxes	$	(32)	$	(461)	$	(493)
Balance at January 1,2022, net of taxes	$	(13)	$	(500)	$	(513)
Other comprehensive loss, pretax	(1)		(173)		(174)
Tax	1		—		1
Other comprehensive loss, net of taxes	—		(173)		(173)
Balance at September 30, 2022, net of taxes	$	(13)	$	(673)	$	(686)

-22-

Notes to Condensed Consolidated Financial Statements (unaudited) (continued)

12. Product and Geographic Information

The Company’s operations include the following product portfolios, which constitute one operating segment engaged in developing and delivering innovative health solutions through its portfolio of prescription therapies within women’s health, biosimilars and established brands.

Revenues of the Company’s products were as follows:

	Three Months Ended September 30,												Nine Months Ended September 30,
	2022						2021						2022						2021
($ in millions)	U.S.		Int’l		Total		U.S.		Int’l		Total		U.S.		Int’l		Total		U.S.		Int’l		Total
Women’s Health
Nexplanon/Implanon NXT	$	151	$	78	$	229	$	120	$	55	$	175	$	401	$	194	$	595	$	389	$	154	$	543
Follistim AQ	27		33		60		29		32		61		79		100		179		81		97		178
NuvaRing	27		23		50		21		28		49		65		68		133		68		79		147
Ganirelix Acetate Injection	6		30		36		5		20		25		20		77		97		19		66		85
Cerazette	—		15		15		—		18		18		—		47		47		—		53		53
Other Women's Health (1)	24		39		63		18		35		53		80		108		188		80		111		191
Biosimilars
Renflexis	54		7		60		48		6		54		145		20		166		119		17		136
Ontruzant	15		14		29		9		47		56		35		52		87		20		81		101
Brenzys	—		24		24		—		14		14		—		52		52		—		35		35
Aybintio	—		10		10		—		10		10		—		29		29		—		26		26
Hadlima	—		6		6		—		5		5		—		14		14		—		9		9
Established Brands
Cardiovascular
Zetia	2		85		87		1		90		91		7		280		287		6		276		282
Vytorin	1		30		31		3		38		41		6		98		104		8		119		127
Atozet	—		109		109		—		114		114		—		350		350		—		347		347
Rosuzet	—		17		17		—		15		15		—		55		55		—		48		48
Cozaar/Hyzaar	2		68		70		3		84		87		11		244		256		9		256		265
Other Cardiovascular (1)	1		34		35		1		48		49		3		117		120		3		145		148
Respiratory
Singulair	3		92		94		2		98		100		8		308		316		10		289		300
Nasonex	—		49		49		—		49		48		9		173		182		3		141		144
Dulera	31		9		40		48		8		56		98		30		127		121		25		146
Clarinex	—		25		26		2		27		28		3		96		99		5		78		83
Other Respiratory (1)	11		10		21		14		5		18		34		32		66		43		20		64
Non-Opioid Pain, Bone and Dermatology
Arcoxia	—		64		64		—		65		65		—		185		185		—		184		184
Fosamax	1		35		36		1		45		46		2		115		117		3		130		132
Diprospan	—		28		28		—		34		34		—		91		91		—		92		92
Other Non-Opioid Pain, Bone and Dermatology (1)	2		63		65		9		69		79		10		200		210		12		201		213
Other
Proscar	—		26		27		—		27		27		1		76		77		1		91		92
Propecia	2		28		30		1		33		34		5		90		95		5		96		101
Other (1)	6		81		87		10		83		95		21		230		251		32		230		262
Other (2)	—		39		39		1		51		52		—		115		116		(2)		171		168
Revenues	$	366	$	1,171	$	1,537	$	346	$	1,254	$	1,600	$	1,043	$	3,646	$	4,689	$	1,035	$	3,666	$	4,701

Totals may not foot due to rounding. Trademarks appearing above in italics are trademarks of, or are used under license by, the Organon group of companies.

(1) Includes sales of products not listed separately. Revenue from an arrangement for the sale of generic etonogestrel/ethinyl estradiol vaginal ring is included in Other Women's Health.

(2) Includes manufacturing sales to Merck and third parties for current and prior periods and allocated amounts from revenue hedging activities through the date of Separation.

-23-

Notes to Condensed Consolidated Financial Statements (unaudited) (continued)

Revenues by geographic area where derived are as follows:

	Three Months Ended September 30,				Nine Months Ended September 30,
($ in millions)	2022		2021		2022		2021
Europe and Canada	$	363	$	410	$	1,243	$	1,314
United States	366		346		1,043		1,035
Asia Pacific and Japan	283		287		888		874
China	241		252		721		693
Latin America, Middle East, Russia and Africa	236		238		665		595
Other (1)	48		67		129		190
Revenues	$	1,537	$	1,600	$	4,689	$	4,701

(1) Primarily reflects manufacturing sales to Merck and third parties for current and prior periods and allocated amounts from revenue hedging activities through the date of Separation.

13. Third Party Arrangements and Related Party Disclosures

Pursuant to the Separation, Merck ceased to be a related party to Organon and accordingly, no related party transactions or balances have been reported since June 2, 2021.

In connection with the Separation, the Company entered into the Separation and Distribution Agreement, which contains provisions that, among other things, relate to (i) assets, liabilities and contracts to be transferred, assumed and assigned to each of Organon and Merck as part of the Separation, (ii) cross-indemnities principally designed to place financial responsibility for the obligations and liabilities of the Organon business with Organon and financial responsibility for the obligations and liabilities of Merck’s remaining business with Merck, (iii) procedures with respect to claims subject to indemnification and related matters, (iv) the allocation between Organon and Merck of rights and obligations under existing insurance policies with respect to occurrences prior to completion of the Distribution, as well as the right to proceeds and the obligation to incur certain deductibles under certain insurance policies, and (v) procedures governing Organon’s and Merck’s obligations and allocations of liabilities with respect to ongoing litigation matters that may implicate each of Merck’s business and Organon’s business.

Organon entered into other agreements with Merck that govern aspects of Organon’s relationship with Merck following the Separation, including the Transition Services Agreement, Interim Operating Model Agreements ("IOM") agreements, Manufacturing and Supply Agreement, Tax Matters Agreement, Employee Matters Agreement as well as Intellectual Property License Agreements and Regulatory Agreements. For the three and nine months ended September 30, 2022, material transactions occurred in connection with the IOM agreements. For details on the rights and responsibilities of the parties under the IOM agreements, refer below; for all other agreements refer to Note 19 to the audited Consolidated Financial Statements in the Company's 2021 Form 10-K.

•IOM agreements - Merck and Organon entered into a series of IOM agreements pursuant to which Merck and certain of its affiliates that held licenses, permits and other rights in connection with marketing, import and/or distribution of Organon products in various jurisdictions prior to the Separation, will continue to market, import and distribute such products until such time as the relevant licenses and permits are transferred to Organon or its affiliates, while permitting Organon (or Merck, as applicable) to recognize revenue relating to the sale of its respective products, to the extent practicable. Under such IOM agreements and in accordance with the Separation and Distribution Agreement, the relevant Merck entity will continue operations in the affected market on behalf of Organon, with Organon receiving all of the economic benefits and burdens of such activities. Organon began receiving these economic benefits as of June 2, 2021. Based on the terms of the IOM agreements, the Company determined it is the Principal under these arrangements. Organon holds all risks and rewards of ownership inclusive of risk of loss, market risk and benefits related to the inventory. Additionally, Organon has latitude in pricing, has the ability to direct Merck regarding decisions over inventory, and is responsible for all credit and collections risks and losses associated with the related receivables. As such, Organon recognizes these sales on a gross basis.

-24-

Notes to Condensed Consolidated Financial Statements (unaudited) (continued)

The amounts due under such agreements were:

($ in millions)	September 30, 2022		December 31, 2021
Due from Merck in Accounts receivable	$	412	$	403
Due to Merck in Accounts payable	623		928

Sales and cost of sales resulting from the manufacturing and supply agreements with Merck were:

	Three Months Ended September 30,				Nine Months Ended September 30,
($ in millions)	2022		2021		2022		2021
Sales	$	38	$	41	$	104	$	54
Cost of sales	31		35		91		48

Prior to the Separation, the Company did not operate as a standalone business and the Condensed Consolidated Financial Statements were derived from the consolidated financial statements and accounting records of Merck. The following disclosure summarizes activity between the Company and Merck up to the Separation, including the affiliates of Merck that were not part of the Separation.

Cost allocations from Merck

Merck provided significant corporate, manufacturing, selling, marketing, administrative, research services and resources to the Company. The Condensed Consolidated Financial Statements reflect an allocation of these costs. Some of these services continue to be provided by Merck to the Company on a temporary basis under the Transition Services Agreement. The allocations reflected in the Condensed Consolidated Statements of Income for continuing operations are as follows:

	Nine Months Ended September 30,
($ in millions)	2021
Cost of sales	$	69
Selling, general and administrative	134
Research and development	35
	$	238

Management believes these cost allocations are a reasonable reflection of the utilization of services provided to, or the benefit derived by, the Company during the periods presented. The allocations may not, however, be indicative of the actual expenses that would have been incurred had the Company operated as a standalone public company at the time. Actual costs that may have been incurred if the Company had been a standalone public company would depend on a number of factors, including the chosen organizational structure, whether functions were outsourced or performed by the Company’s employees and strategic decisions made in areas such as manufacturing, selling, information technology and infrastructure.

-25-

Notes to Condensed Consolidated Financial Statements (unaudited) (continued)

Related party transactions

The following transactions represent activity between Organon Entities and Transferred Entities with other Merck affiliates prior to the Separation:

	Nine Months Ended September 30,
($ in millions)	2021
Included in continuing operations
Supply sales to Merck affiliates	$	143
Purchases from Merck affiliates	65
Cost reimbursements and fees from Merck affiliates	1
Included in discontinued operations
Supply sales to Merck affiliates	$	12
Purchases from Merck affiliates	53

Net transfers to Merck & Co., Inc.

Prior to the Separation, net transfers to Merck were included within Net investment from Merck & Co., Inc. on the Condensed Consolidated Statement of Equity and represent the net effect of transactions between the Company and Merck. The components of Net transfers to Merck & Co., Inc. for the nine months ended September 30, 2021 were as follows:

	Nine Months Ended September 30,
($ in millions)	2021 (1)
Cash pooling and general financing activities	$	168
Cost allocations, excluding non-cash stock-based compensation	(209)
Taxes deemed settled with Merck	(259)
Allocated derivative and hedging (losses) gains	(88)
Net transfers (from) to Merck & Co., Inc. as reflected in the Condensed Consolidated Statement of Cash Flows for Continuing Operations (2)	$	(388)
Net transfers to (from) Merck included in Net Cash Provided by (Used in) Discontinued Operations	597
Total net transfers to Merck as included in the Condensed Consolidated Statement of Cash Flows	$	209
Stock-based compensation expense (includes $3 of discontinued operations for the nine months ended September 30, 2021)	(32)
Net assets contributed by Merck affiliates	(778)
Derecognition of amounts in Accumulated other comprehensive loss related to employee benefit plan transfers to Merck affiliates	13
Net transfers (from) to Merck & Co., Inc. as reflected in the Condensed Consolidated Statement of Equity	$	(588)

(1) Amounts represent activity through the date of the Separation.

(2) Net transfers (from) to Merck & Co., Inc. as reflected in the Condensed Consolidated Statement of Cash Flows for Continuing Operations for the nine months ended September 30, 2021 include Separation adjustments of $66 million, identified after the date of the Separation.

Prior to the Separation, transfers between the Organon Entities, the Transferred Entities and Merck affiliates were recognized in Net transfers to Merck & Co., Inc. in the Condensed Consolidated Statement of Equity at Merck’s historical cost. Additionally, in connection with the Separation, certain assets and liabilities included in the pre-Separation balance sheet were retained by Merck and certain assets and liabilities not included in the pre-Separation balance sheet were transferred to Organon. Adjustments for transfers are reflected in the Company's Condensed Consolidated Financial Statements for the three and nine months ended September 30, 2021.

-26-

Notes to Condensed Consolidated Financial Statements (unaudited) (continued)

14. Discontinued Operations

In contemplation of the Separation, the Merck Retained Products business in the Transferred Entities was distributed to Merck affiliates and, accordingly, the historical results of operations, assets and liabilities, and the cash flows of the Merck Retained Products for such Transferred Entities are reflected as discontinued operations.

The components of Income (loss) from discontinued operations, net of tax for the Merck Retained Products business are as follows:

	Nine Months Ended September 30,
($ in millions)	2021
Sales	$	93
Costs, Expenses and Other
Cost of Sales	65
Selling, general and administrative	15
Research and development	4
Other (income) expense, net	4
Income from discontinued operations before taxes	$	5
Taxes on income	5
Income from discontinued operations, net of taxes	$	—

Discontinued operations include related party sales of $12 million for the nine months ended September 30, 2021. Costs for inventory purchases from related parties were $53 million for the nine months ended September 30, 2021.

15. Earnings per Share ("EPS")

On June 2, 2021, the date of the Separation, 253,516,000 shares of the Common Stock were distributed to Merck stockholders of record as of the Record Date. This share amount is utilized for the calculation of basic and diluted earnings per share for all periods presented prior to the Separation. For the three and nine months ended September 30, 2021, these shares are treated as issued and outstanding as of January 1, 2021 for purposes of calculating historical basic and diluted earnings per share.

Prior to the Separation, certain of the Company's employees participated in stock-based compensation plans sponsored by Merck. Under these plans employees were granted stock options, PSU's, and RSU's. On June 2, 2021, and in accordance with the Employee Matters Agreement, all Merck stock options, PSU's and RSU's were converted using the conversion ratios set forth in the Employee Matters Agreement. Merck stock options, PSU's and RSUs were converted into Organon stock option awards and RSUs. Awards were equitably adjusted to reflect the spin-off and to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments.

-27-

Notes to Condensed Consolidated Financial Statements (unaudited) (continued)

The calculation of basic and diluted earnings per common share for the three and nine months ended September 30, 2022 and 2021 was as follows:

	Three Months Ended September 30,				Nine Months Ended September 30,
($ in millions and shares in thousands, except per share amounts)	2022		2021		2022		2021
Net income:
Income from continuing operations	$	227	$	323	$	809	$	1,149
Income from discontinued operations	—		—		—		—
Net income	$	227	$	323	$	809	$	1,149
Basic weighted average number of shares outstanding	254,348		253,534		253,986		253,530
Stock awards and equity units (share equivalent)	719		638		1,108		481
Diluted weighted average common shares outstanding	255,067		254,172		255,094		254,011
Earnings per Share - Basic:
Continuing operations	$	0.89	$	1.27	$	3.19	$	4.53
Discontinued operations	—		—		—		—
Net Earnings per Share - Basic	$	0.89	$	1.27	$	3.19	$	4.53
Earnings per Share - Diluted:
Continuing operations	$	0.89	$	1.27	$	3.17	$	4.52
Discontinued operations	—		—		—		—
Net Earnings per Share - Diluted	$	0.89	$	1.27	$	3.17	$	4.52
Anti-dilutive shares excluded from the calculation of EPS	6,313		4,800		4,432		5,015

For periods prior to the Separation, it is assumed that there were no dilutive equity instruments as there were no equity awards of Organon outstanding prior to the Separation.

For periods subsequent to the Separation and the Distribution, diluted earnings per share is computed by giving effect to all potentially dilutive stock awards that are outstanding. The computation of diluted earnings per share excludes the effect of the potential exercise of stock-based awards, when the effect of the potential exercise would be anti-dilutive. The weighted-average number of common shares outstanding for basic and diluted earnings per share for the three and nine months ended September 30, 2022 was based on the weighted-average number of common shares outstanding for the period beginning after June 2, 2021 (the "Distribution date").

-28-

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION

Some statements and disclosures in this document are forward-looking statements. Forward-looking statements include all statements that do not relate solely to historical or current facts and can be identified by the use of words such as "may," "believe," "will," "expect," "project," "estimate," "anticipate," "plan" or "continue." These forward-looking statements are based on our current plans and expectations and are subject to a number of risks and uncertainties that could cause our plans and expectations, including actual results, to differ materially from the forward-looking statements. Risks and uncertainties that may affect our future results include, but are not limited to, expanded brand and class competition in the markets in which Organon operates; difficulties with performance of third parties Organon relies on for its business growth; the failure of any supplier to provide substances, materials, or services as agreed; the increased cost of supply, manufacturing, packaging, and operations; difficulties developing and sustaining relationships with commercial counterparties; competition from generic products as Organon's products lose patent protection; expiration of current patents or loss of patent protection for Organon's products; difficulties and uncertainties inherent in the implementation of Organon's acquisition strategy or failure to recognize the benefits of such acquisitions; pricing pressures globally, including rules and practices of managed care groups, judicial decisions and governmental laws and regulations related to Medicare, Medicaid and health care reform, pharmaceutical reimbursement and pricing in general; and other factors discussed in Organon's most recently filed Annual Report on Form 10-K and subsequently filed Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, including those discussed in the "Business," "Risk Factors," "Cautionary Factors that May Affect Future Results" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of those reports.

General

The following Management’s Discussion and Analysis of Financial Condition and Results of Operations is intended to assist in understanding the Company’s financial condition and results of operations. The following discussion and analysis should be read in conjunction with the Company’s Condensed Consolidated Financial Statements included in Part I, Item 1 of this report and with our audited financial statements, including the accompanying notes, and Management’s Discussion and Analysis of Financial Condition and Results of Operations included in our Annual Report on Form 10-K. Operating results discussed herein are not necessarily indicative of the results of any future period.

Organon & Co. (“Organon” or the “Company”) is a global health care company formed through a spinoff from Merck & Co., Inc. (“Merck”) to focus on improving the health of women throughout their lives. Organon develops and delivers innovative health solutions through a portfolio of prescription therapies within women's health, biosimilars and established brands (the "Organon Products"). Organon has a portfolio of more than 60 medicines and products across a range of therapeutic areas. The Company sells these products through various channels including drug wholesalers and retailers, hospitals, government agencies and managed health care providers such as health maintenance organizations, pharmacy benefit managers and other institutions. The Company operates six manufacturing facilities, which are located in Belgium, Brazil, Indonesia, Mexico, the Netherlands and the United Kingdom. Unless otherwise indicated, trademarks appearing in italics throughout this document are trademarks of, or are used under license by, the Organon group of companies.

Separation from Merck

As previously disclosed, on June 2, 2021, Organon and Merck entered into a Separation and Distribution Agreement (the "Separation and Distribution Agreement"). Pursuant to the Separation and Distribution Agreement, Merck agreed to spin off the Organon Products into Organon, a new, publicly-traded company (the "Separation"). The Separation from Merck was completed on June 2, 2021, in which Organon's Common Stock was distributed to all holders of outstanding shares of Merck Common Stock as of the close of business on May 17, 2021. For each share of Merck Common Stock held, such holder received one tenth of one share of Common Stock, and holders received cash in lieu of any fractional share of Common Stock they otherwise would have been entitled to receive in connection with the Distribution. Organon is now a standalone publicly-traded company and, on June 3, 2021, regular-way trading of the Common Stock commenced on the New York Stock Exchange under the symbol "OGN." Until the Separation on June 2, 2021, Organon’s historical consolidated financial statements were prepared on a standalone basis and were derived from Merck’s consolidated financial statements and accounting records.

For the periods subsequent to June 2, 2021, as a standalone publicly-traded company, Organon presents its financial statements on a consolidated basis. The Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States of America.

-29-

The Separation was completed pursuant to the Separation and Distribution Agreement and other agreements with Merck related to the Separation, including, but not limited to, a Tax Matters Agreement, an Employee Matters Agreement and a Transition Services Agreement (see Note 13 to the Condensed Consolidated Financial Statements for additional details).

Recent Developments

Business Development

Cirqle Biomedical ("Cirqle")

In July 2022, the Company entered into a research collaboration and license agreement with Cirqle for a novel investigational non-hormonal, on-demand contraceptive candidate. Under the terms of the agreement, Cirqle is responsible for conducting preclinical studies according to the mutually agreed research plan. Organon obtained exclusive worldwide rights to develop and commercialize the asset.

Under the terms of the research collaboration and license agreement, Organon expensed a $10 million upfront payment during the third quarter of 2022. Cirqle is eligible to receive potential regulatory and commercial milestone payments of up to $360 million and tiered royalties based on net sales. As of September 30, 2022, the Company recognized the $10 million upfront payment as Acquired in-process research and development and milestones expense. The remaining potential milestone payments will be recognized by Organon when achievement of the contractual milestones is probable.

Shanghai Henlius Biotech, Inc. ("Henlius")

In June 2022, Organon and Henlius, a global biopharmaceutical company, entered into a definitive agreement whereby Organon is licensing commercialization rights for biosimilar candidates referencing Perjeta® (pertuzumab, HLX11), (a trademark of Genentech, Inc.), used for the treatment of certain patients with HER2+ breast cancer in combinations with trastuzumab and chemotherapy and Prolia®/Xgeva® (denosumab, HLX14), (trademarks of Amgen Inc.) used for the treatment of certain patients with osteoporosis with high risk of fracture and for the prevention of skeletal-related events in patients with multiple myeloma and in patients with bone metastasis from solid tumors. Organon obtained exclusive global commercialization rights except for China; including Hong Kong, Macau and Taiwan. The agreement includes an option to negotiate an exclusive license for global commercialization rights for a biosimilar candidate referencing Yervoy® (ipilimumab, HLX13) (a trademark of Bristol-Myers Squibb Company). Ipilimumab is used for the treatment of certain patients with unresectable or metastatic melanoma, as adjuvant treatment of certain patients with cutaneous melanoma, certain patients with renal cell carcinoma, colorectal cancer, hepatocellular carcinoma, non-small cell lung cancer, malignant pleural mesothelioma and esophageal cancer.

Under the terms of the license agreement, Organon paid a $73 million upfront payment during the third quarter of 2022, of which $3 million was reflected in Other current assets. Henlius is eligible to receive potential developmental, regulatory and commercial milestone payments of up to $468 million. During the nine months ended September 30, 2022, the Company paid milestones of $97 million, reflecting a $70 million upfront payment and $27 million related to certain development milestones which were recognized as Acquired in-process research and development and milestones expense during the second quarter of 2022. The remaining potential milestone payments will be recognized by Organon when achievement of the contractual milestones is probable. Henlius will be responsible for development and, if approved, will supply the products to Organon.

Daré Bioscience, Inc. ("Daré")

In March 2022, Organon and Daré, a leader in women’s health innovation, entered into an agreement whereby Organon licensed the global commercial rights to Xaciato® (clindamycin phosphate vaginal gel, 2%). Xaciato is an FDA-approved medication for the treatment of bacterial vaginosis (BV) in females 12 years of age and older. Xaciato received both Qualified Infectious Disease Product (QIDP) and Fast Track designations from the FDA for the treatment of bacterial vaginosis.

Under the terms of the license agreement, Organon paid a $10 million upfront payment during the third quarter of 2022. Daré is eligible to receive potential regulatory and commercial milestone payments of up to $182.5 million and tiered double-digit royalties based on net sales. Xaciato is expected to be available commercially in the U.S. in the first half of 2023. During the nine months ended September 30, 2022 management determined that the first commercial milestone was deemed probable of occurring, and recognized an intangible asset of $12.5 million reflecting the $10 million upfront payment and $2.5 million commercial milestone. The intangible asset will be amortized over its useful life of 12 years. The remaining potential milestone payments will be recognized by Organon when achievement of the contractual milestones is probable.

-30-

Bayer AG

In February 2022, Organon acquired the product rights and related inventory from Bayer AG to Marvelon™ (ethinylestradiol, desogestrel) and Mercilon™ (ethinylestradiol, desogestrel), combined oral hormonal daily contraceptive pills, in China, including Hong Kong and Macau, and entered into an agreement to acquire the rights to these products in Vietnam. Marvelon and Mercilon are already owned, manufactured, and marketed by Organon as prescription oral contraceptives in 20 other markets. The transaction was accounted for as an asset acquisition. In the first quarter of 2022, Organon paid $30 million to acquire the product rights and inventory in China and accrued an additional $35 million related to these rights which was paid during the second quarter of 2022. In the third quarter of 2022, Organon paid $30 million to acquire the product rights in Vietnam. This resulted in Organon recognizing an intangible asset of $72 million in total related to the product rights with the remainder of the consideration recorded to Inventories for the fair value of acquired inventory during 2022. The intangible assets related to currently marketed products will be amortized over their estimated useful lives of 10 years.

COVID-19 Update

Organon remains focused on protecting the safety of its employees and supporting Organon’s communities in response to the COVID-19 pandemic. COVID-19-related disruptions, including patients’ inability to access health care providers, prioritization of COVID-19 patients, as well as social distancing measures have negatively affected our results during 2021 and 2022.

Our product portfolio is comprised of physician prescribed products, mainly in established brands, which have been affected by social distancing measures and fewer medical visits. Additionally, our portfolio in women's health includes products that are physician administered, which have been affected by reduced access to physicians and health care centers. These impacts, as well as the prioritization of COVID-19 patients at health care providers, resulted in reduced administration of certain products within established brands particularly for respiratory and cardiovascular products and women's health products such as Nexplanon® (etonogestrel implant) (sold as Implanon NXT™ in some countries outside the U.S.), as well as our Fertility brands. Since the second quarter of 2022, our business has been impacted by lockdowns in selective cities across China.

We believe that global health systems and patients continue to adapt to the evolving impacts of the COVID-19 pandemic, including the slower than expected ramp up of qualified personnel hiring. Due to the significant uncertainty that exists relative to the duration and overall impact of the COVID-19 pandemic resulting from resurgences in COVID-19 infections or new strains of the virus, our future operating performance, particularly in the short-term, may be subject to volatility.

Operating Results

Sales Overview

	Three Months Ended September 30,				% Change		% Change Excluding Foreign Exchange		Nine Months Ended September 30,				% Change		% Change Excluding Foreign Exchange
($ in millions)	2022		2021						2022		2021
United States	$	366	$	346	6	%	6	%	$	1,043	$	1,035	1	%	1	%
International	1,171		1,254		(7)	%	2	%	3,646		3,666		(1)	%	6	%
Total	$	1,537	$	1,600	(4)	%	3	%	$	4,689	$	4,701	—	%	5	%

U.S. plus international may not equal total due to rounding.

Worldwide sales were $1.5 billion for the three months ended September 30, 2022, a decrease of 4% compared with 2021. The decrease is primarily due to the unfavorable impact of foreign exchange of $106 million and the timing of tenders in Brazil. Offsetting these declines are increases primarily due to the strong performance of women's health product Nexplanon® (etonogestrel implant) (sold as Implanon NXT™ in some countries outside the U.S.), primarily due to the impact of favorable pricing and demand uptake in the United States as well as volume growth across Mexico, Latin America and the institutional business in Africa. Worldwide sales also reflects the continued uptake of Renflexis® (infliximab-abda) in the United States and strong performance for Brenzys™ (etanercept) in Latin America and Canada.

Worldwide sales were $4.7 billion for the nine months ended September 30, 2022, which is consistent with 2021. Worldwide sales were negatively impacted due to the unfavorable impact of foreign exchange of $254 million, the generic competition for women’s health product NuvaRing® (etonogestrel/ethinyl estradiol vaginal ring) and the authorized generic etonogestrel/ethinyl estradiol vaginal ring in the United States and unfavorable discount rates and lower volume growth in the United States related to Dulera® (formoterol/fumarate dihydrate). Offsetting these declines are increases primarily due to strong performance of Nexplanon due to the impact of favorable pricing and demand uptake in the United States as well as volume growth across Mexico, Latin America and the institutional business in Africa and strong volume growth for products within the established brands business, particularly for respiratory products Nasonex® (mometasone) and Singulair® (montelukast sodium) primarily

-31-

in Japan and China. Worldwide sales also reflect strong performance in biosimilar products mainly in the United States, resulting from the continued uptake of Renflexis® in the United States and the strong performance of cardiovascular products, primarily Atozet™ (ezetimibe and atorvastatin calcium) (marketed outside of the United States), due to increased demand in France and Spain.

The loss of exclusivity ("LOE") negatively impacted sales by approximately $40 million during the nine months ended September 30, 2022, compared to the nine months September 30, 2021, based on the decrease in volume period over period, mainly impacting NuvaRing in the United States. There was no material impact from LOE for the three months ended September 30, 2022 compared to the prior year quarter. Volume-based procurement ("VBP") had a de minimus impact on sales during the three and nine months ended September 30, 2022, compared to the prior periods. Organon expects VBP to impact the Company's Established Brands for the next several quarters.

Organon’s operations include a portfolio of products. Highlights of the sales of Organon’s products for the three and nine months ended September 30, 2022 and 2021 are provided below. See Note 12 to the Condensed Consolidated Financial Statements for further details on sales of our products.

Women’s Health

	Three Months Ended September 30,				% Change		% Change Excluding Foreign Exchange		Nine Months Ended September 30,				% Change		% Change Excluding Foreign Exchange
($ in millions)	2022		2021						2022		2021
Nexplanon/Implanon NXT	$	229	$	175	31	%	34	%	$	595	$	543	10	%	12	%
NuvaRing	50		49		3	%	5	%	133		147		(10)	%	(7)	%
Follistim AQ	60		61		(1)	%	2	%	179		178		1	%	3	%
Ganirelix Acetate Injection	36		25		42	%	52	%	97		85		14	%	21	%

Contraception

Worldwide sales of Nexplanon, a single-rod subdermal contraceptive implant, increased 31% and 10% for the three and nine months ended September 30, 2022 compared to 2021, respectively, primarily due to the impact of favorable pricing and demand uptake in the United States, the favorable impact from the timing of tenders in Latin America and volume growth from the institutional business in Africa.

Worldwide sales of NuvaRing, a vaginal contraceptive product remained substantially consistent for the three months ended September 30, 2022, compared to 2021. Sales of NuvaRing declined 10% for the nine months ended September 30, 2022, compared to 2021, due to ongoing generic competition in the United States. We expect a continued decline in NuvaRing sales as a result of generic competition. In addition to sales of branded NuvaRing, we have an agreement with a generic manufacturer that authorizes the sale of a generic etonogestrel/ethinyl estradiol vaginal ring in the United States. Under the terms of the agreement, we are reimbursed on a cost-plus basis by the generic manufacturer for supplying finished goods and receive a share of the net profits recorded by the generic manufacturer. Under the terms of the agreement, our share in the profits declines over time as new participants enter the market. Revenues from this arrangement were $9 million and $12 million for the three months ended September 30, 2022 and 2021, respectively, and $34 million and $63 million for the nine months ended September 30, 2022 and 2021, respectively. The decline in revenue for the nine months ended September 30, 2022, is due to the entry of a new market participant. Given the nature of this arrangement, we expect revenues under this arrangement to continue to decline significantly for the remainder of 2022.

Fertility

Worldwide sales of Follistim AQ® (marketed in most countries outside the United States as Puregon™), a fertility treatment, remained consistent for the three and nine months ended September 30, 2022 compared to 2021, primarily due to higher demand in China during the first and third quarters of 2022 following the COVID lockdowns and continuous demand growth in the United States.

Worldwide sales of ganirelix acetate injection (marketed in certain countries outside the United States as Orgalutran™), a fertility treatment, increased for the three and nine months ended September 30, 2022, compared to 2021, respectively driven by demand uptake in the international markets.

-32-

Biosimilars

	Three Months Ended September 30,				% Change		% Change Excluding Foreign Exchange		Nine Months Ended September 30,				% Change		% Change Excluding Foreign Exchange
($ in millions)	2022		2021						2022		2021
Renflexis	$	60	$	54	11	%	12	%	$	166	$	136	22	%	23	%
Ontruzant	29		56		(47)	%	(45)	%	87		101		(14)	%	(11)	%
Brenzys	24		14		71	%	75	%	52		35		48	%	53	%
Hadlima	6		5		16	%	20	%	14		9		51	%	54	%

The following biosimilar products are part of a development and commercialization agreement between Organon and Samsung Bioepis entered into in 2013. See Note 3 to the Condensed Consolidated Financial Statements. Our commercialization territories under the agreement vary by product as noted below.

Renflexis® (infliximab-abda) is a biosimilar to Remicade® (infliximab) (a trademark of Janssen Biotech, Inc.) for the treatment of certain inflammatory diseases. Sales growth of 11% and 22% for the three and nine months ended September 30, 2022, respectively, was driven primarily by continued demand growth, favorable channel mix and favorable discount rates in the United States. We have commercialization rights to Renflexis in countries outside Europe, Korea, China, Turkey and Russia.

Ontruzant® (trastuzumab-dttb) is a biosimilar to Herceptin® (trastuzumab) (a trademark of Genentech, Inc.) for the treatment of HER2-overexpressing breast cancer and HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma. Sales in the three and nine months ended September 30, 2022 declined 47% and 14%, respectively, driven by the timing of tenders in Brazil and the competitive pressures in Europe offset by the continued uptake in the United States since its launch in July 2020. We have commercialization rights to Ontruzant in countries outside of Korea and China.

Brenzys™ (etanercept) is a biosimilar to Enbrel® (etanercept) (a trademark of Immunex Corporation) for the treatment of certain inflammatory diseases. Sales in the three and nine months ended September 30, 2022 increased 71% and 48%, respectively, primarily driven by the timing of tenders in Brazil and volume growth in Canada. We have commercialization rights to Brenzys in countries outside of the United States, Europe, Korea, China and Japan.

Hadlima™ (adalimumab-bwwd) is a biosimilar to Humira® (adalimumab) (a trademark of AbbVie Biotechnology Ltd.) for the treatment of certain inflammatory diseases. We have worldwide commercialization rights to Hadlima in countries outside of the EU, Korea, China, Turkey and Russia. Samsung Bioepis reached a global settlement with AbbVie permitting us to launch Hadlima outside of the United States starting in 2021 and in the United States in June 2023. Hadlima is currently approved in the United States, Australia, Canada, and Israel. Hadlima was launched in Australia and Canada in February 2021. In August 2022, the U.S. Food and Drug Administration approved the citrate-free, high-concentration (100 mg/mL) formulation of Hadlima. We have recorded sales of $6 million and $14 million during the three and nine months ended September 30, 2022, respectively, reflecting an increase of 16% and 51% from modest sales during the three and nine months ended September 30, 2021.

-33-

Established Brands

Established brands represents a broad portfolio of well-known brands, which generally are beyond market exclusivity, including leading brands in cardiovascular, respiratory, dermatology and non-opioid pain management, for which generic competition varies by market.

Cardiovascular

	Three Months Ended September 30,				% Change		% Change Excluding Foreign Exchange		Nine Months Ended September 30,				% Change		% Change Excluding Foreign Exchange
($ in millions)	2022		2021						2022		2021
Zetia/Vytorin	$	118	$	132	(11)	%	(3)	%	$	390	$	409	(4)	%	1	%
Atozet	109		114		(4)	%	9	%	350		347		1	%	11	%
Rosuzet	17		15		12	%	36	%	55		48		14	%	31	%
Cozaar/Hyzaar	70		87		(20)	%	(13)	%	256		265		(3)	%	2	%

Combined global sales of Zetia® (ezetimibe) (marketed in most countries outside of the United States as Ezetrol™) and Vytorin® (ezetimibe/simvastatin) (marketed outside of the United States as Inegy™), medicines for lowering LDL cholesterol, declined 11% and 4% for the three and nine months ended September 30, 2022, compared to 2021, respectively, primarily driven by increased competition and lower performance in Europe and the impact of foreign exchange, partly offset by volume growth in China.

Sales of Atozet™ (ezetimibe and atorvastatin calcium) (marketed outside of the United States), a medicine for lowering LDL cholesterol, decreased 4% for the three months ended September 30, 2022 and increased 1% for the nine months ended September 30, 2022, compared to 2021, primarily due to increased demand in France and Spain offset by the negative impact of foreign exchange.

Sales of Rosuzet™ (ezetimibe and rosuvastatin calcium) (marketed outside of the United States), a medicine for lowering LDL cholesterol, increased 12% and 14% for the three and nine months ended September 30, 2022, compared to 2021, primarily due to higher demand in Japan offset by the impact of foreign exchange.

Combined global sales of Cozaar® (losartan potassium), and Hyzaar® (losartan potassium and hydrochlorothiazide) (a combination of Cozaar and hydrochlorothiazide that is marketed in Japan as Preminent™), a medicine for the treatment of hypertension, declined 20% and 3% for the three and nine months ended September 30, 2022, compared to 2021, respectively, primarily due to the impact of foreign exchange.

Respiratory

	Three Months Ended September 30,				% Change		% Change Excluding Foreign Exchange		Nine Months Ended September 30,				% Change		% Change Excluding Foreign Exchange
($ in millions)	2022		2021						2022		2021
Singulair	$	94	$	100	(6)	%	4	%	$	316	$	300	5	%	14	%
Nasonex	49		48		2	%	5	%	182		144		27	%	32	%
Dulera	40		56		(28)	%	(28)	%	127		146		(13)	%	(12)	%

Worldwide sales of Singulair, a once-a-day oral medicine for the chronic treatment of asthma and for the relief of symptoms of allergic rhinitis decreased 6% for the three months ended September 30, 2022, compared to 2021 primarily driven by the impact of foreign exchange offset by demand resulting from competitors' supply disruptions in Japan. Singulair sales increased 5% for the nine months ended September 30, 2022, compared to 2021 primarily attributable to volume recovery from the COVID-19 pandemic and demand resulting from competitors' supply disruptions in Japan offset by the impact of foreign exchange.

Global sales of Nasonex, an inhaled nasal corticosteroid for the treatment of nasal allergy symptoms, increased 2% for the three months ended September 30, 2022, compared to 2021, primarily driven by increased demand in Canada and the Middle East region as well as higher demand resulting from competitors' supply disruptions in Japan offset by the impact of foreign exchange. Nasonex sales increased 27% during the nine months ended September 30, 2022 primarily driven by higher demand resulting from competitors' supply disruptions in Japan and increased demand across several markets, offset by the impact of

-34-

foreign exchange. In addition, sales during the nine months ended September 30, 2022 included a $10 million milestone payment related to a regulatory approval in the United States.

Global sales of Dulera® (formoterol/fumarate dihydrate), a combination medicine for the treatment of asthma, decreased 28% and 13% for the three and nine months ended September 30, 2022, compared to 2021, respectively, primarily due to unfavorable government rates and lower volume growth in the United States.

Non-Opioid Pain, Bone and Dermatology

	Three Months Ended September 30,				% Change		% Change Excluding Foreign Exchange		Nine Months Ended September 30,				% Change		% Change Excluding Foreign Exchange
($ in millions)	2022		2021						2022		2021
Arcoxia	$	64	$	65	(2)	%	2	%	$	185	$	184	1	%	5	%

Sales of Arcoxia™ (etoricoxib) (marketed outside of the United States), a medicine for the treatment of arthritis and pain, were slightly lower for the three months ended September 30, 2022, compared to 2021, primarily due to the impact of foreign exchange. Sales of Arcoxia increased 1% during the nine months ended September 30, 2022 compared to 2021, primarily due to the higher demand in China and the South East Asia region offset by the impact of foreign exchange.

Other

	Three Months Ended September 30,				% Change		% Change Excluding Foreign Exchange		Nine Months Ended September 30,				% Change		% Change Excluding Foreign Exchange
($ in millions)	2022		2021						2022		2021
Proscar	$	27	$	27	(4)	%	3	%	$	77	$	92	(16)	%	(13)	%

Worldwide sales of Proscar, a medicine for the treatment of symptomatic benign prostate enlargement, declined 4% and 16% for the three and nine months ended September 30, 2022, compared to 2021, respectively, primarily due to lower demand in China and the impact of foreign exchange.

Costs, Expenses and Other

	Three Months Ended September 30,				% Change		Nine Months Ended September 30,				% Change
($ in millions)	2022		2021				2022		2021
Cost of sales	$	551	$	609	(10)	%	$	1,700	$	1,783	(5)	%
Selling, general and administrative	440		388		13	%	1,234		1,186		4	%
Research and development	127		86		48	%	329		229		44	%
Acquired in-process research and development and milestones	10		25		(60)	%	107		25		*
Restructuring costs	11		1		*		11		3		*
Interest expense	108		98		10	%	303		160		89	%
Exchange losses (gains)	4		1		*		(21)		6		*
Other expense, net	4		3		33	%	15		16		(6)	%
	$	1,255	$	1,211	4	%	$	3,678	$	3,408	8	%

* Calculation not meaningful.

Cost of Sales

Cost of sales decreased 10% for the three months ended September 30, 2022 compared to 2021 primarily due to product mix and a $24 million charge in 2021, that pertained to unavoidable losses associated with a long-term vendor supply contract conveyed as part of the Separation, offset by favorable foreign exchange. For the nine months ended September 30, 2022, cost of sales decreased 5% compared to the same period in 2021, primarily reflecting lower supply sales compared to the prior year, pre-spin allocated costs related to the Separation and a $24 million charge pertaining to unavoidable losses associated with a long-term vendor supply contract incurred during the prior year that were not incurred during the nine months ended September 30, 2022, offset by, favorable foreign exchange. During the nine months ended September 30, 2022, the Company recorded an impairment charge of $9 million related to a product right for a biosimilar product.

-35-

Gross margin was 64% for the three and nine months ended September 30, 2022 compared with 62% for the same periods in 2021. The gross margin increase compared to the prior year reflects lower margin supply sales, pre-spin allocated costs related to the Separation incurred during the prior year which were not incurred during the three and nine months ended September 30, 2022 and a $24 million charge in 2021 which pertained to unavoidable losses associated with a long-term vendor supply contract conveyed as part of the Separation.

Selling, General and Administrative

Selling, general and administrative expenses increased 13% for the three months ended September 30, 2022 due to higher selling and promotional costs related to our women's health portfolio. For the nine months ended September 30, 2022, selling, general and administrative expenses increased 4% due to selling and promotional costs related to our women's health portfolio partially offset by pre-spin allocated costs related to the Separation incurred during the prior year which were not incurred during the nine months ended September 30, 2022.

Research and Development

Research and development expenses increased 48% and 44% for the three and nine months ended September 30, 2022, respectively, primarily due to higher costs associated with the Company's recent acquisitions of clinical stage assets, increased clinical study activity and higher employee-related costs.

Acquired In-Process Research and Development and Milestones

Acquired in-process research and development and milestones for the three months ended September 30, 2022 represents the upfront milestones related to the Cirqle transaction. For the nine months ended September 30, 2022 acquired in-process research and development and milestones represents the upfront and development milestones related to the Cirqle and Henlius transactions. Acquired in-process research and development and milestones for the three and nine months ended September 30, 2021 represents the upfront milestones related to the licensing agreement with ObsEva.

Restructuring Costs

For the three and nine months ended September 30, 2022, the Company incurred $11 million related to headcount related restructuring activities

Interest Expense

For the three and nine months ended September 30, 2022, interest expense increased, due to the $9.5 billion of debt, which was incurred by the Company during the second quarter of 2021.

Exchange Losses (Gains)

For the three and nine months ended September 30, 2022, the change in exchanges losses (gains) was driven by the fluctuations in foreign exchange and the exchange rate impact on the portion of Euro-denominated debt not designated as a net investment hedge.

Taxes on Income

The effective income tax rates were 19.6% and 17.1% for the three months ended September 30, 2022 and 2021, respectively, and 20.0% and 11.2% for the nine months ended September 30, 2022 and 2021, respectively. These effective income tax rates reflect the beneficial impact of foreign earnings, offset by the impact of U.S. inclusions under the Global Intangible Low-Taxed Income regime. The effective income tax rate for the first nine months of 2021 reflects the beneficial impact of foreign earnings, the $70 million tax benefit relating to a portion of the non-U.S. step-up of tax basis as well as the income tax benefit recognized in connection with the conclusion of the Internal Revenue Service (IRS) examination of Merck’s 2015-2016 U.S. federal income tax returns. As a result of that examination conclusion, we reflected an allocation from Merck of $18 million in the Condensed Consolidated Financial Statements representing our portion of the payment made to the IRS. Our portion of reserves for unrecognized tax benefits for the years under examination exceeded the allocated adjustments relating to this examination period. Therefore, for the nine months ended September 30, 2021, we reflected a $29 million net tax benefit. This net benefit reflects reductions in reserves for unrecognized tax benefits and other related liabilities for tax positions relating to the years that were under examination.

-36-

On August 16, 2022, the U.S. enacted the Inflation Reduction Act of 2022. Provisions of the bill that relate to tax include the minimum tax on book income, a 1% excise tax on stock buybacks and certain tax incentives to promote clean energy. There are no impacts of the legislation to the third quarter 2022 results. The Company is currently assessing future impacts of this recently enacted legislation.

Income/Loss from Discontinued Operations

The historical results of certain Merck non-U.S. legal entities that were contributed to Organon in connection with the Separation included operations related to other Merck products that were retained by Merck. The Merck Retained Products business of the Transferred Entities were contributed by Organon to Merck and its affiliates. Accordingly, the historical results of operations of the Merck Retained Products have been reflected as discontinued operations in the Condensed Consolidated Financial Statements for all periods presented.

There was no income or loss from discontinued operations, net of taxes for the three and nine months ended September 30, 2022 and 2021.

Analysis of Liquidity and Capital Resources

Liquidity and Capital Resources

As of September 30, 2022, Organon had cash and cash equivalents of $499 million. On June 6, 2022, the Company made a discretionary prepayment of $100 million on the U.S. Dollar-denominated term loan. The Company has historically generated and expects to continue to generate positive cash flow from operations. We plan to continue to fund our ongoing operating, investing and financing requirements mainly through cash flows from operations, available liquidity through cash on hand, available capacity under our Revolving Credit Facility and access to capital markets.

Working capital of continuing operations was $1.3 billion as of September 30, 2022 and $1.2 billion as of December 31, 2021. The increase in working capital of continuing operations was primarily driven by a decrease in trade accounts payable.

Net cash provided by operating activities was $591 million for the nine months ended September 30, 2022 compared to $2.1 billion for the same period in the prior year. The decrease in cash provided by operating activities in 2022 was primarily attributable to the decrease in trade payables, including balances with Merck.

Net cash used in investing activities was $359 million for the nine months ended September 30, 2022 compared to $348 million for the same period in the prior year, primarily reflecting the asset acquisition of Marvelon and Mercilon and licensing agreements with Daré, Henlius and Cirqle in the nine months ended September 30, 2022 and the asset acquisition of Alydia Health and the licensing agreement with ObsEva in the nine months ended September 30, 2021.

Net cash used in financing activities was $351 million for the nine months ended September 30, 2022 compared to $790 million for the same period in the prior year. The change in cash used in financing activities reflects the settlement of the transactions with Merck in connection with the Separation in 2021 and the prior year issuance of long term debt, partially offset by the payment of dividends in the current year.

Our ability to fund our operations and anticipated capital needs is reliant upon the generation of cash from operations, supplemented as necessary by periodic utilization of our Revolving Credit Facility. Our principal uses of cash in the future will be primarily to fund our operations, working capital needs, capital expenditures, repayment of borrowings, payment of dividends and strategic business development transactions.

In February 2022, the armed conflict between Ukraine and Russia escalated, which may adversely impact Organon’s business. Specifically, trade sanctions, travel bans and asset and financial freezes announced by the United States, European Union and other countries against Russian entities and designated individuals, as well as counter-measures announced by Russia, have impacted and may continue to impact many global businesses in direct and indirect ways (including, but not limited to, product shipping delays, supply shortages, delays in regulatory approvals and audits, constraints in energy supply, currency exchange rates and exchange controls). Such actions may negatively impact the financial institutions, vendors, manufacturers, suppliers, partners and other third parties with whom Organon conducts business. Organon will continue to monitor the impacts of the conflict, which may negatively impact Organon’s operations, financial position or cash flows. For the nine months ended September 30, 2022 and the year ended December 31, 2021, Organon’s combined revenues from Ukraine and Russia were approximately 2% of total revenues. As of September 30, 2022, the Company’s assets in Ukraine and Russia are not material.

-37-

Our contractual obligations as of December 31, 2021, which require material cash requirements in the future, consist of purchase obligations and lease obligations. In addition, Organon is responsible for settlement of certain tax matters, of which the Company expects to pay during 2022. Refer to "Management's Discussion and Analysis of Financial Condition and Results of Operations in our 2021 Form 10-K for further details. As of September 30, 2022, there have been no material changes to our contractual obligations, or settlements of tax matters outside the ordinary course of business.

During the third quarter of 2022, Organon paid cash dividends of $0.28 per share. On November 3, 2022, the Board of Directors declared a quarterly dividend of $0.28 for each issued and outstanding share of the Company's common stock. The dividend is payable on December 15, 2022 to stockholders of record at the close of business on November 14, 2022.

We believe that our financing arrangements, future cash from operations, and access to capital markets will provide adequate resources to fund our future cash flow needs.

The economy of Turkey was deemed hyperinflationary during the second quarter of 2022. Consequently, in accordance with U.S. GAAP, the Company began remeasuring its monetary assets and liabilities for those operations in earnings beginning in the second quarter of 2022. The impact to the Company's results is immaterial.

Critical Accounting Estimates

Our significant accounting policies, which include management’s best estimates and judgments, are included in Note 3 to the Consolidated Financial Statements included in our Form 10-K for the year ended December 31, 2021. See Note 2 to the Condensed Consolidated Financial Statements for information on the adoption of new accounting standards during 2022. There have been no changes to our accounting policies as of September 30, 2022. A discussion of accounting estimates considered critical because of the potential for a significant impact on the financial statements due to the inherent uncertainty in such estimates are disclosed in the Critical Accounting Estimates section of Management’s Discussion and Analysis of Financial Condition and Results of Operations included in Organon's Form 10-K for the year ended December 31, 2021.

Recently Issued Accounting Standards

For a discussion of recently issued accounting standards, see Note 2 to the Condensed Consolidated Financial Statements.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

Foreign Currency Risk

We operate on a global basis and are exposed to the risk that our earnings, cash flows and equity could be adversely affected by fluctuations in foreign exchange rates. We had historically managed our foreign currency risk through Merck foreign currency programs. We are primarily exposed to foreign exchange risk with respect to forecasted transactions and net assets denominated in the euro, Swiss franc, and Japanese yen. Upon Separation, we established a balance sheet risk management program and a net investment hedge to mitigate against volatility of changes in foreign exchange rates. Each quarter subsequent to Separation, €1.75 billion of our euro-denominated debt has been designated as a hedge of the net investment of euro-denominated subsidiaries. See Note 5 to the Condensed Consolidated Financial Statements included elsewhere in this report for further information on Organon’s risk management.

Interest Rate Risk

Our long-term debt portfolio consists of both fixed and variable-rate instruments. For any variable rate debt, interest rate changes in the underlying index rates will impact future interest expense. We do not hold any derivative contracts that hedge our interest rate risk; however, we may consider entering into such contracts in the future.

There have been no changes to Organon’s market risk during the quarter ended September 30, 2022. For a discussion of our exposure to market risk, refer to our market risk disclosures set forth under Item 7A.—Quantitative and Qualitative Disclosures About Market Risk in our Annual Report on Form 10-K for the year ended December 31, 2021.

-38-

Item 4. Controls and Procedures

Management of the Company, with the participation of its Chief Executive Officer ("CEO") and Chief Financial Officer ("CFO"), evaluated the effectiveness of the design and operation of the Company’s disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of the period ending September 30, 2022. Based upon that evaluation, our CEO and our CFO concluded that, as of the period ending September 30, 2022, the Company's disclosure controls and procedures were effective and provide reasonable assurance that information required to be disclosed in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the applicable rules and forms, and that it is accumulated and communicated to our management, including our CEO and our CFO, as appropriate, to allow timely decisions regarding required disclosure.

Our Annual Report on Form 10-K for the year ended December 31, 2021 did not include a report of management's assessment regarding internal control over financial reporting or an attestation of the Company's independent registered public accounting firm due to the transition period established by the rules of the SEC for newly created public companies.

No changes in our internal controls over financial reporting during the quarter ended September 30, 2022 have materially affected, or are reasonably likely to materially affect, our internal controls over financial reporting.

-39-

PART II - OTHER INFORMATION

Item 1. Legal Proceedings

The information called for by this Item is incorporated herein by reference to Note 8 included in Part I, Item. 1.

Item 1A. Risk Factors

There have been no material changes in the Company's risk factors from those disclosed in Item 1A, Risk Factors, in our Form 10-K for the year ended December 31, 2021.

-40-

Item 6. Exhibits

Number			Description
	*31.1	—	Certification of Principal Executive Officer (CEO) pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
	*31.2	—	Certification of Principal Financial Officer (CFO) pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
	**32.1	—	Section 1350 Certification of Principal Executive Officer (CEO) pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
	**32.2	—	Section 1350 Certification of Principal Financial Officer (CFO) pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INS		—	XBRL Instance Document - The instance document does not appear in the interactive data file because its XBRL tags are embedded within the Inline XBRL document.
101.SCH		—	XBRL Taxonomy Extension Schema Document.
101.CAL		—	XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF		—	XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB		—	XBRL Taxonomy Extension Label Linkbase Document.
101.PRE		—	XBRL Taxonomy Extension Presentation Linkbase Document.
	104	—	Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).
		*	Filed herewith
		**	Furnished herewith

-41-

Signatures

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	ORGANON & CO.
Date: November 4, 2022	/s/ Kathryn DiMarco
	Kathryn DiMarco
	Senior Vice President Finance - Corporate Controller
Date: November 4, 2022	/s/ Matthew Walsh
	Matthew Walsh
	Chief Financial Officer

EX-31.1

Exhibit 31.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Kevin Ali certify that:

1. I have reviewed this Form 10-Q of Organon & Co;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:

(a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(c) disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. the registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

November 4, 2022

By	/s/ Kevin Ali
	Kevin Ali
	Chief Executive Officer

EX-31.2

CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

Exhibit 31.2

I, Matthew Walsh certify that:

1. I have reviewed this Form 10-Q of Organon & Co;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:

(a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(c) disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. the registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

November 4, 2022

By	/s/ Matthew Walsh
	Matthew Walsh
	Chief Financial Officer

EX-32.1

Exhibit 32.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. § 1350,

AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Pursuant to 18 U.S.C.§ 1350, the undersigned certifies that, to the best of my knowledge, the Quarterly Report on Form 10-Q for the period ended September 30, 2022 of Organon & Co. fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C.§ 78m or 78o(d)) and that the information contained in the Quarterly Report fairly presents, in all material respects, the financial condition and results of operations of Organon & Co.

November 4, 2022	/s/ Kevin Ali
	Kevin Ali
	Chief Executive Officer

EX-32.2

Exhibit 32.2

CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C. § 1350,

AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Pursuant to 18 U.S.C.§ 1350, the undersigned certifies that, to the best of my knowledge, the Quarterly Report on Form 10-Q for the period ended September 30, 2022 of Organon & Co. fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C.§ 78m or 78o(d)) and that the information contained in the Quarterly Report fairly presents, in all material respects, the financial condition and results of operations of Organon & Co.

Dated: November 4, 2022	/s/ Matthew Walsh
	Matthew Walsh
	Chief Financial Officer

XML

Cover - shares	9 Months Ended
	Sep. 30, 2022	Oct. 30, 2022
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2022
Document Transition Report	false
Entity File Number	001-40235
Entity Registrant Name	Organon & Co.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	46-4838035
Entity Address, Address Line One	30 Hudson Street, Floor 33
Entity Address, City or Town	Jersey City,
Entity Address, State or Province	NJ
Entity Address, Postal Zip Code	07302
City Area Code	(551)
Local Phone Number	430-6900
Title of 12(b) Security	Common Stock ($0.01 par value)
Trading Symbol	OGN
Security Exchange Name	NYSE
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		254,364,409
Entity Central Index Key	0001821825
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q3

XML

Condensed Consolidated Statements of Income - USD ($) shares in Thousands, $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Income Statement [Abstract]
Revenues	$ 1,537	$ 1,600	$ 4,689	$ 4,701
Costs, Expenses and Other
Cost of sales	551	609	1,700	1,783
Selling, general and administrative	440	388	1,234	1,186
Research and development	127	86	329	229
Acquired in-process research and development and milestones	10	25	107	25
Restructuring costs	11	1	11	3
Interest expense	108	98	303	160
Exchange losses (gains)	4	1	(21)	6
Other expense, net	4	3	15	16
Costs, Expenses And Other	1,255	1,211	3,678	3,408
Income From Continuing Operations Before Income Taxes	282	389	1,011	1,293
Taxes on Income	55	66	202	144
Net Income From Continuing Operations	227	323	809	1,149
Loss From Discontinued Operations - Net of Tax	0	0	0	0
Net Income	$ 227	$ 323	$ 809	$ 1,149
Earnings per Share - Basic:
Continuing operations (in dollars per share)	$ 0.89	$ 1.27	$ 3.19	$ 4.53
Discontinued operations (in dollars per share)	0	0	0	0
Basic earnings per common share attributable to Organon common stockholders (in dollar per share)	0.89	1.27	3.19	4.53
Earnings per Share - Diluted:
Continuing operations (in dollars per share)	0.89	1.27	3.17	4.52
Discontinued operations (in dollars per share)	0	0	0	0
Net Earnings per Share Attributable to Organon & Co. Stockholders - Diluted (in dollars per share)	$ 0.89	$ 1.27	$ 3.17	$ 4.52
Weighted Average Shares Outstanding:
Basic (in shares)	254,348	253,534	253,986	253,530
Diluted (in shares)	255,067	254,172	255,094	254,011

XML

Condensed Consolidated Statements of Comprehensive Income - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Statement of Comprehensive Income [Abstract]
Net Income	$ 227	$ 323	$ 809	$ 1,149
Other Comprehensive (Loss) Income, Net of Taxes:
Benefit plan net loss and prior service credit, net of amortization	0	(3)	0	(11)
Cumulative translation adjustment	(97)	(23)	(173)	129
Other comprehensive income (loss)	(97)	(26)	(173)	118
Comprehensive Income	$ 130	$ 297	$ 636	$ 1,267

XML

Condensed Consolidated Balance Sheets - USD ($) shares in Thousands, $ in Millions	Sep. 30, 2022	Dec. 31, 2021
Current Assets
Cash and cash equivalents	$ 499	$ 737
Accounts receivable (net of allowance for doubtful accounts of $8 in 2022 and $7 in 2021)	1,440	1,382
Inventories (excludes inventories of $96 in 2022 and $76 in 2021 classified in Other Assets)	879	915
Other current assets	774	726
Total current assets	3,592	3,760
Property, plant and equipment, net	906	973
Goodwill	4,603	4,603
Other intangibles, net	670	651
Other assets	666	694
Assets	10,437	10,681
Current Liabilities
Current portion of long-term debt	8	9
Trade accounts payable	1,028	1,382
Accrued and other current liabilities	1,075	1,021
Income taxes payable	217	185
Total current liabilities	2,328	2,597
Long-term debt	8,691	9,125
Deferred income taxes	43	4
Other noncurrent liabilities	441	463
Commitments and Contingencies
Organon & Co. Equity
Common stock, $0.01 par value Authorized - 500,000 Issued and outstanding - 254,364 in 2022 and 253,545 in 2021	3	3
Accumulated deficit	(383)	(998)
Accumulated other comprehensive loss	(686)	(513)
Total Deficit	(1,066)	(1,508)
Liabilities and Equity	$ 10,437	$ 10,681
Common stock, shares issued	254,364	253,545
Common stock, shares outstanding	254,364	253,545

XML

Condensed Combined Balance Sheet (Parenthetical) - USD ($) $ in Millions	Sep. 30, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Allowance for doubtful accounts	$ 8	$ 7
Inventories classified in Other Assets	$ 96	$ 76
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized	500,000,000	500,000,000
Common stock, shares issued	254,364,000	253,545,000
Common stock, shares outstanding	254,364,000	253,545,000

XML

Condensed Consolidated Statements of Equity - USD ($) $ in Millions	Total	Common Stock	Additional Paid-In Capital	Accumulated Deficit	Accumulated Deficit Merck and Co., Inc.	Net Investment from Merck & Co., Inc.	Net Investment from Merck & Co., Inc. Merck and Co., Inc.	Accumulated Other Comprehensive Loss
Beginning balance, shares at Dec. 31, 2020		0
Beginning balance at Dec. 31, 2020	$ 5,486	$ 0	$ 0	$ 0			$ 6,108	$ (622)
Stockholders' Equity [Roll Forward]
Net income	1,149			419			730
Other comprehensive loss, net of taxes	118							118
Cash dividends declared on common stock	(74)			(74)
Stock-based compensation plans and other (in shares)		29,000
Stock-based compensation plans and other	23			23
Net transfers from Merck & Co., Inc., including Separation Adjustments	680				$ 81		588	11
Net consideration paid to Merck & Co., Inc. in connection with Separation	(9,000)					$ (9,000)
Issuance of common stock in connection with the Separation and reclassification of Net investment from Merck & Co., inc. (in shares)		253,516,000
Issuance of common stock in connection with the Separation and reclassification of Net Investment from Merck & Co., Inc.	0	$ 3		(1,577)		1,574
Ending balance, shares at Sep. 30, 2021		253,545,000
Ending balance at Sep. 30, 2021	(1,618)	$ 3	0	(1,128)			0	(493)
Beginning balance, shares at Jun. 30, 2021		253,516,000
Beginning balance at Jun. 30, 2021	(1,934)	$ 3	0	(1,473)			0	(464)
Stockholders' Equity [Roll Forward]
Net income	323			323		0
Other comprehensive loss, net of taxes	(26)							(26)
Cash dividends declared on common stock	(74)			(74)
Stock-based compensation plans and other (in shares)		29,000
Stock-based compensation plans and other	15			15
Net transfers from Merck & Co., Inc., including Separation Adjustments	78			81		$ 0		(3)
Ending balance, shares at Sep. 30, 2021		253,545,000
Ending balance at Sep. 30, 2021	(1,618)	$ 3	0	(1,128)			0	(493)
Beginning balance, shares at Dec. 31, 2021		253,550,000
Beginning balance at Dec. 31, 2021	(1,508)	$ 3	0	(998)			0	(513)
Stockholders' Equity [Roll Forward]
Net income	809			809			0
Other comprehensive loss, net of taxes	(173)							(173)
Cash dividends declared on common stock	(218)			(218)
Stock-based compensation plans and other (in shares)		814,000
Stock-based compensation plans and other	41			41
Net transfers from Merck & Co., Inc., including Separation Adjustments	(17)			(17)			0	0
Ending balance, shares at Sep. 30, 2022		254,364,000
Ending balance at Sep. 30, 2022	(1,066)	$ 3	0	(383)			0	(686)
Beginning balance, shares at Jun. 30, 2022		254,321,000
Beginning balance at Jun. 30, 2022	(1,137)	$ 3	0	(551)			0	(589)
Stockholders' Equity [Roll Forward]
Net income	227			227
Other comprehensive loss, net of taxes	(97)							(97)
Cash dividends declared on common stock	(74)			(74)
Stock-based compensation plans and other (in shares)		43,000
Stock-based compensation plans and other	15			15
Ending balance, shares at Sep. 30, 2022		254,364,000
Ending balance at Sep. 30, 2022	$ (1,066)	$ 3	$ 0	$ (383)			$ 0	$ (686)

XML

Condensed Consolidated Statement of Equity (Parentheticals) - $ / shares	3 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Statement of Stockholders' Equity [Abstract]
Common stock dividends declared (in dollars per share)	$ 0.28	$ 0.28

XML

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Cash Flows from Operating Activities
Net income from continuing operations	$ 809	$ 1,149
Adjustments to reconcile net income from continuing operations to net cash flows provided by operating activities:
Depreciation	72	64
Amortization	88	69
Impairment of assets	9	0
Acquired in-process research and development and milestones	107	25
Deferred income taxes	(18)	(212)
Stock-based compensation	52	44
Unrealized foreign exchange (gain) loss	(45)	37
Other	24	7
Net changes in assets and liabilities
Accounts receivable	(119)	(376)
Inventories	(134)	(90)
Other current assets	(76)	177
Trade accounts payable	(323)	944
Accrued and other current liabilities	108	386
Due from/due to related party	0	(164)
Income taxes payable	45	7
Other	(8)	46
Net Cash Flows Provided by Operating Activities from Continuing Operations	591	2,113
Cash Flows from Investing Activities
Capital expenditures	(133)	(133)
Proceeds from sale of property, plant and equipment	3	2
Acquired In Process Research & Development	(105)	(25)
Purchase of product rights and asset acquisition, net of cash acquired	(124)	(192)
Net Cash Flows Used in Investing Activities from Continuing Operations	(359)	(348)
Cash Flows from Financing Activities
Proceeds from issuance of long-term debt	0	9,470
Repayments of debt	(106)	(10)
Payment of long-term debt issuance costs	0	(118)
Repayments of short-term borrowings from Merck & Co., Inc., net	0	(1,512)
Net consideration paid to Merck & Co. Inc. in connection with the Separation	0	(9,000)
Net transfers (to) from Merck & Co., Inc.	(17)	454
Employee withholding taxes related to share-based awards	(11)	0
Dividend payments	(217)	(74)
Net Cash Flows Used in Financing Activities from Continuing Operations	(351)	(790)
Discontinued Operations
Net Cash Provided by Operating Activities	0	298
Net Cash Used in Investing Activities	0	0
Net Cash Used in Financing Activities	0	(356)
Net Cash Flows Used in Discontinued Operations	0	(58)
Effect of Exchange Rate Changes on Cash and Cash Equivalents from Continuing Operations	(119)	21
Effect of Exchange Rate Changes on Cash and Cash Equivalents from Discontinued Operations	0	0
Net (Decrease) Increase in Cash and Cash Equivalents	(238)	938
Cash and Cash Equivalents, Beginning of Period	737	12
Cash and Cash Equivalents of Discontinued Operations, Beginning of Period	0	58
Total Cash and Cash Equivalents, End of Period	499	1,008
Less: Cash and Cash Equivalents of Discontinued Operations, End of Period	0
Cash and Cash Equivalents, End of Period	$ 499	$ 1,008

XML

Background and Nature of Operations

9 Months Ended

Sep. 30, 2022

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Background and Nature of Operations

Background and Nature of Operations

Organon & Co. (“Organon” or the “Company”) is a global health care company formed through a spinoff from Merck & Co., Inc. (“Merck”) to focus on improving the health of women throughout their lives. Organon develops and delivers innovative health solutions through a portfolio of prescription therapies within women's health, biosimilars and established brands (the "Organon Products"). Organon has a portfolio of more than 60 medicines and products across a range of therapeutic areas. The Company sells these products through various channels including drug wholesalers and retailers, hospitals, government agencies and managed health care providers such as health maintenance organizations, pharmacy benefit managers and other institutions. The Company operates six manufacturing facilities, which are located in Belgium, Brazil, Indonesia, Mexico, the Netherlands and the United Kingdom. Unless otherwise indicated, trademarks appearing in italics throughout this document are trademarks of, or are used under license by, the Organon group of companies.

The Company’s operations include the following product portfolios:

•Women’s Health: the Company has a portfolio of contraception and fertility brands, such as Nexplanon® (etonogestrel implant) (sold as Implanon NXT™ in some countries outside the U.S.), a long-acting reversible contraceptive, which is a class of contraceptives that are recognized as the most effective type of hormonal contraception available to patients with a lower long-term average cost.

•Biosimilars: the Company’s current portfolio spans across immunology and oncology treatments. All five of the biosimilars in Organon’s portfolio have launched in certain countries globally, including two biosimilars in the United States.

•Established Brands: the Company has a portfolio of established brands, which generally are beyond market exclusivity, including leading brands in cardiovascular, respiratory, dermatology and non-opioid pain management.

On June 2, 2021, Organon and Merck entered into a Separation and Distribution Agreement (the "Separation and Distribution Agreement"). Pursuant to the Separation and Distribution Agreement, Merck agreed to spin off the Organon Products into Organon, a new, publicly-traded company (the "Separation").

In connection with the Separation, on June 2, 2021, Merck distributed (the "Distribution"), on a pro rata basis, to holders of the outstanding shares of common stock of Merck, par value $0.50 per share (the "Merck Common Stock") on May 17, 2021 (the "Record Date"), all of the outstanding shares of common stock, par value $0.01 per share, of Organon (the "Common Stock"). Each Merck stockholder was entitled to receive one-tenth of a share of the Common Stock for each share of Merck Common Stock held on the Record Date. Organon is now a standalone publicly-traded company and, on June 3, 2021, regular-way trading of the Common Stock commenced on the New York Stock Exchange under the ticker symbol "OGN."

The Separation was completed pursuant to the Separation and Distribution Agreement and other agreements with Merck related to the Separation, including, but not limited to a tax matters agreement (the "Tax Matters Agreement" or "TMA"), an employee matters agreement (the "Employee Matters Agreement" or "EMA") and a transition services agreement (the "Transition Service Agreement" or "TSA"). Following the Separation, certain functions continue to be provided by Merck under the TSA or are being performed using the Company’s own resources or third-party service providers. Under the TSA, Merck is providing Organon various services and, similarly, Organon is providing Merck various services. The provision of services under the TSA generally will terminate within 25 months following the spin-off; however, the provision of certain services has been extended to at least 31 months. Additionally, under manufacturing and supply agreements, the Company manufactures certain products for Merck, or its applicable affiliate and Merck manufactures certain products for the Company or its applicable affiliate (see Note 13 for additional details). The Company incurred certain costs in its establishment as a standalone public company and expects to incur ongoing additional costs associated with operating as an independent, publicly-traded company.

XML

Basis of Presentation

9 Months Ended

Sep. 30, 2022

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Basis of Presentation

Basis of PresentationThe unaudited financial statements for all periods presented, including the historical results of the Company prior to June 2, 2021, are referred to as "Condensed Consolidated Financial Statements," and have been prepared pursuant to the rules and regulations for reporting on Form 10-Q. Accordingly, certain information and disclosures required by U.S. generally accepted accounting principles ("GAAP") for complete consolidated financial statements are not included herein. The results of operations of any interim period are not necessarily indicative of the results of operations for the full year. In the Company’s opinion, all adjustments necessary for a fair statement of these interim statements have been included and are of a normal and recurring nature. All intercompany transactions and accounts within Organon have been eliminated. These interim statements should be read in conjunction with the audited financial statements and notes thereto included in Organon’s Annual Report on Form 10-K for the year ended December 31, 2021.

Prior to the Separation on June 2, 2021, the Company’s historical Consolidated Financial Statements were prepared on a standalone basis and were derived from Merck’s consolidated financial statements and accounting records. The assets, liabilities, revenue and expenses of the Company were reflected in the Condensed Consolidated Financial Statements on a historical cost basis, as included in the consolidated financial statements of Merck, using the historical accounting policies applied by Merck, following a legal entity approach. For such periods prior to the Separation, certain corporate and shared costs were allocated to the Company based on a specific identification basis or, when specific identification was not practicable, a proportional cost allocation method. Refer to Note 2 of the audited Consolidated Financial Statements in the Company's 2021 Form 10-K for additional details on Organon's basis of presentation during periods prior to the Separation, at Separation and post Separation.

The Company’s historical results prior to the Separation included certain Merck non-U.S. legal entities that were conveyed to Organon in connection with the Separation (collectively, the "Transferred Entities" and each, a "Transferred Entity") and included operations related to other Merck products that were retained by Merck (the "Merck Retained Products"). The Merck Retained Products business of the Transferred Entities was contributed by the Company to Merck and its affiliates and any remaining assets and liabilities were transferred as of June 2, 2021. Accordingly, the historical results of operations of the Merck Retained Products have been reflected as discontinued operations in these Condensed Consolidated Financial Statements.

For periods prior to the Separation, income tax expense in the Condensed Consolidated Statement of Income was calculated on a separate tax return basis and the Company’s operations were included in the tax returns of certain legal entities established to operate the Organon Products business (the "Organon Entities"), Transferred Entities, or the respective Merck entities of which the Company’s business was a part. As of June 2, 2021, and in connection with the Separation, the Company adjusted its deferred tax balances and computed its related tax provision to reflect operations as a standalone entity. As a standalone entity, the Company files tax returns on its own behalf, and tax balances and effective income tax rates may differ from the amounts reported in the historical periods.

Certain assets and liabilities, including accounts receivables, inventories and trade payables included on the Condensed Consolidated Balance Sheet prior to the Separation, were retained by Merck post-Separation and therefore were recorded through Net investment from Merck & Co., Inc. in the Company’s Condensed Consolidated Financial Statements. As part of the Separation, Net investment from Merck & Co., Inc. was reclassified to Common Stock and Accumulated Deficit.

Use of Estimates

The presentation of these Condensed Consolidated Financial Statements and accompanying notes in conformity with U.S. GAAP require management to make estimates and assumptions that affect the amounts reported, as further described in our Form 10-K for the year ended December 31, 2021. Accordingly, actual results could differ materially from management's estimates and assumptions.

Due to the significant uncertainty that exists relative to the duration and overall impact of the COVID-19 pandemic, our future operating performance, particularly in the short-term, may be subject to volatility. The assessment of certain accounting matters and specifically its effect on the Company's results require consideration of forecasted financial information in the context of the information reasonably available to the Company and the unknown future impacts of the COVID-19 pandemic as of September 30, 2022 and through the date of this report.

Recently Adopted Accounting Standards

There were no recently issued accounting standards adopted by the Company during the three and nine months ended September 30, 2022. Refer to Note 3 of the audited Consolidated Financial Statements in Organon's Form 10-K for the year ended December 31, 2021 for standards adopted in 2021.

Recently Issued Accounting Standards Not Yet Adopted

In March 2022, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2022-02, Financial Instruments—Credit Losses (Topic 326): Troubled Debt Restructurings and Vintage Disclosures, an amendment to the accounting for credit losses on financial instruments. This amendment eliminates the recognition and measurement guidance on troubled debt restructurings for creditors that have adopted the new credit losses guidance in Accounting Standards Codification 326 ("ASC 326") and requires enhanced disclosures about loan modifications for borrowers experiencing financial difficulty. The new guidance also requires public business entities to present gross write-offs by year of origination in their

vintage disclosures. The guidance is effective for the Company on January 1, 2023, including interim periods. Early adoption is permitted, and the amendment applied prospectively, except for the recognition and remeasurement of troubled debt restructurings. Entities can elect to adopt the guidance on troubled debt restructurings using either a prospective or modified retrospective transition. If an entity elects to apply a modified retrospective transition, it will record a cumulative effect adjustment to retained earnings in the period of adoption. The Company does not expect the adoption of this guidance to have a material impact on the Consolidated Financial Statements.

In November 2021, the FASB issued ASU 2021-10, Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance, new guidance requiring disclosures about transactions with a government that have been accounted for by analogizing to a grant or contribution accounting model. The guidance increases transparency about the types of transactions, the accounting for the transactions, and the effect of the transactions to the Company’s financial statements. The guidance is effective for annual periods in 2022 and can be applied on a prospective or retrospective basis. The Company is currently evaluating the impact of adoption on its Consolidated Financial Statements. The Company does not anticipate a material impact to its Consolidated Financial Statements.

In October 2021, the FASB issued ASU 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers, guidance to improve the accounting for contract assets and contract liabilities from acquired revenue contracts with customers in a business combination. The guidance addresses diversity in practice and inconsistency related to the recognition of an acquired contract liability, payment terms and their effect on subsequent revenue recognized by an acquirer. The guidance is effective for the Company on January 1, 2023 and its amendments will be applied prospectively to business combinations occurring on or after the effective date of the guidance. Early adoption is permitted, including adoption in an interim period and subject to different transition requirements. The adoption of this guidance will not have an impact on the Company’s Consolidated Financial Statements for prior acquisitions; however, the impact in future periods will be dependent upon the contract assets and contract liabilities acquired in future business combinations.

In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting, optional guidance to ease the potential burden in accounting for (or recognizing the effects of) reference rate reform on financial reporting and subsequently issued clarifying amendments. The guidance provides optional expedients and exceptions for applying GAAP to contracts, hedging relationships, and other transactions that reference the London Interbank Offered Rate ("LIBOR") or another reference rate expected to be discontinued because of reference rate reform. The optional guidance is effective upon issuance and can be applied on a prospective basis at any time between January 1, 2020 and December 31, 2022. The Company is currently evaluating the impact of adoption on its Consolidated Financial Statements. The Company does not anticipate a material impact to its Consolidated Financial Statements.

XML

Samsung Collaboration

9 Months Ended

Sep. 30, 2022

Revenue from Contract with Customer [Abstract]

Samsung Collaboration

Samsung Collaboration

The Company has an agreement with Samsung Bioepis Co., Ltd. ("Samsung Bioepis") to develop and commercialize multiple pre-specified biosimilar candidates, which have since launched and are part of the Company’s product portfolio. Under the agreement, Samsung Bioepis is responsible for preclinical and clinical development, process development and manufacturing, clinical trials and registration of product candidates, and the Company has an exclusive license for worldwide commercialization with certain geographic exceptions specified on a product-by-product basis. The Company’s access rights to each product under the agreement last for 10 years from each product’s launch date on a market-by-market basis. Gross profits are shared equally in all markets with the exception of Brazil where gross profits are shared 65% to Samsung Bioepis and 35% to the Company. Since the Company is the principal on sales transactions with third parties, the Company recognizes sales, cost of sales and selling, general and administrative expenses on a gross basis. Generally, profit sharing adjustments are recorded either to Cost of sales (after commercialization) or Selling, general and administrative expenses (prior to commercialization).

In August 2022, the U.S. Food and Drug Administration ("FDA") approved the citrate-free, high-concentration (100 mg/mL) formulation of Hadlima™ (adalimumab-bwwd), a biosimilar referencing Humira® (adalimumab) (trademark of Abbvie Biotechnology Ltd). During the third quarter of 2022, Organon paid Samsung Bioepis $18 million. This amount was recognized as an intangible asset which will be amortized over the estimated useful life of approximately 10 years.

Samsung Bioepis is eligible for additional payments associated with pre-specified clinical and regulatory milestones. As of September 30, 2022, potential future regulatory milestone payments of $25 million remain under the agreement.

Summarized information related to this collaboration is as follows:

	Three Months Ended September 30,				Nine Months Ended September 30,
($ in millions)	2022		2021		2022		2021
Sales	$	129	$	139	$	346	$	305
Cost of sales	86		83		221		183
Selling, general and administrative	18		18		60		50

($ in millions)	September 30, 2022		December 31, 2021
Receivables from Samsung included in Other current assets	$	10	$	15
Payables to Samsung included in Trade accounts payable	24		21

XML

Acquisitions and Licensing Arrangements

9 Months Ended

Sep. 30, 2022

Business Combination and Asset Acquisition [Abstract]

Acquisitions and Licensing Arrangements

Acquisitions and Licensing Arrangements

Cirqle Biomedical ("Cirqle")

In July 2022, the Company entered into a research collaboration and license agreement with Cirqle for a novel investigational non-hormonal, on-demand contraceptive candidate. Under the terms of the agreement, Cirqle is responsible for conducting preclinical studies according to the mutually agreed research plan. Organon obtained exclusive worldwide rights to develop and commercialize the asset.

Under the terms of the research collaboration and license agreement, Organon expensed a $10 million upfront payment during the third quarter of 2022. Cirqle is eligible to receive potential regulatory and commercial milestone payments of up to $360 million and tiered royalties based on net sales. As of September 30, 2022, the Company recognized the $10 million upfront payment as Acquired in-process research and development and milestones expense. The remaining potential milestone payments will be recognized by Organon when achievement of the contractual milestones is probable.

Shanghai Henlius Biotech, Inc. ("Henlius")

In June 2022, Organon and Henlius, a global biopharmaceutical company, entered into a definitive agreement whereby Organon is licensing commercialization rights for biosimilar candidates referencing Perjeta® (pertuzumab, HLX11), (a trademark of Genentech, Inc.), used for the treatment of certain patients with HER2+ breast cancer in combinations with trastuzumab and chemotherapy and Prolia®/Xgeva® (denosumab, HLX14), (trademarks of Amgen Inc.) used for the treatment of certain patients with osteoporosis with high risk of fracture and for the prevention of skeletal-related events in patients with multiple myeloma and in patients with bone metastasis from solid tumors. Organon obtained exclusive global commercialization rights except for China; including Hong Kong, Macau and Taiwan. The agreement includes an option to negotiate an exclusive license for global commercialization rights for a biosimilar candidate referencing Yervoy® (ipilimumab, HLX13) (a trademark of Bristol-Myers Squibb Company). Ipilimumab is used for the treatment of certain patients with unresectable or metastatic melanoma, as adjuvant treatment of certain patients with cutaneous melanoma, certain patients with renal cell carcinoma, colorectal cancer, hepatocellular carcinoma, non-small cell lung cancer, malignant pleural mesothelioma and esophageal cancer.

Under the terms of the license agreement, Organon paid a $73 million upfront payment during the third quarter of 2022, of which $3 million was reflected in Other current assets. Henlius is eligible to receive potential developmental, regulatory and commercial milestone payments of up to $468 million. During the nine months ended September 30, 2022, the Company paid milestones of $97 million, reflecting a $70 million upfront payment and $27 million related to certain development milestones which were recognized as Acquired in-process research and development and milestones expense during the second quarter of 2022. The remaining potential milestone payments will be recognized by Organon when achievement of the contractual milestones is probable. Henlius will be responsible for development and, if approved, will supply the products to Organon.

Daré Bioscience, Inc. ("Daré")

In March 2022, Organon and Daré, a leader in women’s health innovation, entered into an agreement whereby Organon licensed the global commercial rights to Xaciato® (clindamycin phosphate vaginal gel, 2%). Xaciato is an FDA-approved medication for the treatment of bacterial vaginosis (BV) in females 12 years of age and older. Xaciato received both Qualified Infectious Disease Product (QIDP) and Fast Track designations from the FDA for the treatment of bacterial vaginosis.

Under the terms of the license agreement, Organon paid a $10 million upfront payment during the third quarter of 2022. Daré is eligible to receive potential regulatory and commercial milestone payments of up to $182.5 million and tiered double-digit royalties based on net sales. Xaciato is expected to be available commercially in the U.S. in the first half of 2023. During the nine months ended September 30, 2022 management determined that the first commercial milestone was deemed probable of occurring, and recognized an intangible asset of $12.5 million reflecting the $10 million upfront payment and $2.5 million commercial milestone. The intangible asset will be amortized over its useful life of 12 years. The remaining potential milestone payments will be recognized by Organon when achievement of the contractual milestones is probable.

Bayer AG

In February 2022, Organon acquired the product rights and related inventory from Bayer AG to Marvelon™ (ethinylestradiol, desogestrel) and Mercilon™ (ethinylestradiol, desogestrel), combined oral hormonal daily contraceptive pills, in China, including Hong Kong and Macau, and entered into an agreement to acquire the rights to these products in Vietnam. Marvelon and Mercilon are already owned, manufactured, and marketed by Organon as prescription oral contraceptives in 20 other markets. The transaction was accounted for as an asset acquisition. In the first quarter of 2022, Organon paid $30 million to acquire the product rights and inventory in China and accrued an additional $35 million related to these rights which was paid during the second quarter of 2022. In the third quarter of 2022, Organon paid $30 million to acquire the product rights in Vietnam. This resulted in Organon recognizing an intangible asset of $72 million in total related to the product rights with the remainder of the consideration recorded to Inventories for the fair value of acquired inventory during 2022. The intangible assets related to currently marketed products will be amortized over their estimated useful lives of 10 years.

Alydia Health

During the three months ended September 30, 2022, a cumulative sales-based contingent milestone payment, related to the Jada system device, was determined to be probable of being achieved and the Company recognized an intangible asset and noncurrent liability of $25 million. The intangible asset is subject to amortization over its expected useful life.

For details regarding Organon's 2021 acquisitions and licensing agreements, see Note 5 to the audited Consolidated Financial Statements in the Company's 2021 Form 10-K.

XML

Financial Instruments

9 Months Ended

Sep. 30, 2022

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Financial Instruments

Financial Instruments

Foreign Currency Risk Management

The Company has a balance sheet risk management and a net investment hedging program to mitigate against volatility of changes in foreign exchange rates.

The Company uses a balance sheet risk management program to mitigate the exposure of net monetary assets of its subsidiaries that are denominated in a currency other than a subsidiary’s functional currency from the effects of volatility in foreign exchange. In these instances, Organon principally utilizes forward exchange contracts to offset the effects of exchange on exposures denominated in developed country currencies, primarily the euro, Swiss franc and Japanese yen. For exposures in developing country currencies, the Company enters into forward contracts to partially offset the effects of exchange on exposures when it is deemed economical to do so based on a cost-benefit analysis that considers the magnitude of the exposure, the volatility of the exchange rate and the cost of the hedging instrument.

Monetary assets and liabilities denominated in a currency other than the functional currency of a given subsidiary are remeasured at spot rates in effect on the balance sheet date with the effects of changes in spot rates reported in Other (income) expense, net. The forward contracts are not designated as hedges and are marked to market through Other (income) expense, net. Accordingly, fair value changes in the forward contracts help mitigate the changes in the value of the remeasured assets and liabilities attributable to changes in foreign currency exchange rates, except to the extent of the spot-forward differences. These differences are not significant due to the short-term nature of the contracts, which typically have average maturities at inception of less than one year. The notional amount of forward contracts was $1.3 billion as of September 30, 2022 and $2.1 billion as of

December 31, 2021. The cash flows from these contracts are reported as operating activities in the Condensed Consolidated Statements of Cash Flows.

The Company measures fair value based on the prices that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value measurements are based on a three-tier hierarchy that prioritizes the inputs used to measure fair value. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs for which little or no market data exists, therefore requiring an entity to develop its own assumptions.

The following financial instruments were recorded at their estimated fair value. The recurring fair value measurement of our assets and liabilities were as follows:

($ in millions)	Fair Value Measurement Level	September 30, 2022		December 31, 2021
Forward contracts in Other current assets	2	$	35	$	19
Forward contracts in Accrued and other current liabilities	2	23		5

Foreign exchange risk is also managed through the use of economic hedges on foreign currency debt (see Note 7). In each quarter subsequent to the Separation, €1.75 billion in the aggregate of both the euro-denominated term loan (€750 million) and of the 2.875% euro-denominated secured notes (€1.25 billion) has been designated and is effective as an economic hedge of the net investment in euro-denominated subsidiaries.

Foreign currency gains due to spot rate fluctuations on the euro-denominated debt instruments included in foreign currency translation adjustments were as follows:

	Three Months Ended September 30,				Nine Months Ended September 30,
($ in millions)	2022		2021		2022		2021
Foreign currency gains in Other comprehensive income	$	176	$	38	$	303	$	94

The Condensed Consolidated Statements of Income include the impact of actual net gains and losses of Organon's derivative financial instruments, as well as the impact of Merck’s derivative financial instruments prior to the Separation allocated to the Company utilizing a proportional allocation method:

	Three Months Ended September 30,				Nine Months Ended September 30,
($ in millions)	2022		2021		2022		2021
Allocated net loss in Revenues	$	—	$	1	$	—	$	56
Foreign exchange loss (gain) in Other expense, net	4		1		(21)		6

Prior to the Separation, Merck managed the impact of foreign exchange rate movements on its affiliates’ earnings, cash flows and fair values of assets and liabilities through operational means and through the use of various financial instruments, including derivative instruments. Merck established revenue hedging and balance sheet risk management programs that the Company participated in to protect against the volatility of future foreign currency cash flows and changes in fair value caused by volatility in exchange rates.

Organon has established accounts receivable factoring agreements with financial institutions in certain countries to sell accounts receivable. Under these agreements, Organon factored $61 million and $87 million of accounts receivable as of September 30, 2022 and December 31, 2021, respectively, which reduced outstanding accounts receivable. The cash received from the financial institutions is reported within operating activities in the Condensed Consolidated Statements of Cash Flows.

XML

Inventories

9 Months Ended

Sep. 30, 2022

Inventory Disclosure [Abstract]

Inventories

Inventories

Inventories consisted of:

($ in millions)	September 30, 2022		December 31, 2021
Finished goods	$	403	$	377
Raw materials	71		95
Work in process	479		490
Supplies	40		40
Total (approximates current cost)	$	993	$	1,002
Decrease to LIFO costs	(18)		(11)
	$	975	$	991
Recognized as:
Inventories	$	879	$	915
Other assets	96		76
Inventories valued under the last in, first out ("LIFO") method	82		52

Amounts recognized as Other assets are comprised primarily of raw materials and work in process inventories and are not expected to be converted to finished goods that will be sold within one year. The Company has a long-term vendor supply contract conveyed as part of the Separation that includes certain annual minimum purchase commitments.

During the third quarter of 2021, the Company recorded $24 million within Other noncurrent liabilities due to estimated unavoidable losses associated with the supply contract. The charge was recognized as a component of Cost of sales during the third quarter of 2021 and the nine months ended September 30, 2021.

XML

Long-Term Debt

9 Months Ended

Sep. 30, 2022

Debt Disclosure [Abstract]

Long-Term Debt

Long-Term Debt

The following is a summary of Organon's total debt:

($ in millions)	September 30, 2022		December 31, 2021
Term Loan B Facility:
LIBOR plus 300 bps term loan due 2028	$	2,793	$	2,893
LIBOR plus 300 bps euro-denominated term loan due 2028 (€750 million)	708		843
4.125% secured notes due 2028	2,100		2,100
2.875% euro-denominated secured notes due 2028 (€1.25 billion)	1,196		1,412
5.125% notes due 2031	2,000		2,000
Other borrowings	8		10
Other (discounts and debt issuance costs)	(106)		(124)
Total principal long-term debt	$	8,699	$	9,134
Less: Current portion of long-term debt	8		9
Total Long-term debt, net of current portion	$	8,691	$	9,125

Other borrowings represent debt assumed in connection with the acquisition of Forendo Pharma in December 2021.

In June 2021, the Company entered into a credit agreement (the “Senior Credit Agreement”) providing for a Term Loan B Facility, consisting of (i) a U.S. Dollar-denominated senior secured “tranche B” term loan in the amount of $3.0 billion due 2028 (ii) a euro-denominated senior secured “tranche B” term loan in the amount of €750 million due 2028; and (iii) a Revolving Credit Facility (“Revolving Credit Facility”), in an aggregate principal amount of up to $1 billion, with a five-year term that matures in 2026.

The interest rate on revolving loans under the Revolving Credit Facility is subject to a step-down based on meeting a leverage ratio target. A commitment fee applies to the unused portion of the Revolving Credit Facility, initially equal to 0.50% and subject to a step-down to 0.375% based on meeting a leverage ratio target. There were no outstanding balances under the Revolving Credit Facility as of September 30, 2022 or December 31, 2021.

Long-term debt was recorded at the carrying amount. The estimated fair value of long-term debt (including current portion) is as follows:

($ in millions)	September 30, 2022		December 31, 2021
Long-term debt (includes a reduction for amortized debt issuance costs)	$	7,772	$	9,412

Fair value was estimated using inputs other than quoted prices in active markets for identical assets and liabilities that are observable either directly or indirectly for substantially the full term of the asset or liability and would be considered Level 2 in the fair value hierarchy.

The Company made interest payments of $218 million for the nine months ended September 30, 2022 related to its debt instruments. The average maturity of the Company's long-term debt as of September 30, 2022 is approximately 6.3 years and the weighted-average interest rate on total borrowings as of September 30, 2022 is 4.5%.

On June 6, 2022, the Company made a discretionary prepayment of $100 million on the U.S. Dollar-denominated term loan.

The schedule of principal payments required on long-term debt for the next five years and thereafter is as follows:

($ in millions)
2022	$	2
2023	8
2024	8
2025	8
2026	11
Thereafter	8,768

The Senior Credit Agreement contains customary financial covenants, including a total leverage ratio covenant, which measures the ratio of (i) consolidated total debt to (ii) consolidated earnings before interest, taxes, depreciation and amortization, and subject to other adjustments, that must meet certain defined limits which are tested on a quarterly basis. In addition, the Senior Credit Agreement contains covenants that limit, among other things, Organon’s ability to prepay, redeem or repurchase its subordinated and junior lien debt, incur additional debt, make acquisitions, merge with other entities, pay dividends or distributions, redeem or repurchase equity interests, and create or become subject to liens. As of September 30, 2022, the Company is in compliance with all financial covenants and no default or event of default has occurred.

XML

Contingencies

9 Months Ended

Sep. 30, 2022

Commitments and Contingencies Disclosure [Abstract]

Contingencies

Contingencies

Organon is involved in various claims and legal proceedings of a nature considered normal to its business, including product liability, intellectual property, and commercial litigation, as well as certain additional matters including governmental and environmental matters. In the opinion of Organon as of September 30, 2022, it is unlikely that the resolution of these matters will be material to Organon's financial condition, results of operations or cash flows.

Given the nature of the litigation discussed in this note and the complexities involved in these matters, Organon is unable to reasonably estimate a possible loss or range of possible loss for such matters until Organon knows, among other factors, (i) what claims, if any, will survive dispositive motion practice, (ii) the extent of the claims, including the size of any potential class, particularly when damages are not specified or are indeterminate, (iii) how the discovery process will affect the litigation, (iv) the settlement posture of the other parties to the litigation, and (v) any other factors that may have a material effect on the litigation.

Organon records accruals for contingencies when it is probable that a liability has been incurred and the amount can be reasonably estimated. These accruals are adjusted periodically as assessments change or additional information becomes available. Individually significant contingent losses are accrued when probable and reasonably estimable. Legal defense costs expected to be incurred in connection with a loss contingency are accrued when probable and reasonably estimable.

Organon's decision to obtain insurance coverage is dependent on market conditions, including cost and availability, existing at the time such decisions are made. Organon has evaluated its risks and has determined that the cost of obtaining product liability insurance outweighs the likely benefits of the coverage that is available and, as such, has no insurance for most product liabilities.

Reference is made below to certain litigation in which Merck, but not Organon, is named as a defendant. Pursuant to the Separation and Distribution Agreement, Organon is required to indemnify Merck for liabilities relating to, arising from, or resulting from such litigation.

Product Liability Litigation

Fosamax

Merck is a defendant in product liability lawsuits in the United States involving Fosamax® (alendronate sodium) (the "Fosamax Litigation"). As of September 30, 2022, approximately 3,285 cases comprising the Fosamax Litigation are pending against Merck in either federal or state court. Plaintiffs in the vast majority of these cases generally allege that they sustained femur fractures and/or other bone injuries ("Femur Fractures") in association with the use of Fosamax.

All federal cases involving allegations of Femur Fractures have been or will be transferred to a multidistrict litigation in the District of New Jersey ("Femur Fracture MDL"). In the only bellwether case tried to date in the Femur Fracture MDL, Glynn v. Merck, the jury returned a verdict in Merck's favor. In addition, in June 2013, the Femur Fracture MDL court granted Merck's motion for judgment as a matter of law in the Glynn case and held that the plaintiff's failure to warn claim was preempted by federal law.

In August 2013, the Femur Fracture MDL court entered an order requiring plaintiffs in the Femur Fracture MDL to show cause why those cases asserting claims for a femur fracture injury that took place prior to September 14, 2010, should not be dismissed based on the court's preemption decision in the Glynn case. Pursuant to the show cause order, in March 2014, the Femur Fracture MDL court dismissed with prejudice approximately 650 cases on preemption grounds. Plaintiffs in approximately 515 of those cases appealed that decision to the U.S. Court of Appeals for the Third Circuit ("Third Circuit"). In March 2017, the Third Circuit issued a decision reversing the Femur Fracture MDL court's preemption ruling and remanding the appealed cases back to the Femur Fracture MDL court. In May 2019, the U.S. Supreme Court decided that the Third Circuit had incorrectly concluded that the issue of preemption should be resolved by a jury, and accordingly vacated the judgment of the Third Circuit and remanded the proceedings back to the Third Circuit to address the issue in a manner consistent with the Supreme Court's opinion. In November 2019, the Third Circuit remanded the cases back to the District Court in order to allow that court to determine in the first instance whether the plaintiffs' state law claims are preempted by federal law under the standards described by the Supreme Court in its opinion. On March 23, 2022, the District Court granted Merck's motion and ruled that plaintiffs' failure to warn claims are preempted as a matter of law to the extent they assert that Merck should have added a Warning or Precaution regarding atypical femur fractures prior to October 2010. On July 11, 2022, the District Court entered an Order to Show Cause as to why the Court should not dismiss either with prejudice or conditionally all of plaintiffs' claims that are not dependent on the preempted failure to warn claims.

Accordingly, as of September 30, 2022, approximately 975 cases were actively pending in the Femur Fracture MDL.

As of September 30, 2022, approximately 2,030 cases alleging Femur Fractures have been filed in New Jersey state court and are pending in Middlesex County. The parties selected an initial group of cases to be reviewed through fact discovery, and Merck has continued to select additional cases to be reviewed.

As of September 30, 2022, approximately 275 cases alleging Femur Fractures have been filed and are pending in California state court. All of the Femur Fracture cases filed in California state court have been coordinated before a single judge in Orange County, California.

Additionally, there are four Femur Fracture cases pending in other state courts.

Discovery is presently stayed in the Femur Fracture MDL and in the state court in California.

Nexplanon/Implanon

Merck is a defendant in lawsuits brought by individuals relating to the use of Nexplanon and Implanon™ (etonogestrel implant). In the United States, as of September 30, 2022, there was one filed product liability action involving Nexplanon pending in the Western District of Arkansas (in which Organon is also named as a defendant). The court's schedule for the matter provides for a trial date in the fourth quarter of 2023, should it be necessary. In addition, there were two filed product liability actions involving Implanon, both of which are pending in the Northern District of Ohio as well as 56 unfiled cases involving Implanon alleging similar injuries, which have been tolled under a written tolling agreement. As of September 30, 2022, Merck had 18 cases pending outside the United States, of which 12 relate to Implanon and six relate to Nexplanon.

Propecia/Proscar

Merck is a defendant in product liability lawsuits in the United States involving Propecia® (finasteride) and/or Proscar® (finasteride). The federal lawsuits were consolidated for pretrial purposes in federal multidistrict litigation in the Eastern District of New York (the "MDL"), and the matters in state court in New Jersey were consolidated in Middlesex County ("N.J. Coordinated Proceedings"). In 2018, Merck and the plaintiffs' Executive Committee in the MDL and the plaintiffs' Liaison Counsel in the N.J. Coordinated Proceedings entered into an agreement to resolve the lawsuits for an aggregate amount of $4.3 million. The settlement was subject to certain contingencies, including 95% plaintiff participation and a per plaintiff clawback if the participation rate was less than 100%. The contingencies were satisfied and the settlement agreement has been finalized.

As of September 30, 2022, only three cases remain pending in the United States, (1) a case currently pending in the MDL; (2) a matter involving Propecia in state court in Los Angeles, California in which Merck's motion for summary judgment was granted and subsequently appealed; and (3) a matter involving Proscar in the United States District Court for the Eastern District of California in which Merck's motion to dismiss was granted by the District Court. In the Propecia case in the MDL, the Court granted Merck's motion for partial summary judgment on September 8, 2022. In the Proscar case, the plaintiff can appeal the decision. The Company is also defending 16 product liability cases outside the United States, two of which are class actions and four of which are putative class actions.

Governmental Proceedings

From time to time, Organon's subsidiaries may receive inquiries and may be the subject of preliminary investigation activities from competition and/or other governmental authorities, including in markets outside the United States. These authorities may include regulators, administrative authorities, and law enforcement and other similar officials, and these preliminary investigation activities may include site visits, formal or informal requests or demands for documents or materials, inquiries or interviews and similar matters. Certain of these preliminary inquiries or activities may lead to the commencement of formal proceedings. Should those proceedings be determined adversely to Organon, monetary fines and/or remedial undertakings may be required. Subject to certain exceptions specified in the Separation and Distribution Agreement, Organon assumed liability for all pending and threatened legal matters related to products transferred to Organon, including competition investigations resulting from enforcement activity concerning Merck's conduct involving Organon's products. Organon could be obligated to indemnify Merck for fines or penalties, or a portion thereof, resulting from such investigations. In one such enforcement matter in Spain concerning NuvaRing® (etonogestrel/ethinyl estradiol vaginal ring), the National Commission on Markets and Competition (CNMC) recently imposed a fine on Merck in the amount of €39 million for abuse of a dominant position in the market for contraceptive vaginal rings from June 2017 to April 2018. The CNMC decision to impose the fine is appealable to the National High Court in Spain. If the fine ultimately stands, Organon could be obligated to indemnify Merck for a portion thereof.

Hadlima™ (adalimumab-bwwd)

In July 2021, Organon received a Civil Investigation Demand ("CID") from the Office of the Attorney General for the State of Washington. The CID requests answers to interrogatories, as well as various documents, regarding certain activities related to adalimumab and adalimumab biosimilars. Organon is cooperating with the government's investigation and has produced information in response to the CID.

Patent Litigation

From time to time, generic manufacturers of pharmaceutical products file Abbreviated New Drug Applications ("ANDAs") with the U.S. Food and Drug Administration ("FDA") seeking to market generic forms of Organon's products prior to the expiration of relevant patents owned by Organon. To protect its patent rights, Organon may file patent infringement lawsuits against such generic companies. Similar lawsuits defending Organon's patent rights may exist in other countries. Organon intends to vigorously defend its patents, which it believes are valid, against infringement by companies attempting to market products prior to the expiration of such patents. As with any litigation, there can be no assurance of the outcomes, which, if adverse, could result in significantly shortened periods of exclusivity for these products, potential payment of damages and legal fees, and, with respect to products acquired through acquisitions, potentially significant intangible asset impairment charges.

Nexplanon

In June 2017, Microspherix LLC ("Microspherix") sued Organon in the U.S. District Court for the District of New Jersey asserting that the manufacturing, use, sale and importation of Nexplanon infringed several of Microspherix's patents that claim radio-opaque, implantable drug delivery devices. Microspherix is claiming damages from September 2014 until the patents expired in May 2021. Organon brought Inter Partes Review ("IPR") proceedings in the United States Patent and Trademark Office ("USPTO") and successfully stayed the district court action. The USPTO invalidated some, but not all, of the claims asserted against Organon. Organon appealed the decisions that found claims valid, and the Court of Appeals for the Federal Circuit affirmed the USPTO's decisions. The matter is no longer stayed in the district court, and Organon is currently litigating the invalidity and non-infringement of the remaining asserted claims. A claim construction hearing was held on March 2, 2022, and any further dates in the schedule will be set based on the date the court issues a claim construction order.

Other Litigation

There are various other pending legal proceedings involving Organon, principally product liability and intellectual property lawsuits. While it is not feasible to predict the outcome of such proceedings, in the opinion of Organon as of September 30, 2022, either the likelihood of loss is remote or any reasonably possible loss associated with the resolution of such proceedings is not expected to be material to Organon's financial condition, results of operations or cash flows either individually or in the aggregate.

Legal Defense Reserves

Legal defense costs expected to be incurred in connection with a loss contingency are accrued when probable and reasonably estimable. Some of the significant factors considered in the review of these legal defense reserves are as follows: the actual costs incurred by Organon; the development of Organon's legal defense strategy and structure in light of the scope of its litigation; the number of cases being brought against Organon; and the costs and outcomes of completed trials and the most current information regarding anticipated timing, progression, and related costs of pre-trial activities and trials in the associated litigation. The legal defense reserve as of September 30, 2022 and December 31, 2021 was $15 million and $9 million, respectively, and represented Organon's best estimate of the minimum amount of defense costs to be incurred in connection with its outstanding litigation; however, events such as additional trials and other events that could arise in the course of its litigation could affect the ultimate amount of legal defense costs to be incurred by Organon. Organon will continue to monitor its legal defense costs and review the adequacy of the associated reserves and may determine to increase the reserves at any time in the future if, based upon the factors set forth, it believes it would be appropriate to do so.

XML

Stock-based Compensation Plans

9 Months Ended

Sep. 30, 2022

Share-Based Payment Arrangement [Abstract]

Stock-based Compensation Plans

Stock-Based Compensation Plans

The Company grants stock option awards, performance share units ("PSUs") and restricted share units ("RSUs") pursuant to its 2021 Incentive Stock Plan.

Employee stock options are granted to purchase shares of Company stock at the fair market value at the time of grant. Generally, stock options have a contractual term of ten years and vest one-third each year over a three-year period, subject to limited exceptions.

RSUs are stock awards that are granted to employees and entitle the holder to shares of common stock as the awards vest. RSU awards generally vest one-third each year over a three-year period. The fair value of the stock option and RSU awards is determined and fixed on the grant date based on the Company’s stock price.

The terms of the Company's PSU awards allow the recipients of such awards to earn a variable number of common shares based on the cumulative results of specified performance factors. The Company has PSU awards based on the following performance factors:

•total stockholder return of the Company relative to an index of peer companies ("relative TSR") specified in the awards

•the results of the cumulative free cash flow ("FCF") of the Company over a three year period

For FCF and TSR awards, the Company recognizes compensation costs ratably over the performance period. The PSU Awards will generally vest at the end of the three year performance period, however, the number of shares delivered will vary based upon the attained level of performance. For PSUs with a performance-based FCF goal, stock-based compensation expense is recognized based on the probability of the achievement of the financial performance metric for the respective vesting period and is assessed at each reporting date. For PSUs with a market-based relative TSR goal, stock-based compensation expense is recognized based on the estimated fair value of the award at the grant date regardless of the actual number of shares earned. PSU awards generally vest after three years.

For RSUs and PSUs, dividends declared during the vesting period are payable to the employees only upon vesting. RSU and PSU distributions will be in shares of Company stock after the end of the vesting or performance period, subject to the terms applicable to such awards.

Stock-based compensation expense incurred by the Company was as follows:

	Three Months Ended September 30,				Nine Months Ended September 30,
($ in millions)	2022		2021		2022		2021
Stock-based compensation expense recognized in:
Cost of sales	$	3	$	3	$	9	$	8
Selling, general and administrative	12		10		35		26
Research and development	3		2		8		10
Income tax benefits	3		3		11		9

The Company used the Black-Scholes model to determine the fair value of the stock options as of the grant date using the following assumptions:

	Nine Months Ended September 30,
	2022
Expected dividend yield	3.12	%
Risk-free interest rate	2.47	%
Expected volatility	43.43	%
Expected life (years)	5.89

A summary of the equity award transactions for the nine months ended September 30, 2022 are as follows:

	Stock Options					Restricted Share Units			Performance Share Units
(shares in thousands)	Shares	Weighted average exercise price		Weighted average grant date fair value		Shares	Weighted average grant date fair value		Shares	Weighted average grant date fair value
Outstanding as of January 1, 2022	4,394	$	34.35	$	8.63	3,280	$	36.69	120	$	51.63
Granted	556	$	34.93	$	11.34	2,299	$	34.87	373	$	45.23
Vested/Exercised	(15)	$	37.39	$	9.72	(1,251)	$	37.50	—	$	—
Forfeited/Cancelled	(160)	$	35.72	$	9.70	(242)	$	35.76	(7)	$	51.63
Outstanding as of September 30, 2022	4,775	$	34.36	$	8.91	4,086	$	35.48	486	$	46.72

The following table summarizes information about equity awards outstanding that are vested and expected to vest and equity awards outstanding that are exercisable as of September 30, 2022:

	Equity Awards Vested and Expected to Vest						Equity Awards That are Exercisable
(shares in thousands; aggregate intrinsic value in millions)	Awards	Weighted Average Exercise Price		Aggregate Intrinsic Value		Remaining Term	Awards	Weighted Average Exercise Price		Aggregate Intrinsic Value		Remaining Term
Stock Options	4,585	$	34.36	$	—	7.48	2,429	$	32.98	$	—	6.23
Restricted Share Units	3,781			96		2.03
Performance Share Units	402			11		2.63

The amount of unrecognized compensation costs as of September 30, 2022 was $145 million, which will be recognized in operating expense ratably over the weighted average vesting period of 2.08 years.

XML

Taxes on Income

9 Months Ended

Sep. 30, 2022

Income Tax Disclosure [Abstract]

Taxes on Income

Taxes on Income

The effective income tax rates were 19.6% and 17.1% for the three months ended September 30, 2022 and 2021, respectively, and 20.0% and 11.2% for the nine months ended September 30, 2022 and 2021, respectively. These effective income tax rates reflect the beneficial impact of foreign earnings, offset by the impact of U.S. inclusions under the Global Intangible Low-Taxed Income regime. The effective income tax rate for the first nine months of 2021 reflects the beneficial impact of foreign earnings, a $70 million tax benefit relating to a portion of the non-U.S. step-up of tax basis as well as the income tax benefit recognized in connection with the conclusion of the Internal Revenue Service (IRS) examination of Merck’s 2015-2016 U.S. federal income tax returns. As a result, the Company reflected an allocation from Merck of $18 million representing the Company's portion of the payment made to the IRS in the Condensed Consolidated Financial Statements. The Company's portion of reserves for unrecognized tax benefits for the years under examination exceeded the allocated adjustments relating to this examination period and therefore the Company included a $29 million net tax benefit also included in the nine months ended September 30, 2021. This net benefit reflects reductions in reserves for unrecognized tax benefits and other related liabilities for tax positions relating to the years that were under examination.

On August 16, 2022, the U.S. enacted the Inflation Reduction Act of 2022. Provisions of the bill that relate to tax include the minimum tax on book income, a 1% excise tax on stock buybacks and certain tax incentives to promote clean energy. There are no impacts of the legislation to the third quarter 2022 results. The Company is currently assessing future impacts of this recently enacted legislation.

XML

Other Comprehensive Income (Loss)

9 Months Ended

Sep. 30, 2022

Equity [Abstract]

Other Comprehensive Income (Loss)

Other Comprehensive Income (Loss)

Changes in Accumulated other comprehensive loss (income) by component are as follows:

($ in millions)	Employee Benefit Plans		Cumulative Translation Adjustment		Accumulated Other Comprehensive Loss
Balance at July 1, 2021, net of taxes	$	(26)	$	(438)	$	(464)
Other comprehensive loss, pretax	(3)		(23)		(26)
Tax	—		—		—
Other comprehensive loss, net of taxes	(3)		(23)		(26)
Transfer of benefit plans from Merck affiliates	(3)		—		(3)
Balance at September 30, 2021, net of taxes	$	(32)	$	(461)	$	(493)
Balance at July 1, 2022, net of taxes	$	(13)	$	(576)	$	(589)
Other comprehensive loss, pretax	—		(97)		(97)
Tax	—		—		—
Other comprehensive loss, net of taxes	—		(97)		(97)
Balance at September 30, 2022, net of taxes	$	(13)	$	(673)	$	(686)

($ in millions)	Employee Benefit Plans		Cumulative Translation Adjustment		Accumulated Other Comprehensive (Loss) Income
Balance at January 1, 2021, net of taxes	$	(32)	$	(590)	$	(622)
Other comprehensive (loss) income, pretax	(1)		129		128
Tax	(10)		—		(10)
Other comprehensive (loss) income, net of taxes	(11)		129		118
Transfer of benefit plans to/from Merck affiliates	11		—		11
Balance at September 30, 2021, net of taxes	$	(32)	$	(461)	$	(493)
Balance at January 1,2022, net of taxes	$	(13)	$	(500)	$	(513)
Other comprehensive loss, pretax	(1)		(173)		(174)
Tax	1		—		1
Other comprehensive loss, net of taxes	—		(173)		(173)
Balance at September 30, 2022, net of taxes	$	(13)	$	(673)	$	(686)

XML

Product and Geographic Information

9 Months Ended

Sep. 30, 2022

Segment Reporting [Abstract]

Product and Geographic Information

Product and Geographic Information

The Company’s operations include the following product portfolios, which constitute one operating segment engaged in developing and delivering innovative health solutions through its portfolio of prescription therapies within women’s health, biosimilars and established brands.

Revenues of the Company’s products were as follows:

	Three Months Ended September 30,												Nine Months Ended September 30,
	2022						2021						2022						2021
($ in millions)	U.S.		Int’l		Total		U.S.		Int’l		Total		U.S.		Int’l		Total		U.S.		Int’l		Total
Women’s Health
Nexplanon/Implanon NXT	$	151	$	78	$	229	$	120	$	55	$	175	$	401	$	194	$	595	$	389	$	154	$	543
Follistim AQ	27		33		60		29		32		61		79		100		179		81		97		178
NuvaRing	27		23		50		21		28		49		65		68		133		68		79		147
Ganirelix Acetate Injection	6		30		36		5		20		25		20		77		97		19		66		85
Cerazette	—		15		15		—		18		18		—		47		47		—		53		53
Other Women's Health (1)	24		39		63		18		35		53		80		108		188		80		111		191
Biosimilars
Renflexis	54		7		60		48		6		54		145		20		166		119		17		136
Ontruzant	15		14		29		9		47		56		35		52		87		20		81		101
Brenzys	—		24		24		—		14		14		—		52		52		—		35		35
Aybintio	—		10		10		—		10		10		—		29		29		—		26		26
Hadlima	—		6		6		—		5		5		—		14		14		—		9		9
Established Brands
Cardiovascular
Zetia	2		85		87		1		90		91		7		280		287		6		276		282
Vytorin	1		30		31		3		38		41		6		98		104		8		119		127
Atozet	—		109		109		—		114		114		—		350		350		—		347		347
Rosuzet	—		17		17		—		15		15		—		55		55		—		48		48
Cozaar/Hyzaar	2		68		70		3		84		87		11		244		256		9		256		265
Other Cardiovascular (1)	1		34		35		1		48		49		3		117		120		3		145		148
Respiratory
Singulair	3		92		94		2		98		100		8		308		316		10		289		300
Nasonex	—		49		49		—		49		48		9		173		182		3		141		144
Dulera	31		9		40		48		8		56		98		30		127		121		25		146
Clarinex	—		25		26		2		27		28		3		96		99		5		78		83
Other Respiratory (1)	11		10		21		14		5		18		34		32		66		43		20		64
Non-Opioid Pain, Bone and Dermatology
Arcoxia	—		64		64		—		65		65		—		185		185		—		184		184
Fosamax	1		35		36		1		45		46		2		115		117		3		130		132
Diprospan	—		28		28		—		34		34		—		91		91		—		92		92
Other Non-Opioid Pain, Bone and Dermatology (1)	2		63		65		9		69		79		10		200		210		12		201		213
Other
Proscar	—		26		27		—		27		27		1		76		77		1		91		92
Propecia	2		28		30		1		33		34		5		90		95		5		96		101
Other (1)	6		81		87		10		83		95		21		230		251		32		230		262
Other (2)	—		39		39		1		51		52		—		115		116		(2)		171		168
Revenues	$	366	$	1,171	$	1,537	$	346	$	1,254	$	1,600	$	1,043	$	3,646	$	4,689	$	1,035	$	3,666	$	4,701

Totals may not foot due to rounding. Trademarks appearing above in italics are trademarks of, or are used under license by, the Organon group of companies.

(1) Includes sales of products not listed separately. Revenue from an arrangement for the sale of generic etonogestrel/ethinyl estradiol vaginal ring is included in Other Women's Health.

(2) Includes manufacturing sales to Merck and third parties for current and prior periods and allocated amounts from revenue hedging activities through the date of Separation.

Revenues by geographic area where derived are as follows:

	Three Months Ended September 30,				Nine Months Ended September 30,
($ in millions)	2022		2021		2022		2021
Europe and Canada	$	363	$	410	$	1,243	$	1,314
United States	366		346		1,043		1,035
Asia Pacific and Japan	283		287		888		874
China	241		252		721		693
Latin America, Middle East, Russia and Africa	236		238		665		595
Other (1)	48		67		129		190
Revenues	$	1,537	$	1,600	$	4,689	$	4,701

(1) Primarily reflects manufacturing sales to Merck and third parties for current and prior periods and allocated amounts from revenue hedging activities through the date of Separation.

XML

Third Party Arrangements Related Party Disclosures

9 Months Ended

Sep. 30, 2022

Related Party Transactions [Abstract]

Third Party Arrangements Related Party Disclosures

Third Party Arrangements and Related Party Disclosures

Pursuant to the Separation, Merck ceased to be a related party to Organon and accordingly, no related party transactions or balances have been reported since June 2, 2021.

In connection with the Separation, the Company entered into the Separation and Distribution Agreement, which contains provisions that, among other things, relate to (i) assets, liabilities and contracts to be transferred, assumed and assigned to each of Organon and Merck as part of the Separation, (ii) cross-indemnities principally designed to place financial responsibility for the obligations and liabilities of the Organon business with Organon and financial responsibility for the obligations and liabilities of Merck’s remaining business with Merck, (iii) procedures with respect to claims subject to indemnification and related matters, (iv) the allocation between Organon and Merck of rights and obligations under existing insurance policies with respect to occurrences prior to completion of the Distribution, as well as the right to proceeds and the obligation to incur certain deductibles under certain insurance policies, and (v) procedures governing Organon’s and Merck’s obligations and allocations of liabilities with respect to ongoing litigation matters that may implicate each of Merck’s business and Organon’s business.

Organon entered into other agreements with Merck that govern aspects of Organon’s relationship with Merck following the Separation, including the Transition Services Agreement, Interim Operating Model Agreements ("IOM") agreements, Manufacturing and Supply Agreement, Tax Matters Agreement, Employee Matters Agreement as well as Intellectual Property License Agreements and Regulatory Agreements. For the three and nine months ended September 30, 2022, material transactions occurred in connection with the IOM agreements. For details on the rights and responsibilities of the parties under the IOM agreements, refer below; for all other agreements refer to Note 19 to the audited Consolidated Financial Statements in the Company's 2021 Form 10-K.

•IOM agreements - Merck and Organon entered into a series of IOM agreements pursuant to which Merck and certain of its affiliates that held licenses, permits and other rights in connection with marketing, import and/or distribution of Organon products in various jurisdictions prior to the Separation, will continue to market, import and distribute such products until such time as the relevant licenses and permits are transferred to Organon or its affiliates, while permitting Organon (or Merck, as applicable) to recognize revenue relating to the sale of its respective products, to the extent practicable. Under such IOM agreements and in accordance with the Separation and Distribution Agreement, the relevant Merck entity will continue operations in the affected market on behalf of Organon, with Organon receiving all of the economic benefits and burdens of such activities. Organon began receiving these economic benefits as of June 2, 2021. Based on the terms of the IOM agreements, the Company determined it is the Principal under these arrangements. Organon holds all risks and rewards of ownership inclusive of risk of loss, market risk and benefits related to the inventory. Additionally, Organon has latitude in pricing, has the ability to direct Merck regarding decisions over inventory, and is responsible for all credit and collections risks and losses associated with the related receivables. As such, Organon recognizes these sales on a gross basis.

The amounts due under such agreements were:

($ in millions)	September 30, 2022		December 31, 2021
Due from Merck in Accounts receivable	$	412	$	403
Due to Merck in Accounts payable	623		928

Sales and cost of sales resulting from the manufacturing and supply agreements with Merck were:

	Three Months Ended September 30,				Nine Months Ended September 30,
($ in millions)	2022		2021		2022		2021
Sales	$	38	$	41	$	104	$	54
Cost of sales	31		35		91		48

Prior to the Separation, the Company did not operate as a standalone business and the Condensed Consolidated Financial Statements were derived from the consolidated financial statements and accounting records of Merck. The following disclosure summarizes activity between the Company and Merck up to the Separation, including the affiliates of Merck that were not part of the Separation.

Cost allocations from Merck

Merck provided significant corporate, manufacturing, selling, marketing, administrative, research services and resources to the Company. The Condensed Consolidated Financial Statements reflect an allocation of these costs. Some of these services continue to be provided by Merck to the Company on a temporary basis under the Transition Services Agreement. The allocations reflected in the Condensed Consolidated Statements of Income for continuing operations are as follows:

	Nine Months Ended September 30,
($ in millions)	2021
Cost of sales	$	69
Selling, general and administrative	134
Research and development	35
	$	238

Management believes these cost allocations are a reasonable reflection of the utilization of services provided to, or the benefit derived by, the Company during the periods presented. The allocations may not, however, be indicative of the actual expenses that would have been incurred had the Company operated as a standalone public company at the time. Actual costs that may have been incurred if the Company had been a standalone public company would depend on a number of factors, including the chosen organizational structure, whether functions were outsourced or performed by the Company’s employees and strategic decisions made in areas such as manufacturing, selling, information technology and infrastructure.

Related party transactions

The following transactions represent activity between Organon Entities and Transferred Entities with other Merck affiliates prior to the Separation:

	Nine Months Ended September 30,
($ in millions)	2021
Included in continuing operations
Supply sales to Merck affiliates	$	143
Purchases from Merck affiliates	65
Cost reimbursements and fees from Merck affiliates	1
Included in discontinued operations
Supply sales to Merck affiliates	$	12
Purchases from Merck affiliates	53

Net transfers to Merck & Co., Inc.

Prior to the Separation, net transfers to Merck were included within Net investment from Merck & Co., Inc. on the Condensed Consolidated Statement of Equity and represent the net effect of transactions between the Company and Merck. The components of Net transfers to Merck & Co., Inc. for the nine months ended September 30, 2021 were as follows:

	Nine Months Ended September 30,
($ in millions)	2021 (1)
Cash pooling and general financing activities	$	168
Cost allocations, excluding non-cash stock-based compensation	(209)
Taxes deemed settled with Merck	(259)
Allocated derivative and hedging (losses) gains	(88)
Net transfers (from) to Merck & Co., Inc. as reflected in the Condensed Consolidated Statement of Cash Flows for Continuing Operations (2)	$	(388)
Net transfers to (from) Merck included in Net Cash Provided by (Used in) Discontinued Operations	597
Total net transfers to Merck as included in the Condensed Consolidated Statement of Cash Flows	$	209
Stock-based compensation expense (includes $3 of discontinued operations for the nine months ended September 30, 2021)	(32)
Net assets contributed by Merck affiliates	(778)
Derecognition of amounts in Accumulated other comprehensive loss related to employee benefit plan transfers to Merck affiliates	13
Net transfers (from) to Merck & Co., Inc. as reflected in the Condensed Consolidated Statement of Equity	$	(588)

(1) Amounts represent activity through the date of the Separation.

(2) Net transfers (from) to Merck & Co., Inc. as reflected in the Condensed Consolidated Statement of Cash Flows for Continuing Operations for the nine months ended September 30, 2021 include Separation adjustments of $66 million, identified after the date of the Separation.

Prior to the Separation, transfers between the Organon Entities, the Transferred Entities and Merck affiliates were recognized in Net transfers to Merck & Co., Inc. in the Condensed Consolidated Statement of Equity at Merck’s historical cost. Additionally, in connection with the Separation, certain assets and liabilities included in the pre-Separation balance sheet were retained by Merck and certain assets and liabilities not included in the pre-Separation balance sheet were transferred to Organon. Adjustments for transfers are reflected in the Company's Condensed Consolidated Financial Statements for the three and nine months ended September 30, 2021.

XML

Discontinued Operations

9 Months Ended

Sep. 30, 2022

Discontinued Operations and Disposal Groups [Abstract]

Discontinued Operations

Discontinued Operations

In contemplation of the Separation, the Merck Retained Products business in the Transferred Entities was distributed to Merck affiliates and, accordingly, the historical results of operations, assets and liabilities, and the cash flows of the Merck Retained Products for such Transferred Entities are reflected as discontinued operations.

The components of Income (loss) from discontinued operations, net of tax for the Merck Retained Products business are as follows:

	Nine Months Ended September 30,
($ in millions)	2021
Sales	$	93
Costs, Expenses and Other
Cost of Sales	65
Selling, general and administrative	15
Research and development	4
Other (income) expense, net	4
Income from discontinued operations before taxes	$	5
Taxes on income	5
Income from discontinued operations, net of taxes	$	—

Discontinued operations include related party sales of $12 million for the nine months ended September 30, 2021. Costs for inventory purchases from related parties were $53 million for the nine months ended September 30, 2021.

XML

Earnings per Share ("EPS")

9 Months Ended

Sep. 30, 2022

Earnings Per Share [Abstract]

Earnings per Share ("EPS")

Earnings per Share ("EPS")

On June 2, 2021, the date of the Separation, 253,516,000 shares of the Common Stock were distributed to Merck stockholders of record as of the Record Date. This share amount is utilized for the calculation of basic and diluted earnings per share for all periods presented prior to the Separation. For the three and nine months ended September 30, 2021, these shares are treated as issued and outstanding as of January 1, 2021 for purposes of calculating historical basic and diluted earnings per share.

Prior to the Separation, certain of the Company's employees participated in stock-based compensation plans sponsored by Merck. Under these plans employees were granted stock options, PSU's, and RSU's. On June 2, 2021, and in accordance with the Employee Matters Agreement, all Merck stock options, PSU's and RSU's were converted using the conversion ratios set forth in the Employee Matters Agreement. Merck stock options, PSU's and RSUs were converted into Organon stock option awards and RSUs. Awards were equitably adjusted to reflect the spin-off and to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments.

The calculation of basic and diluted earnings per common share for the three and nine months ended September 30, 2022 and 2021 was as follows:

	Three Months Ended September 30,				Nine Months Ended September 30,
($ in millions and shares in thousands, except per share amounts)	2022		2021		2022		2021
Net income:
Income from continuing operations	$	227	$	323	$	809	$	1,149
Income from discontinued operations	—		—		—		—
Net income	$	227	$	323	$	809	$	1,149
Basic weighted average number of shares outstanding	254,348		253,534		253,986		253,530
Stock awards and equity units (share equivalent)	719		638		1,108		481
Diluted weighted average common shares outstanding	255,067		254,172		255,094		254,011
Earnings per Share - Basic:
Continuing operations	$	0.89	$	1.27	$	3.19	$	4.53
Discontinued operations	—		—		—		—
Net Earnings per Share - Basic	$	0.89	$	1.27	$	3.19	$	4.53
Earnings per Share - Diluted:
Continuing operations	$	0.89	$	1.27	$	3.17	$	4.52
Discontinued operations	—		—		—		—
Net Earnings per Share - Diluted	$	0.89	$	1.27	$	3.17	$	4.52
Anti-dilutive shares excluded from the calculation of EPS	6,313		4,800		4,432		5,015

For periods prior to the Separation, it is assumed that there were no dilutive equity instruments as there were no equity awards of Organon outstanding prior to the Separation.

For periods subsequent to the Separation and the Distribution, diluted earnings per share is computed by giving effect to all potentially dilutive stock awards that are outstanding. The computation of diluted earnings per share excludes the effect of the potential exercise of stock-based awards, when the effect of the potential exercise would be anti-dilutive. The weighted-average number of common shares outstanding for basic and diluted earnings per share for the three and nine months ended September 30, 2022 was based on the weighted-average number of common shares outstanding for the period beginning after June 2, 2021 (the "Distribution date").

XML

Basis of Presentation (Policies)

9 Months Ended

Sep. 30, 2022

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Basis of Accounting

The unaudited financial statements for all periods presented, including the historical results of the Company prior to June 2, 2021, are referred to as "Condensed Consolidated Financial Statements," and have been prepared pursuant to the rules and regulations for reporting on Form 10-Q. Accordingly, certain information and disclosures required by U.S. generally accepted accounting principles ("GAAP") for complete consolidated financial statements are not included herein. The results of operations of any interim period are not necessarily indicative of the results of operations for the full year. In the Company’s opinion, all adjustments necessary for a fair statement of these interim statements have been included and are of a normal and recurring nature. All intercompany transactions and accounts within Organon have been eliminated. These interim statements should be read in conjunction with the audited financial statements and notes thereto included in Organon’s Annual Report on Form 10-K for the year ended December 31, 2021.

Prior to the Separation on June 2, 2021, the Company’s historical Consolidated Financial Statements were prepared on a standalone basis and were derived from Merck’s consolidated financial statements and accounting records. The assets, liabilities, revenue and expenses of the Company were reflected in the Condensed Consolidated Financial Statements on a historical cost basis, as included in the consolidated financial statements of Merck, using the historical accounting policies applied by Merck, following a legal entity approach. For such periods prior to the Separation, certain corporate and shared costs were allocated to the Company based on a specific identification basis or, when specific identification was not practicable, a proportional cost allocation method. Refer to Note 2 of the audited Consolidated Financial Statements in the Company's 2021 Form 10-K for additional details on Organon's basis of presentation during periods prior to the Separation, at Separation and post Separation.

The Company’s historical results prior to the Separation included certain Merck non-U.S. legal entities that were conveyed to Organon in connection with the Separation (collectively, the "Transferred Entities" and each, a "Transferred Entity") and included operations related to other Merck products that were retained by Merck (the "Merck Retained Products"). The Merck Retained Products business of the Transferred Entities was contributed by the Company to Merck and its affiliates and any remaining assets and liabilities were transferred as of June 2, 2021. Accordingly, the historical results of operations of the Merck Retained Products have been reflected as discontinued operations in these Condensed Consolidated Financial Statements.

For periods prior to the Separation, income tax expense in the Condensed Consolidated Statement of Income was calculated on a separate tax return basis and the Company’s operations were included in the tax returns of certain legal entities established to operate the Organon Products business (the "Organon Entities"), Transferred Entities, or the respective Merck entities of which the Company’s business was a part. As of June 2, 2021, and in connection with the Separation, the Company adjusted its deferred tax balances and computed its related tax provision to reflect operations as a standalone entity. As a standalone entity, the Company files tax returns on its own behalf, and tax balances and effective income tax rates may differ from the amounts reported in the historical periods.

Certain assets and liabilities, including accounts receivables, inventories and trade payables included on the Condensed Consolidated Balance Sheet prior to the Separation, were retained by Merck post-Separation and therefore were recorded through Net investment from Merck & Co., Inc. in the Company’s Condensed Consolidated Financial Statements. As part of the Separation, Net investment from Merck & Co., Inc. was reclassified to Common Stock and Accumulated Deficit.

Use of Estimates

Use of Estimates

The presentation of these Condensed Consolidated Financial Statements and accompanying notes in conformity with U.S. GAAP require management to make estimates and assumptions that affect the amounts reported, as further described in our Form 10-K for the year ended December 31, 2021. Accordingly, actual results could differ materially from management's estimates and assumptions.

Due to the significant uncertainty that exists relative to the duration and overall impact of the COVID-19 pandemic, our future operating performance, particularly in the short-term, may be subject to volatility. The assessment of certain accounting matters and specifically its effect on the Company's results require consideration of forecasted financial information in the context of the information reasonably available to the Company and the unknown future impacts of the COVID-19 pandemic as of September 30, 2022 and through the date of this report.

Recently Adopted Accounting Standards and Recently Issued Accounting Standards Not Yet Adopted

Recently Adopted Accounting Standards

There were no recently issued accounting standards adopted by the Company during the three and nine months ended September 30, 2022. Refer to Note 3 of the audited Consolidated Financial Statements in Organon's Form 10-K for the year ended December 31, 2021 for standards adopted in 2021.

Recently Issued Accounting Standards Not Yet Adopted

In March 2022, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2022-02, Financial Instruments—Credit Losses (Topic 326): Troubled Debt Restructurings and Vintage Disclosures, an amendment to the accounting for credit losses on financial instruments. This amendment eliminates the recognition and measurement guidance on troubled debt restructurings for creditors that have adopted the new credit losses guidance in Accounting Standards Codification 326 ("ASC 326") and requires enhanced disclosures about loan modifications for borrowers experiencing financial difficulty. The new guidance also requires public business entities to present gross write-offs by year of origination in their

vintage disclosures. The guidance is effective for the Company on January 1, 2023, including interim periods. Early adoption is permitted, and the amendment applied prospectively, except for the recognition and remeasurement of troubled debt restructurings. Entities can elect to adopt the guidance on troubled debt restructurings using either a prospective or modified retrospective transition. If an entity elects to apply a modified retrospective transition, it will record a cumulative effect adjustment to retained earnings in the period of adoption. The Company does not expect the adoption of this guidance to have a material impact on the Consolidated Financial Statements.

In November 2021, the FASB issued ASU 2021-10, Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance, new guidance requiring disclosures about transactions with a government that have been accounted for by analogizing to a grant or contribution accounting model. The guidance increases transparency about the types of transactions, the accounting for the transactions, and the effect of the transactions to the Company’s financial statements. The guidance is effective for annual periods in 2022 and can be applied on a prospective or retrospective basis. The Company is currently evaluating the impact of adoption on its Consolidated Financial Statements. The Company does not anticipate a material impact to its Consolidated Financial Statements.

In October 2021, the FASB issued ASU 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers, guidance to improve the accounting for contract assets and contract liabilities from acquired revenue contracts with customers in a business combination. The guidance addresses diversity in practice and inconsistency related to the recognition of an acquired contract liability, payment terms and their effect on subsequent revenue recognized by an acquirer. The guidance is effective for the Company on January 1, 2023 and its amendments will be applied prospectively to business combinations occurring on or after the effective date of the guidance. Early adoption is permitted, including adoption in an interim period and subject to different transition requirements. The adoption of this guidance will not have an impact on the Company’s Consolidated Financial Statements for prior acquisitions; however, the impact in future periods will be dependent upon the contract assets and contract liabilities acquired in future business combinations.

In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting, optional guidance to ease the potential burden in accounting for (or recognizing the effects of) reference rate reform on financial reporting and subsequently issued clarifying amendments. The guidance provides optional expedients and exceptions for applying GAAP to contracts, hedging relationships, and other transactions that reference the London Interbank Offered Rate ("LIBOR") or another reference rate expected to be discontinued because of reference rate reform. The optional guidance is effective upon issuance and can be applied on a prospective basis at any time between January 1, 2020 and December 31, 2022. The Company is currently evaluating the impact of adoption on its Consolidated Financial Statements. The Company does not anticipate a material impact to its Consolidated Financial Statements.

XML

Samsung Collaboration (Tables)

9 Months Ended

Sep. 30, 2022

Revenue from Contract with Customer [Abstract]

Collaborative Arrangement and Arrangement Other than Collaborative

Summarized information related to this collaboration is as follows:

	Three Months Ended September 30,				Nine Months Ended September 30,
($ in millions)	2022		2021		2022		2021
Sales	$	129	$	139	$	346	$	305
Cost of sales	86		83		221		183
Selling, general and administrative	18		18		60		50

($ in millions)	September 30, 2022		December 31, 2021
Receivables from Samsung included in Other current assets	$	10	$	15
Payables to Samsung included in Trade accounts payable	24		21

XML

Financial Instruments (Tables)

9 Months Ended

Sep. 30, 2022

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Schedule of Financial Instruments Recorded at Estimated Fair Value

The following financial instruments were recorded at their estimated fair value. The recurring fair value measurement of our assets and liabilities were as follows:

($ in millions)	Fair Value Measurement Level	September 30, 2022		December 31, 2021
Forward contracts in Other current assets	2	$	35	$	19
Forward contracts in Accrued and other current liabilities	2	23		5

Schedule of Foreign Exchange Contracts, Statement of Financial Position

Foreign currency gains due to spot rate fluctuations on the euro-denominated debt instruments included in foreign currency translation adjustments were as follows:

	Three Months Ended September 30,				Nine Months Ended September 30,
($ in millions)	2022		2021		2022		2021
Foreign currency gains in Other comprehensive income	$	176	$	38	$	303	$	94

(Gain) Loss Derivative Instruments

The Condensed Consolidated Statements of Income include the impact of actual net gains and losses of Organon's derivative financial instruments, as well as the impact of Merck’s derivative financial instruments prior to the Separation allocated to the Company utilizing a proportional allocation method:

	Three Months Ended September 30,				Nine Months Ended September 30,
($ in millions)	2022		2021		2022		2021
Allocated net loss in Revenues	$	—	$	1	$	—	$	56
Foreign exchange loss (gain) in Other expense, net	4		1		(21)		6

XML

Inventories (Tables)

9 Months Ended

Sep. 30, 2022

Inventory Disclosure [Abstract]

Schedule of Inventory

Inventories consisted of:

($ in millions)	September 30, 2022		December 31, 2021
Finished goods	$	403	$	377
Raw materials	71		95
Work in process	479		490
Supplies	40		40
Total (approximates current cost)	$	993	$	1,002
Decrease to LIFO costs	(18)		(11)
	$	975	$	991
Recognized as:
Inventories	$	879	$	915
Other assets	96		76
Inventories valued under the last in, first out ("LIFO") method	82		52

Schedule of Inventory, Noncurrent

Inventories consisted of:

($ in millions)	September 30, 2022		December 31, 2021
Finished goods	$	403	$	377
Raw materials	71		95
Work in process	479		490
Supplies	40		40
Total (approximates current cost)	$	993	$	1,002
Decrease to LIFO costs	(18)		(11)
	$	975	$	991
Recognized as:
Inventories	$	879	$	915
Other assets	96		76
Inventories valued under the last in, first out ("LIFO") method	82		52

XML

Long-Term Debt (Tables)

9 Months Ended

Sep. 30, 2022

Debt Disclosure [Abstract]

Schedule of Long-term Debt Instruments

The following is a summary of Organon's total debt:

($ in millions)	September 30, 2022		December 31, 2021
Term Loan B Facility:
LIBOR plus 300 bps term loan due 2028	$	2,793	$	2,893
LIBOR plus 300 bps euro-denominated term loan due 2028 (€750 million)	708		843
4.125% secured notes due 2028	2,100		2,100
2.875% euro-denominated secured notes due 2028 (€1.25 billion)	1,196		1,412
5.125% notes due 2031	2,000		2,000
Other borrowings	8		10
Other (discounts and debt issuance costs)	(106)		(124)
Total principal long-term debt	$	8,699	$	9,134
Less: Current portion of long-term debt	8		9
Total Long-term debt, net of current portion	$	8,691	$	9,125

Schedule of Carrying Values and Estimated Fair Values of Debt Instruments

Long-term debt was recorded at the carrying amount. The estimated fair value of long-term debt (including current portion) is as follows:

($ in millions)	September 30, 2022		December 31, 2021
Long-term debt (includes a reduction for amortized debt issuance costs)	$	7,772	$	9,412

Schedule of Maturities of Long-term Debt

The schedule of principal payments required on long-term debt for the next five years and thereafter is as follows:

($ in millions)
2022	$	2
2023	8
2024	8
2025	8
2026	11
Thereafter	8,768

XML

Stock-based Compensation Plans (Tables)

9 Months Ended

Sep. 30, 2022

Share-Based Payment Arrangement [Abstract]

Share-based Payment Arrangement, Expensed and Capitalized, Amount

Stock-based compensation expense incurred by the Company was as follows:

	Three Months Ended September 30,				Nine Months Ended September 30,
($ in millions)	2022		2021		2022		2021
Stock-based compensation expense recognized in:
Cost of sales	$	3	$	3	$	9	$	8
Selling, general and administrative	12		10		35		26
Research and development	3		2		8		10
Income tax benefits	3		3		11		9

Schedule of Stock Option Valuation Assumptions

The Company used the Black-Scholes model to determine the fair value of the stock options as of the grant date using the following assumptions:

	Nine Months Ended September 30,
	2022
Expected dividend yield	3.12	%
Risk-free interest rate	2.47	%
Expected volatility	43.43	%
Expected life (years)	5.89

Share-based Payment Arrangement, Performance Shares, Activity

A summary of the equity award transactions for the nine months ended September 30, 2022 are as follows:

	Stock Options					Restricted Share Units			Performance Share Units
(shares in thousands)	Shares	Weighted average exercise price		Weighted average grant date fair value		Shares	Weighted average grant date fair value		Shares	Weighted average grant date fair value
Outstanding as of January 1, 2022	4,394	$	34.35	$	8.63	3,280	$	36.69	120	$	51.63
Granted	556	$	34.93	$	11.34	2,299	$	34.87	373	$	45.23
Vested/Exercised	(15)	$	37.39	$	9.72	(1,251)	$	37.50	—	$	—
Forfeited/Cancelled	(160)	$	35.72	$	9.70	(242)	$	35.76	(7)	$	51.63
Outstanding as of September 30, 2022	4,775	$	34.36	$	8.91	4,086	$	35.48	486	$	46.72

Share-based Payment Arrangement, Activity

The following table summarizes information about equity awards outstanding that are vested and expected to vest and equity awards outstanding that are exercisable as of September 30, 2022:

	Equity Awards Vested and Expected to Vest						Equity Awards That are Exercisable
(shares in thousands; aggregate intrinsic value in millions)	Awards	Weighted Average Exercise Price		Aggregate Intrinsic Value		Remaining Term	Awards	Weighted Average Exercise Price		Aggregate Intrinsic Value		Remaining Term
Stock Options	4,585	$	34.36	$	—	7.48	2,429	$	32.98	$	—	6.23
Restricted Share Units	3,781			96		2.03
Performance Share Units	402			11		2.63

XML

Other Comprehensive Income (Loss) (Tables)

9 Months Ended

Sep. 30, 2022

Equity [Abstract]

Changes of AOCI by Component

Changes in Accumulated other comprehensive loss (income) by component are as follows:

($ in millions)	Employee Benefit Plans		Cumulative Translation Adjustment		Accumulated Other Comprehensive Loss
Balance at July 1, 2021, net of taxes	$	(26)	$	(438)	$	(464)
Other comprehensive loss, pretax	(3)		(23)		(26)
Tax	—		—		—
Other comprehensive loss, net of taxes	(3)		(23)		(26)
Transfer of benefit plans from Merck affiliates	(3)		—		(3)
Balance at September 30, 2021, net of taxes	$	(32)	$	(461)	$	(493)
Balance at July 1, 2022, net of taxes	$	(13)	$	(576)	$	(589)
Other comprehensive loss, pretax	—		(97)		(97)
Tax	—		—		—
Other comprehensive loss, net of taxes	—		(97)		(97)
Balance at September 30, 2022, net of taxes	$	(13)	$	(673)	$	(686)

($ in millions)	Employee Benefit Plans		Cumulative Translation Adjustment		Accumulated Other Comprehensive (Loss) Income
Balance at January 1, 2021, net of taxes	$	(32)	$	(590)	$	(622)
Other comprehensive (loss) income, pretax	(1)		129		128
Tax	(10)		—		(10)
Other comprehensive (loss) income, net of taxes	(11)		129		118
Transfer of benefit plans to/from Merck affiliates	11		—		11
Balance at September 30, 2021, net of taxes	$	(32)	$	(461)	$	(493)
Balance at January 1,2022, net of taxes	$	(13)	$	(500)	$	(513)
Other comprehensive loss, pretax	(1)		(173)		(174)
Tax	1		—		1
Other comprehensive loss, net of taxes	—		(173)		(173)
Balance at September 30, 2022, net of taxes	$	(13)	$	(673)	$	(686)

XML

Product and Geographic Information (Tables)

9 Months Ended

Sep. 30, 2022

Segment Reporting [Abstract]

Sales of Company's Products

Revenues of the Company’s products were as follows:

	Three Months Ended September 30,												Nine Months Ended September 30,
	2022						2021						2022						2021
($ in millions)	U.S.		Int’l		Total		U.S.		Int’l		Total		U.S.		Int’l		Total		U.S.		Int’l		Total
Women’s Health
Nexplanon/Implanon NXT	$	151	$	78	$	229	$	120	$	55	$	175	$	401	$	194	$	595	$	389	$	154	$	543
Follistim AQ	27		33		60		29		32		61		79		100		179		81		97		178
NuvaRing	27		23		50		21		28		49		65		68		133		68		79		147
Ganirelix Acetate Injection	6		30		36		5		20		25		20		77		97		19		66		85
Cerazette	—		15		15		—		18		18		—		47		47		—		53		53
Other Women's Health (1)	24		39		63		18		35		53		80		108		188		80		111		191
Biosimilars
Renflexis	54		7		60		48		6		54		145		20		166		119		17		136
Ontruzant	15		14		29		9		47		56		35		52		87		20		81		101
Brenzys	—		24		24		—		14		14		—		52		52		—		35		35
Aybintio	—		10		10		—		10		10		—		29		29		—		26		26
Hadlima	—		6		6		—		5		5		—		14		14		—		9		9
Established Brands
Cardiovascular
Zetia	2		85		87		1		90		91		7		280		287		6		276		282
Vytorin	1		30		31		3		38		41		6		98		104		8		119		127
Atozet	—		109		109		—		114		114		—		350		350		—		347		347
Rosuzet	—		17		17		—		15		15		—		55		55		—		48		48
Cozaar/Hyzaar	2		68		70		3		84		87		11		244		256		9		256		265
Other Cardiovascular (1)	1		34		35		1		48		49		3		117		120		3		145		148
Respiratory
Singulair	3		92		94		2		98		100		8		308		316		10		289		300
Nasonex	—		49		49		—		49		48		9		173		182		3		141		144
Dulera	31		9		40		48		8		56		98		30		127		121		25		146
Clarinex	—		25		26		2		27		28		3		96		99		5		78		83
Other Respiratory (1)	11		10		21		14		5		18		34		32		66		43		20		64
Non-Opioid Pain, Bone and Dermatology
Arcoxia	—		64		64		—		65		65		—		185		185		—		184		184
Fosamax	1		35		36		1		45		46		2		115		117		3		130		132
Diprospan	—		28		28		—		34		34		—		91		91		—		92		92
Other Non-Opioid Pain, Bone and Dermatology (1)	2		63		65		9		69		79		10		200		210		12		201		213
Other
Proscar	—		26		27		—		27		27		1		76		77		1		91		92
Propecia	2		28		30		1		33		34		5		90		95		5		96		101
Other (1)	6		81		87		10		83		95		21		230		251		32		230		262
Other (2)	—		39		39		1		51		52		—		115		116		(2)		171		168
Revenues	$	366	$	1,171	$	1,537	$	346	$	1,254	$	1,600	$	1,043	$	3,646	$	4,689	$	1,035	$	3,666	$	4,701

Totals may not foot due to rounding. Trademarks appearing above in italics are trademarks of, or are used under license by, the Organon group of companies.

(1) Includes sales of products not listed separately. Revenue from an arrangement for the sale of generic etonogestrel/ethinyl estradiol vaginal ring is included in Other Women's Health.

(2) Includes manufacturing sales to Merck and third parties for current and prior periods and allocated amounts from revenue hedging activities through the date of Separation.

Consolidated Revenues by Geographic Area

Revenues by geographic area where derived are as follows:

	Three Months Ended September 30,				Nine Months Ended September 30,
($ in millions)	2022		2021		2022		2021
Europe and Canada	$	363	$	410	$	1,243	$	1,314
United States	366		346		1,043		1,035
Asia Pacific and Japan	283		287		888		874
China	241		252		721		693
Latin America, Middle East, Russia and Africa	236		238		665		595
Other (1)	48		67		129		190
Revenues	$	1,537	$	1,600	$	4,689	$	4,701

(1) Primarily reflects manufacturing sales to Merck and third parties for current and prior periods and allocated amounts from revenue hedging activities through the date of Separation.

XML

Third Party Arrangements Related Party Disclosures (Tables)

9 Months Ended

Sep. 30, 2022

Related Party Transactions [Abstract]

Schedule of Related Party Transactions

The amounts due under such agreements were:

($ in millions)	September 30, 2022		December 31, 2021
Due from Merck in Accounts receivable	$	412	$	403
Due to Merck in Accounts payable	623		928

Sales and cost of sales resulting from the manufacturing and supply agreements with Merck were:

	Three Months Ended September 30,				Nine Months Ended September 30,
($ in millions)	2022		2021		2022		2021
Sales	$	38	$	41	$	104	$	54
Cost of sales	31		35		91		48

The allocations reflected in the Condensed Consolidated Statements of Income for continuing operations are as follows:

	Nine Months Ended September 30,
($ in millions)	2021
Cost of sales	$	69
Selling, general and administrative	134
Research and development	35
	$	238

The following transactions represent activity between Organon Entities and Transferred Entities with other Merck affiliates prior to the Separation:

	Nine Months Ended September 30,
($ in millions)	2021
Included in continuing operations
Supply sales to Merck affiliates	$	143
Purchases from Merck affiliates	65
Cost reimbursements and fees from Merck affiliates	1
Included in discontinued operations
Supply sales to Merck affiliates	$	12
Purchases from Merck affiliates	53

The components of Net transfers to Merck & Co., Inc. for the nine months ended September 30, 2021 were as follows:

	Nine Months Ended September 30,
($ in millions)	2021 (1)
Cash pooling and general financing activities	$	168
Cost allocations, excluding non-cash stock-based compensation	(209)
Taxes deemed settled with Merck	(259)
Allocated derivative and hedging (losses) gains	(88)
Net transfers (from) to Merck & Co., Inc. as reflected in the Condensed Consolidated Statement of Cash Flows for Continuing Operations (2)	$	(388)
Net transfers to (from) Merck included in Net Cash Provided by (Used in) Discontinued Operations	597
Total net transfers to Merck as included in the Condensed Consolidated Statement of Cash Flows	$	209
Stock-based compensation expense (includes $3 of discontinued operations for the nine months ended September 30, 2021)	(32)
Net assets contributed by Merck affiliates	(778)
Derecognition of amounts in Accumulated other comprehensive loss related to employee benefit plan transfers to Merck affiliates	13
Net transfers (from) to Merck & Co., Inc. as reflected in the Condensed Consolidated Statement of Equity	$	(588)

(1) Amounts represent activity through the date of the Separation.

(2) Net transfers (from) to Merck & Co., Inc. as reflected in the Condensed Consolidated Statement of Cash Flows for Continuing Operations for the nine months ended September 30, 2021 include Separation adjustments of $66 million, identified after the date of the Separation.

XML

Discontinued Operations (Tables)

9 Months Ended

Sep. 30, 2022

Discontinued Operations and Disposal Groups [Abstract]

Disposal Groups, Including Discontinued Operations

The components of Income (loss) from discontinued operations, net of tax for the Merck Retained Products business are as follows:

	Nine Months Ended September 30,
($ in millions)	2021
Sales	$	93
Costs, Expenses and Other
Cost of Sales	65
Selling, general and administrative	15
Research and development	4
Other (income) expense, net	4
Income from discontinued operations before taxes	$	5
Taxes on income	5
Income from discontinued operations, net of taxes	$	—

XML

Earnings per Share ("EPS") (Tables)

9 Months Ended

Sep. 30, 2022

Earnings Per Share [Abstract]

Schedule of Earnings Per Share, Basic and Diluted

The calculation of basic and diluted earnings per common share for the three and nine months ended September 30, 2022 and 2021 was as follows:

	Three Months Ended September 30,				Nine Months Ended September 30,
($ in millions and shares in thousands, except per share amounts)	2022		2021		2022		2021
Net income:
Income from continuing operations	$	227	$	323	$	809	$	1,149
Income from discontinued operations	—		—		—		—
Net income	$	227	$	323	$	809	$	1,149
Basic weighted average number of shares outstanding	254,348		253,534		253,986		253,530
Stock awards and equity units (share equivalent)	719		638		1,108		481
Diluted weighted average common shares outstanding	255,067		254,172		255,094		254,011
Earnings per Share - Basic:
Continuing operations	$	0.89	$	1.27	$	3.19	$	4.53
Discontinued operations	—		—		—		—
Net Earnings per Share - Basic	$	0.89	$	1.27	$	3.19	$	4.53
Earnings per Share - Diluted:
Continuing operations	$	0.89	$	1.27	$	3.17	$	4.52
Discontinued operations	—		—		—		—
Net Earnings per Share - Diluted	$	0.89	$	1.27	$	3.17	$	4.52
Anti-dilutive shares excluded from the calculation of EPS	6,313		4,800		4,432		5,015

XML

Background and Nature of Operations (Details)	Sep. 30, 2022 manufacturingFacility $ / shares	Dec. 31, 2021 $ / shares	May 17, 2021 $ / shares shares
Class of Stock [Line Items]
Number of manufacturing facilities | manufacturingFacility	6
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01	$ 0.01
Merck and Co., Inc.
Class of Stock [Line Items]
Common stock, par value (in dollars per share)			$ 0.50
Shares distributed to each shareholder | shares			0.1

XML

Samsung Collaboration - Narrative (Details) - USD ($) $ in Millions	1 Months Ended	3 Months Ended	9 Months Ended
	Aug. 31, 2022	Sep. 30, 2022	Sep. 30, 2022	Sep. 30, 2021
Disaggregation of Revenue [Line Items]
Purchase of product rights and asset acquisition			$ 124	$ 192
Brazil
Disaggregation of Revenue [Line Items]
Gross profit sharing arrangement percentage		35.00%	35.00%
Samsung Bioepis
Disaggregation of Revenue [Line Items]
Collaboration agreement period			10 years
Potential future regulatory milestone payments		$ 25	$ 25
Estimated useful life	10 years
Purchase of product rights and asset acquisition		$ 18
Samsung Bioepis | Brazil
Disaggregation of Revenue [Line Items]
Gross profit sharing arrangement percentage		65.00%	65.00%

XML

Samsung Collaboration - Summarization of Collaboration Information (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Disaggregation of Revenue [Line Items]
Sales	$ 1,537	$ 1,600	$ 4,689	$ 4,701
Cost of sales	551	609	1,700	1,783
Selling, general and administrative	440	388	1,234	1,186
Receivables from Samsung included in Other current assets	1,440		1,440		$ 1,382
Payables to Samsung included in Trade accounts payable	1,028		1,028		1,382
Samsung Bioepis
Disaggregation of Revenue [Line Items]
Sales	129	139	346	305
Cost of sales	86	83	221	183
Selling, general and administrative	18	$ 18	60	$ 50
Receivables from Samsung included in Other current assets	10		10		15
Payables to Samsung included in Trade accounts payable	$ 24		$ 24		$ 21

XML

Acquisitions and Licensing Arrangements (Details) - USD ($) $ in Millions	1 Months Ended		3 Months Ended			9 Months Ended
	Mar. 31, 2022	Feb. 28, 2022	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Sep. 30, 2022
Cirqle
Asset Acquisition [Line Items]
Upfront payments			$ 10.0			$ 10.0
Variable consideration amount			360.0			360.0
Shanghai Henlius Biotech, Inc.
Asset Acquisition [Line Items]
Upfront payments			73.0			73.0
Commercial milestone payments			468.0			468.0
Shanghai Henlius Biotech, Inc. | Other Current Assets
Asset Acquisition [Line Items]
Upfront payments			3.0			3.0
Shanghai Henlius Biotech, Inc. | Product rights
Asset Acquisition [Line Items]
Intangible assets acquired						97.0
Contractual upfront payments						70.0
Research and development						27.0
Dare Bioscience, Inc.
Asset Acquisition [Line Items]
Upfront payments			10.0			10.0
Commercial milestone payments			182.5			182.5
Dare Bioscience, Inc. | Product rights
Asset Acquisition [Line Items]
Intangible assets acquired						12.5
Contractual upfront payments						10.0
Research and development						$ 2.5
Expected useful life	12 years
Bayer AG
Asset Acquisition [Line Items]
Transaction consideration			30.0		$ 30.0
Accrued consideration				$ 35.0
Bayer AG | Product rights
Asset Acquisition [Line Items]
Intangible assets acquired			72.0
Expected useful life		10 years
Alydia Health | Product rights
Asset Acquisition [Line Items]
Intangible assets acquired			$ 25.0

XML

Financial Instruments - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details) - Level 2 - USD ($) $ in Millions	Sep. 30, 2022	Dec. 31, 2021
Derivative Instruments, Gain (Loss) [Line Items]
Fair Value Hedge Assets	$ 35	$ 19
Fair Value Hedge Liabilities	$ 23	$ 5

XML

Financial Instruments - Narrative (Details) $ in Millions	Sep. 30, 2022 USD ($)	Sep. 30, 2022 EUR (€)	Dec. 31, 2021 USD ($)	Jun. 30, 2021 EUR (€)
Derivative Instruments, Gain (Loss) [Line Items]
Accounts receivables factored | $	$ 61		$ 87
Foreign Exchange Forward
Derivative Instruments, Gain (Loss) [Line Items]
Notional amount | $	$ 1,300		$ 2,100
Euro Denominated Term Loan | Senior Notes
Derivative Instruments, Gain (Loss) [Line Items]
Face amount of debt (in euros)		€ 1,750,000,000
Euro Denominated Term Loan B | Senior Notes
Derivative Instruments, Gain (Loss) [Line Items]
Face amount of debt (in euros)		750,000,000		€ 750,000,000
2.875% Senior Secured Notes Due 2028 | Senior Notes | Organon Finance 1 LLC
Derivative Instruments, Gain (Loss) [Line Items]
Face amount of debt (in euros)		€ 1,250,000,000
Stated interest rate	2.875%	2.875%

XML

Financial Instruments - Schedule of Long-term Debt Instruments (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Euro Denominated Term Loan | Senior Notes
Derivative Instruments, Gain (Loss) [Line Items]
Gain on derivative	$ 176	$ 38	$ 303	$ 94

XML

Financial Instruments - Impact of Actual Net Gains and Losses on Derivative Instruments (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Derivative Instruments, Gain (Loss) [Line Items]
Allocated net loss in Revenues	$ 0	$ 1	$ 0	$ 56
Exchange losses (gains)	(4)	(1)	$ 21	$ (6)
Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]			Revenues	Revenues
Other (income) expense
Derivative Instruments, Gain (Loss) [Line Items]
Exchange losses (gains)	$ 4	$ 1	$ (21)	$ 6

XML

Inventories (Details) - USD ($) $ in Millions	Sep. 30, 2022	Dec. 31, 2021
Inventory Disclosure [Abstract]
Finished goods	$ 403	$ 377
Raw materials	71	95
Work in process	479	490
Supplies	40	40
Total (approximates current cost)	993	1,002
Decrease to LIFO costs	(18)	(11)
Inventory	975	991
Recognized as:
Inventories	879	915
Other assets	96	76
Inventories valued under LIFO	$ 82	$ 52

XML

Inventories (Details) $ in Millions	3 Months Ended
	Sep. 30, 2021 USD ($)
Vendor Supply Contract
Inventory [Line Items]
Inventory impairment	$ 24

XML

Long-Term Debt - Summary of Debt (Details)	9 Months Ended
	Sep. 30, 2022 USD ($)	Sep. 30, 2022 EUR (€)	Dec. 31, 2021 USD ($)	Jun. 30, 2021 USD ($)	Jun. 30, 2021 EUR (€)
Debt Instrument [Line Items]
Other (discounts and debt issuance costs)	$ (106,000,000)		$ (124,000,000)
Total principal long-term debt	8,699,000,000		9,134,000,000
Current portion of long-term debt	8,000,000		9,000,000
Total Long-term debt, net of current portion	8,691,000,000		9,125,000,000
Notes Payable, Other Payables
Debt Instrument [Line Items]
Long-term debt	8,000,000		10,000,000
Term Loan B Facility | Senior Notes
Debt Instrument [Line Items]
Long-term debt	$ 2,793,000,000		2,893,000,000
Face amount of debt				$ 3,000,000,000
Term Loan B Facility | Senior Notes | London Interbank Offered Rate (LIBOR)
Debt Instrument [Line Items]
Spread on variable rate	3.00%
Euro Denominated Term Loan B | Senior Notes
Debt Instrument [Line Items]
Long-term debt	$ 708,000,000		843,000,000
Face amount of debt | €		€ 750,000,000			€ 750,000,000
Euro Denominated Term Loan B | Senior Notes | London Interbank Offered Rate (LIBOR)
Debt Instrument [Line Items]
Spread on variable rate	3.00%
4.125% Senior Secured Notes Due 2028 | Senior Notes
Debt Instrument [Line Items]
Long-term debt	$ 2,100,000,000		2,100,000,000
4.125% Senior Secured Notes Due 2028 | Senior Notes | Organon Finance 1 LLC
Debt Instrument [Line Items]
Stated interest rate	4.125%	4.125%
2.875% Senior Secured Notes Due 2028 | Senior Notes
Debt Instrument [Line Items]
Long-term debt	$ 1,196,000,000		1,412,000,000
2.875% Senior Secured Notes Due 2028 | Senior Notes | Organon Finance 1 LLC
Debt Instrument [Line Items]
Stated interest rate	2.875%	2.875%
Face amount of debt | €		€ 1,250,000,000
5.125% Senior Unsecured Notes Due 2031 | Senior Notes
Debt Instrument [Line Items]
Long-term debt	$ 2,000,000,000		$ 2,000,000,000
5.125% Senior Unsecured Notes Due 2031 | Senior Notes | Organon Finance 1 LLC
Debt Instrument [Line Items]
Stated interest rate	5.125%	5.125%

XML

Long-Term Debt - Narrative (Details)		1 Months Ended	3 Months Ended	9 Months Ended
	Jun. 06, 2022 USD ($)	Jun. 30, 2021 EUR (€)	Sep. 30, 2022 EUR (€)	Sep. 30, 2022 USD ($)	Sep. 30, 2022 USD ($)	Dec. 31, 2021 USD ($)	Jun. 30, 2021 USD ($)
Debt Instrument [Line Items]
Debt instrument interest payments				$ 218,000,000
Average maturity of long-term debt				6 years 3 months 18 days
Weighted average interest rate of debt			4.50%
Revolving Credit Facility
Debt Instrument [Line Items]
Borrowing capacity							$ 1,000,000,000
Debt term		5 years
Unused capacity commitment fee percentage		0.50%
Step down on unused capacity commitment fee		0.375%
Line of credit					$ 0	$ 0
Term Loan B Facility | Senior Notes
Debt Instrument [Line Items]
Face amount of debt							$ 3,000,000,000
Early Repayment of Senior Debt	$ 100,000,000
Euro Denominated Term Loan B | Senior Notes
Debt Instrument [Line Items]
Face amount of debt | €		€ 750,000,000	€ 750,000,000

XML

Long-Term Debt - Estimated Fair Value of Long-term Debt (Details) - USD ($) $ in Millions	Sep. 30, 2022	Dec. 31, 2021
Debt Disclosure [Abstract]
Fair value of long-term debt	$ 7,772	$ 9,412

XML

Long-Term Debt - Schedule of Debt Principal Payments (Details) $ in Millions	Sep. 30, 2022 USD ($)
Debt Disclosure [Abstract]
2022	$ 2
2023	8
2024	8
2025	8
2026	11
Thereafter	$ 8,768

XML

Contingencies (Details) € in Millions, $ in Millions	1 Months Ended	9 Months Ended	12 Months Ended
	Mar. 31, 2014 case	Sep. 30, 2022 EUR (€) case	Dec. 31, 2018 USD ($)	Sep. 30, 2022 USD ($) case	Dec. 31, 2021 USD ($)
Loss Contingencies [Line Items]
Amount of legal defense reserves | $				$ 15.0	$ 9.0
Spain
Loss Contingencies [Line Items]
Governmental fine | €		€ 39
Fosamax
Loss Contingencies [Line Items]
Number of pending claims				3,285
Fosamax | Federal | Femur Fracture Litigation
Loss Contingencies [Line Items]
Number of pending claims				975
Number of claims dismissed	650
Number of claims on appeal		515
Fosamax | New Jersey State Court | Femur Fracture Litigation
Loss Contingencies [Line Items]
Number of pending claims				2,030
Fosamax | California State Court | Femur Fracture Litigation
Loss Contingencies [Line Items]
Number of pending claims				275
Fosamax | Other State Courts | Femur Fracture Litigation
Loss Contingencies [Line Items]
Number of pending claims				4
Nexplanon | International
Loss Contingencies [Line Items]
Number of pending claims				6
Nexplanon | Western District of Arkansas
Loss Contingencies [Line Items]
Number of pending claims				1
Implanon | International
Loss Contingencies [Line Items]
Number of pending claims				12
Implanon | Northern District of Ohio
Loss Contingencies [Line Items]
Number of pending claims				2
Number of unfiled claims				56
Nexplanon/Implanon NXT | International
Loss Contingencies [Line Items]
Number of pending claims				18
Propecia/ Proscar | International
Loss Contingencies [Line Items]
Number of pending claims				16
Number of pending class actions				2
Number of pending putative class actions				4
Propecia/ Proscar | U.S.
Loss Contingencies [Line Items]
Number of pending claims				3
Propecia/ Proscar | New Jersey Coordinated Proceedings
Loss Contingencies [Line Items]
Amount awarded to other party | $			$ 4.3
Plaintiff participation percentage			95.00%
Plaintiff clawback participation rate percentage			100.00%

XML

Stock-based Compensation Plans - Narrative (Details) $ in Millions	3 Months Ended	9 Months Ended
	Sep. 30, 2022 USD ($)	Sep. 30, 2022 USD ($)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Amount of unrecognized compensation costs	$ 145	$ 145
Amount of unrecognized compensation costs period for recognition		2 years 29 days
Options | 2021 Incentive Stock Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award expiration period		10 years
Award vesting rights		three-year
Award vesting rights, percentage	33.30%
Restricted Stock Units (RSUs) | 2021 Incentive Stock Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting rights		three-year
Award vesting rights, percentage	33.30%
TSR PSU's | 2021 Incentive Stock Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting rights		three year
FCF PSU's | 2021 Incentive Stock Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting rights		three years

XML

Stock-based Compensation Plans - Summary of Transactions (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Income tax benefits	$ 3	$ 3	$ 11	$ 9
Cost of sales
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	3	3	9	8
Selling, general and administrative
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	12	10	35	26
Research and development
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 3	$ 2	$ 8	$ 10

XML

Stock-based Compensation Plans - Stock Option Valuation Assumptions (Details)	9 Months Ended
	Sep. 30, 2022
Share-Based Payment Arrangement [Abstract]
Expected dividend yield	3.12%
Risk-free interest rate	2.47%
Expected volatility	43.43%
Expected life (years)	5 years 10 months 20 days

XML

Stock-based Compensation Plans - Summary of Transactions (Details)	9 Months Ended
	Sep. 30, 2022 $ / shares shares
Stock Options
Outstanding at December 31, 2021 (in shares) | shares	4,394,000,000
Grants (in shares) | shares	556,000,000
Vested/Exercised (in shares) | shares	(15,000,000)
Forfeited/Cancelled (in shares) | shares	(160,000,000)
Outstanding at March 31, 2022 (in shares) | shares	4,775,000,000
Stock Options Weighted Average Exercise Price
Options outstanding, Weighted average exercise price per share - December 31, 2021 (in usd per share)	$ 34.35
Options Granted, Weighted average exercise price per share (in usd per share)	34.93
Options Vested/Exercised, Weighted average exercise price per share (in usd per share)	37.39
Options Forfeited/Cancelled, Weighted average exercise price per share (in usd per share)	35.72
Options outstanding, Weighted average exercise price per share - March 31, 2022 (in usd per share)	34.36
Stock Options Weighted Average Grant Date Fair Value
Options outstanding, Weighted average grant date fair value price per share - December 31, 2021 (in usd per share)	8.63
Granted, Weighted average grant date fair value price per share (in usd per share)	11.34
Vested/Exercised, Weighted average grant date fair value price per share (in usd per share)	9.72
Forfeited/Cancelled, Weighted average grant date fair value price per share (in usd per share)	9.70
Options outstanding, Weighted average grant date fair value price per share - March 31, 2022 (in usd per share)	$ 8.91
Restricted Share Units
Outstanding Share Awards
Outstanding as of December 31, 2021 (in shares) | shares	3,280,000,000
Granted (in shares) | shares	2,299,000,000
Vested/ Exercised (in shares) | shares	(1,251,000,000)
Forfeited/Cancelled (in shares) | shares	(242,000,000)
Outstanding at March 31, 2022 (in shares) | shares	4,086,000,000
Weighted Average Grant Date Fair Value
Outstanding, Weighted average grant date fair value at December 31, 2021 (in USD per share)	$ 36.69
Granted, Weighted average grant date fair value (in USD per share)	34.87
Vested/Exercised, Weighted average grant date fair value (in USD per share)	37.50
Forfeited/Cancelled, Weighted average grant date fair value (in USD per share)	35.76
Outstanding, Weighted average grant date fair value at March 31, 2022 (in USD per share)	$ 35.48
Performance Share Units
Outstanding Share Awards
Outstanding as of December 31, 2021 (in shares) | shares	120,000,000
Granted (in shares) | shares	373,000,000
Vested/ Exercised (in shares) | shares	0
Forfeited/Cancelled (in shares) | shares	(7,000,000)
Outstanding at March 31, 2022 (in shares) | shares	486,000,000
Weighted Average Grant Date Fair Value
Outstanding, Weighted average grant date fair value at December 31, 2021 (in USD per share)	$ 51.63
Granted, Weighted average grant date fair value (in USD per share)	45.23
Vested/Exercised, Weighted average grant date fair value (in USD per share)	0
Forfeited/Cancelled, Weighted average grant date fair value (in USD per share)	51.63
Outstanding, Weighted average grant date fair value at March 31, 2022 (in USD per share)	$ 46.72

XML

Stock-based Compensation Plans - Equity Awards Outstanding (Details) $ / shares in Units, $ in Millions	9 Months Ended
	Sep. 30, 2022 USD ($) $ / shares shares
Equity Awards Vested and Expected to Vest
Stock Options, Awards (in shares) | shares	4,585,000,000
Stock Options, Average Price (in usd per share) | $ / shares	$ 34.36
Stock Options, Aggregate Intrinsic Value | $	$ 0
Stock Options, Remaining Term (in years)	7 years 5 months 23 days
Equity Awards That are Exercisable
Stock Options, Awards (in shares) | shares	2,429,000,000
Stock Options, Average Price (in usd per share) | $ / shares	$ 32.98
Stock Options, Aggregate Intrinsic Value | $	$ 0
Stock Options, Remaining Term	6 years 2 months 23 days
Restricted Share Units
Equity Awards That are Exercisable
Stock Options, Remaining Term
Equity Awards Vested and Expected to Vest
Restricted Stock, Awards (in shares) | shares	3,781,000,000
Restricted Stock, Average Price (in usd per share) | $ / shares
Restricted Stock, Aggregate Intrinsic Value | $	$ 96
Restricted Stock, Remaining Term	2 years 10 days
Equity Awards That are Exercisable
Restricted Stock, Awards (in shares) | shares
Restricted Stock, Average Price (in usd per share) | $ / shares
Restricted Stock, Aggregate Intrinsic Value | $
Performance Share Units
Equity Awards That are Exercisable
Stock Options, Remaining Term
Equity Awards Vested and Expected to Vest
Restricted Stock, Awards (in shares) | shares	402,000,000
Restricted Stock, Average Price (in usd per share) | $ / shares
Restricted Stock, Aggregate Intrinsic Value | $	$ 11
Restricted Stock, Remaining Term	2 years 7 months 17 days
Equity Awards That are Exercisable
Restricted Stock, Awards (in shares) | shares
Restricted Stock, Average Price (in usd per share) | $ / shares
Restricted Stock, Aggregate Intrinsic Value | $

XML

Taxes on Income (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Income Tax Disclosure [Abstract]
Effective income tax rate	19.60%	17.10%	20.00%	11.20%
Step-up in tax basis				$ 70
Income taxes paid		$ 18
Tax benefits recognized related to settlement				$ 29

XML

Other Comprehensive Income (Loss) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Beginning balance	$ (1,137)	$ (1,934)	$ (1,508)	$ 5,486
Other comprehensive (loss) income, pretax	(97)	(26)	(174)	128
Tax	0	0	1	(10)
Other comprehensive (loss) income, net of taxes	(97)	(26)	(173)	118
Transfer of benefit plans to/from Merck affiliates		(3)		11
Ending balance	(1,066)	(1,618)	(1,066)	(1,618)
Accumulated Other Comprehensive Loss
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Beginning balance	(589)	(464)	(513)	(622)
Ending balance	(686)	(493)	(686)	(493)
Employee Benefit Plans
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Beginning balance	(13)	(26)	(13)	(32)
Other comprehensive (loss) income, pretax	0	(3)	(1)	(1)
Tax	0	0	1	(10)
Other comprehensive (loss) income, net of taxes	0	(3)	0	(11)
Transfer of benefit plans to/from Merck affiliates		(3)		11
Ending balance	(13)	(32)	(13)	(32)
Cumulative Translation Adjustment
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Beginning balance	(576)	(438)	(500)	(590)
Other comprehensive (loss) income, pretax	(97)	(23)	(173)	129
Other comprehensive (loss) income, net of taxes	(97)	(23)	(173)	129
Ending balance	$ (673)	$ (461)	$ (673)	$ (461)

XML

Product and Geographic Information - Narrative (Details)	9 Months Ended
	Sep. 30, 2022 segment
Segment Reporting [Abstract]
Number of operating segments	1

XML

Product and Geographic Information - Sales of Company's Products (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Revenue from External Customer [Line Items]
Revenues	$ 1,537	$ 1,600	$ 4,689	$ 4,701
Nexplanon/Implanon NXT
Revenue from External Customer [Line Items]
Revenues	229	175	595	543
Follistim AQ
Revenue from External Customer [Line Items]
Revenues	60	61	179	178
NuvaRing
Revenue from External Customer [Line Items]
Revenues	50	49	133	147
Ganirelix Acetate Injection
Revenue from External Customer [Line Items]
Revenues	36	25	97	85
Cerazette
Revenue from External Customer [Line Items]
Revenues	15	18	47	53
Other Womens Health
Revenue from External Customer [Line Items]
Revenues	63	53	188	191
Renflexis
Revenue from External Customer [Line Items]
Revenues	60	54	166	136
Ontruzant
Revenue from External Customer [Line Items]
Revenues	29	56	87	101
Brenzys
Revenue from External Customer [Line Items]
Revenues	24	14	52	35
Aybintio
Revenue from External Customer [Line Items]
Revenues	10	10	29	26
Hadlima
Revenue from External Customer [Line Items]
Revenues	6	5	14	9
Zetia
Revenue from External Customer [Line Items]
Revenues	87	91	287	282
Vytorin
Revenue from External Customer [Line Items]
Revenues	31	41	104	127
Atozet
Revenue from External Customer [Line Items]
Revenues	109	114	350	347
Rosuzet
Revenue from External Customer [Line Items]
Revenues	17	15	55	48
Cozaar/Hyzaar
Revenue from External Customer [Line Items]
Revenues	70	87	256	265
Other Cardiovascular
Revenue from External Customer [Line Items]
Revenues	35	49	120	148
Singulair
Revenue from External Customer [Line Items]
Revenues	94	100	316	300
Nasonex
Revenue from External Customer [Line Items]
Revenues	49	48	182	144
Dulera
Revenue from External Customer [Line Items]
Revenues	40	56	127	146
Clarinex
Revenue from External Customer [Line Items]
Revenues	26	28	99	83
Other Respiratory
Revenue from External Customer [Line Items]
Revenues	21	18	66	64
Arcoxia
Revenue from External Customer [Line Items]
Revenues	64	65	185	184
Fosamax
Revenue from External Customer [Line Items]
Revenues	36	46	117	132
Diprospan
Revenue from External Customer [Line Items]
Revenues	28	34	91	92
Other Non-Opiod Pain, Bone and Dermatology
Revenue from External Customer [Line Items]
Revenues	65	79	210	213
Proscar
Revenue from External Customer [Line Items]
Revenues	27	27	77	92
Propecia
Revenue from External Customer [Line Items]
Revenues	30	34	95	101
Other
Revenue from External Customer [Line Items]
Revenues	87	95	251	262
Other
Revenue from External Customer [Line Items]
Revenues	39	52	116	168
U.S.
Revenue from External Customer [Line Items]
Revenues	366	346	1,043	1,035
U.S. | Nexplanon/Implanon NXT
Revenue from External Customer [Line Items]
Revenues	151	120	401	389
U.S. | Follistim AQ
Revenue from External Customer [Line Items]
Revenues	27	29	79	81
U.S. | NuvaRing
Revenue from External Customer [Line Items]
Revenues	27	21	65	68
U.S. | Ganirelix Acetate Injection
Revenue from External Customer [Line Items]
Revenues	6	5	20	19
U.S. | Cerazette
Revenue from External Customer [Line Items]
Revenues	0	0	0	0
U.S. | Other Womens Health
Revenue from External Customer [Line Items]
Revenues	24	18	80	80
U.S. | Renflexis
Revenue from External Customer [Line Items]
Revenues	54	48	145	119
U.S. | Ontruzant
Revenue from External Customer [Line Items]
Revenues	15	9	35	20
U.S. | Brenzys
Revenue from External Customer [Line Items]
Revenues	0	0	0	0
U.S. | Aybintio
Revenue from External Customer [Line Items]
Revenues	0	0	0	0
U.S. | Hadlima
Revenue from External Customer [Line Items]
Revenues	0	0	0	0
U.S. | Zetia
Revenue from External Customer [Line Items]
Revenues	2	1	7	6
U.S. | Vytorin
Revenue from External Customer [Line Items]
Revenues	1	3	6	8
U.S. | Atozet
Revenue from External Customer [Line Items]
Revenues	0	0	0	0
U.S. | Rosuzet
Revenue from External Customer [Line Items]
Revenues	0	0	0	0
U.S. | Cozaar/Hyzaar
Revenue from External Customer [Line Items]
Revenues	2	3	11	9
U.S. | Other Cardiovascular
Revenue from External Customer [Line Items]
Revenues	1	1	3	3
U.S. | Singulair
Revenue from External Customer [Line Items]
Revenues	3	2	8	10
U.S. | Nasonex
Revenue from External Customer [Line Items]
Revenues	0	0	9	3
U.S. | Dulera
Revenue from External Customer [Line Items]
Revenues	31	48	98	121
U.S. | Clarinex
Revenue from External Customer [Line Items]
Revenues	0	2	3	5
U.S. | Other Respiratory
Revenue from External Customer [Line Items]
Revenues	11	14	34	43
U.S. | Arcoxia
Revenue from External Customer [Line Items]
Revenues	0	0	0	0
U.S. | Fosamax
Revenue from External Customer [Line Items]
Revenues	1	1	2	3
U.S. | Diprospan
Revenue from External Customer [Line Items]
Revenues	0	0	0	0
U.S. | Other Non-Opiod Pain, Bone and Dermatology
Revenue from External Customer [Line Items]
Revenues	2	9	10	12
U.S. | Proscar
Revenue from External Customer [Line Items]
Revenues	0	0	1	1
U.S. | Propecia
Revenue from External Customer [Line Items]
Revenues	2	1	5	5
U.S. | Other
Revenue from External Customer [Line Items]
Revenues	6	10	21	32
U.S. | Other
Revenue from External Customer [Line Items]
Revenues	0	1	0	(2)
International
Revenue from External Customer [Line Items]
Revenues	1,171	1,254	3,646	3,666
International | Nexplanon/Implanon NXT
Revenue from External Customer [Line Items]
Revenues	78	55	194	154
International | Follistim AQ
Revenue from External Customer [Line Items]
Revenues	33	32	100	97
International | NuvaRing
Revenue from External Customer [Line Items]
Revenues	23	28	68	79
International | Ganirelix Acetate Injection
Revenue from External Customer [Line Items]
Revenues	30	20	77	66
International | Cerazette
Revenue from External Customer [Line Items]
Revenues	15	18	47	53
International | Other Womens Health
Revenue from External Customer [Line Items]
Revenues	39	35	108	111
International | Renflexis
Revenue from External Customer [Line Items]
Revenues	7	6	20	17
International | Ontruzant
Revenue from External Customer [Line Items]
Revenues	14	47	52	81
International | Brenzys
Revenue from External Customer [Line Items]
Revenues	24	14	52	35
International | Aybintio
Revenue from External Customer [Line Items]
Revenues	10	10	29	26
International | Hadlima
Revenue from External Customer [Line Items]
Revenues	6	5	14	9
International | Zetia
Revenue from External Customer [Line Items]
Revenues	85	90	280	276
International | Vytorin
Revenue from External Customer [Line Items]
Revenues	30	38	98	119
International | Atozet
Revenue from External Customer [Line Items]
Revenues	109	114	350	347
International | Rosuzet
Revenue from External Customer [Line Items]
Revenues	17	15	55	48
International | Cozaar/Hyzaar
Revenue from External Customer [Line Items]
Revenues	68	84	244	256
International | Other Cardiovascular
Revenue from External Customer [Line Items]
Revenues	34	48	117	145
International | Singulair
Revenue from External Customer [Line Items]
Revenues	92	98	308	289
International | Nasonex
Revenue from External Customer [Line Items]
Revenues	49	49	173	141
International | Dulera
Revenue from External Customer [Line Items]
Revenues	9	8	30	25
International | Clarinex
Revenue from External Customer [Line Items]
Revenues	25	27	96	78
International | Other Respiratory
Revenue from External Customer [Line Items]
Revenues	10	5	32	20
International | Arcoxia
Revenue from External Customer [Line Items]
Revenues	64	65	185	184
International | Fosamax
Revenue from External Customer [Line Items]
Revenues	35	45	115	130
International | Diprospan
Revenue from External Customer [Line Items]
Revenues	28	34	91	92
International | Other Non-Opiod Pain, Bone and Dermatology
Revenue from External Customer [Line Items]
Revenues	63	69	200	201
International | Proscar
Revenue from External Customer [Line Items]
Revenues	26	27	76	91
International | Propecia
Revenue from External Customer [Line Items]
Revenues	28	33	90	96
International | Other
Revenue from External Customer [Line Items]
Revenues	81	83	230	230
International | Other
Revenue from External Customer [Line Items]
Revenues	$ 39	$ 51	$ 115	$ 171

XML

Product and Geographic Information - Revenues by Geographic Area (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Revenue from External Customer [Line Items]
Revenues	$ 1,537	$ 1,600	$ 4,689	$ 4,701
Europe and Canada
Revenue from External Customer [Line Items]
Revenues	363	410	1,243	1,314
United States
Revenue from External Customer [Line Items]
Revenues	366	346	1,043	1,035
Asia Pacific and Japan
Revenue from External Customer [Line Items]
Revenues	283	287	888	874
China
Revenue from External Customer [Line Items]
Revenues	241	252	721	693
Latin America, Middle East, Russia and Africa
Revenue from External Customer [Line Items]
Revenues	236	238	665	595
Other
Revenue from External Customer [Line Items]
Revenues	$ 48	$ 67	$ 129	$ 190

XML

Third Party Arrangements Related Party Disclosures - Narrative (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Related Party Transaction [Line Items]
Accounts receivable	$ 412		$ 412		$ 403
Accounts payable	623		623		$ 928
Related Party
Related Party Transaction [Line Items]
Sales	38	$ 41	104	$ 54
Cost of sales	$ 31	$ 35	$ 91	$ 48

XML

Third Party Arrangements Related Party Disclosures - Allocations Included in Statement of Operations (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Related Party Transaction [Line Items]
Cost of sales	$ 551	$ 609	$ 1,700	$ 1,783
Selling, general and administrative	440	388	1,234	1,186
Costs, Expenses And Other	$ 1,255	$ 1,211	$ 3,678	3,408
Related Party | Merck and Co., Inc. | Transition Services Agreement
Related Party Transaction [Line Items]
Cost of sales				69
Selling, general and administrative				134
Research and development				35
Costs, Expenses And Other				$ 238

XML

Third Party Arrangements Related Party Disclosures - Transactions with Merck Affiliates (Details) $ in Millions	9 Months Ended
	Sep. 30, 2021 USD ($)
Discontinued Operations
Related Party Transaction [Line Items]
Supply sales to Merck affiliates	$ 12
Purchases from Merck affiliates	53
Other Merck Affiliates | Continuing Operations
Related Party Transaction [Line Items]
Supply sales to Merck affiliates	143
Purchases from Merck affiliates	65
Other Merck Affiliates | Continuing Operations | Cost Reimbursements and Fees
Related Party Transaction [Line Items]
Cost reimbursements and fees from Merck affiliates	1
Other Merck Affiliates | Discontinued Operations
Related Party Transaction [Line Items]
Supply sales to Merck affiliates	12
Purchases from Merck affiliates	$ 53

XML

Third Party Arrangements Related Party Disclosures - Net Transfers to Parent (Details) $ in Millions	9 Months Ended
	Sep. 30, 2021 USD ($)
Related Party Transaction [Line Items]
Cash pooling and general financing activities	$ 168
Cost allocations, excluding non-cash stock-based compensation	(209)
Taxes deemed settled with Merck	(259)
Allocated derivative and hedging (losses) gains	(88)
Net transfers (from) to Merck & Co., Inc. as reflected in the Condensed Consolidated Statement of Cash Flows for Continuing Operations (2)	(388)
Net transfers to (from) Merck included in Net Cash Provided by (Used in) Discontinued Operations	597
Total net transfers to Merck as included in the Condensed Consolidated Statement of Cash Flows	209
Stock-based compensation expense (includes $3 of discontinued operations for the nine months ended September 30, 2021)	(32)
Net assets contributed by Merck affiliates	(778)
Derecognition of amounts in Accumulated other comprehensive loss related to employee benefit plan transfers to Merck affiliates	13
Net transfers (from) to Merck & Co., Inc. as reflected in the Condensed Consolidated Statement of Equity	(588)
Adjustment to net transfers reflected in Cash Flows from Continuing Operations	66
Discontinued Operations
Related Party Transaction [Line Items]
Stock-based compensation expense (includes $3 of discontinued operations for the nine months ended September 30, 2021)	$ (3)

XML

Discontinued Operations - Components of Income (Loss) from Discontinued Operations (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Costs, Expenses and Other
Income from discontinued operations, net of taxes	$ 0	$ 0	$ 0	$ 0
Discontinued Operations, Held-for-sale or Disposed of by Sale
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Sales				93
Costs, Expenses and Other
Cost of Sales				65
Selling, general and administrative				15
Research and development				4
Other (income) expense, net				4
Income from discontinued operations before taxes				5
Taxes on income				5
Income from discontinued operations, net of taxes				$ 0

XML

Discontinued Operations - Narrative (Details) - Discontinued Operations $ in Millions	9 Months Ended
	Sep. 30, 2021 USD ($)
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Sales	$ 12
Costs for inventory purchases	$ 53

XML

Earnings per Share ("EPS") - Narrative (Details) - shares shares in Thousands		3 Months Ended		9 Months Ended
	Jun. 02, 2021	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Earnings Per Share [Abstract]
Basic (in shares)	253,516	254,348	253,534	253,986	253,530

XML

Earnings per Share ("EPS") - Calculation of Basic and Diluted Earnings Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Millions		3 Months Ended		9 Months Ended
	Jun. 02, 2021	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Net income from continuing operations		$ 227	$ 323	$ 809	$ 1,149
Income from discontinued operations		0	0	0	0
Net Income		$ 227	$ 323	$ 809	$ 1,149
Basic weighted average number of shares outstanding (in shares)	253,516	254,348	253,534	253,986	253,530
Stock awards and equity units (share equivalent) (in shares)		719	638	1,108	481
Diluted weighted average common shares outstanding (in shares)		255,067	254,172	255,094	254,011
Earnings per Share - Basic:
Continuing operations (in dollars per share)		$ 0.89	$ 1.27	$ 3.19	$ 4.53
Discontinued operations (in dollars per share)		0	0	0	0
Basic earnings per common share attributable to Organon common stockholders (in dollar per share)		0.89	1.27	3.19	4.53
Earnings per Share - Diluted:
Continuing operations (in dollars per share)		0.89	1.27	3.17	4.52
Discontinued operations (in dollars per share)		0	0	0	0
Net Earnings per Share Attributable to Organon & Co. Stockholders - Diluted (in dollars per share)		$ 0.89	$ 1.27	$ 3.17	$ 4.52
Share-based compensation plans
Earnings per Share - Diluted:
Anti-dilutive shares excluded from the calculation of EPS (in shares)		6,313	4,800	4,432	5,015